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 ABSTRACT  
  
Introduction: Dementia may be caused by Alzheimer’s disease (AD), 
cerebrovascular disease (CVD), or a combination of both. When CVD is 
associated with dementia, survival is thought to be reduced. It is unclear whether 
treatment with cholinesterase inhibitors (ChEIs), which has been found to 
improve cognitive symptoms and global function in AD patients, has similar 
benefits in vascular forms of dementia.   
 
Objectives: The present study was designed to determine whether co-existing 
CVD is associated with survival or time to nursing home placement (NHP) among 
AD patients treated with ChEIs. Findings of poorer outcomes in patients with 
versus without CVD might argue against the use of ChEIs for AD patients in 
whom CVD co-exists. The objective of a second analysis was to assess for the 
first time in patients with AD the potential impact of immortal time (and follow-
up) bias on risk for these outcomes. 
 
Methods: A retrospective cohort study was undertaken using the Régie de 
l’Assurance Maladie du Québec (RAMQ) databases to examine the time to NHP 
or death for AD patients aged 66+, with or without CVD, treated with ChEIs 
between July 1, 2000, and June 30, 2003. Because ChEIs are approved only for 
AD in Canada, a ChEI prescription was used as a surrogate for an AD diagnosis. 
Concomitant CVD was identified on the basis of a lifetime diagnosis of stroke or 
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endarterectomy, or a diagnosis of transient ischemic attack within the six months 
prior to the index date. Separate analyses were performed for patients with 
persistent ChEI use and those who discontinued ChEI therapy. Seven Cox 
proportional hazard regression models which varied in the definition of the index 
date (start of follow-up) and the duration of follow-up were used to evaluate the 
impact of immortal time bias. 
 
Results: 4,428 patients met inclusion criteria for AD with CVD; 13,512 were 
classified as having AD alone. For the composite endpoint of NHP or death, 
1,000-day survival rates were lower among AD patients with versus without CVD 
(p<0.01), but absolute differences were very small (84% vs. 86% with continuous 
ChEI use; 77% vs. 78% with discontinuous ChEI therapy). Of the secondary 
endpoints, time to death was shorter for patients with versus without CVD, but 
time to NHP did not differ between groups. In the primary, unbiased analysis, no 
association was found between ChEI treatment type and death or NHP. However, 
after introduction of immortal time bias, a strong differential effect was observed. 
 
Limitations: Results may have been affected by selection (misclassification) bias, 
between-group differences in smoking and body mass index (information on 
which was not available in the RAMQ databases), and duration of ChEI therapy. 
 
Conclusions: Associations between co-existing CVD and time to NHP or death 
appeared to be of little clinical relevance among AD patients treated with ChEIs. 
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The lack of difference between AD patients with and without CVD suggests that 
CVD should not be used as a reason to deny AD patients access to ChEI 
treatment. Properly accounting for unexposed person-time in the analysis 
eliminates biased estimates of drug efficacy. 
 
Keywords: cholinesterase inhibitors; dementia; Alzheimer’s disease; 
cerebrovascular disease; administrative database 
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RĒSUMĒ  
 
Introduction: La démence peut être causée par la maladie d’Alzheimer (MA), la 
maladie cérébrovasculaire (MCEREV), ou une combinaison des deux. Lorsque la 
maladie cérébrovasculaire est associée à la démence, les chances de survie sont 
considérées réduites. Il reste à démontrer si le traitement avec des inhibiteurs de la 
cholinestérase (ChEIs), qui améliore les symptômes cognitifs et la fonction 
globale chez les patients atteints de la MA, agit aussi sur les formes vasculaires de 
démence.  
 
Objectifs: La présente étude a été conçue pour déterminer si la coexistence d’une 
MCEREV était associée avec les chances de survie ou la durée de la période 
jusqu’au placement en hebergement chez les patients atteints de la MA et traités 
avec des ChEIs. Des études montrant de moins bons résultats chez les patients 
souffrant de MCEREV que chez ceux n’en souffrant pas pourrait militer contre 
l’utilisation des ChEIs chez les patients atteints à la fois de la MA et la MCEREV. 
L'objectif d'une seconde analyse était d'évaluer pour la première fois chez les 
patients atteints de la MA l'impact potentiel du biais de « temps-immortel » (et de 
suivi) sur ces résultats (mort ou placement en hebergement).  
 
Méthodes: Une étude de cohorte rétrospective a été conduite en utilisant les bases 
de données de la Régie de l’Assurance Maladie du Québec (RAMQ) pour 
examiner la durée de la période jusqu’au placement en hebergement ou jusqu’au 
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décès des patients atteints de la MA, âgés de 66 ans et plus, avec ou sans 
MCEREV, et traités avec des ChEIs entre le 1er Juillet 2000 et le 30 Juin 2003. 
Puisque les ChEIs sont uniquement indiquées pour la MA au Canada, chaque 
prescription de ChEIs a été considérée comme un diagnostic de la MA. La 
MCEREV concomitante a été identifié sur la base d'un diagnostic à vie d’un 
accident vasculaire cérébral (AVC) ou d’une endartériectomie, ou d’un diagnostic 
d'un accident ischémique transitoire au cours des six mois précédant la date 
d’entrée. Des analyses séparées ont été conduites pour les patients utilisant les 
ChEIs de façon persistante et pour ceux ayant interrompu la thérapie. Sept 
modèles de régression à risque proportionnel de Cox qui ont varié par rapport à la 
définition de la date d’entrée (début du suivi) et à la durée du suivi ont été utilisés 
pour évaluer l'impact du biais de temps-immortel. 
 
Résultats: 4,428 patients ont répondu aux critères d’inclusion pour la MA avec 
MCEREV; le groupe de patients souffrant seulement de la MA comptait 13,512 
individus. Pour le critère d’évaluation composite considérant la durée de la 
période jusqu’au placement en hebergement ou jusqu’au décès, les taux de survie 
à 1,000 jours étaient plus faibles parmi les patients atteints de la MA avec 
MCEREV que parmi ceux atteints seulement de la MA (p<0.01), mais les 
différences absolues étaient très faibles (84% vs. 86% pour l’utilisation continue 
de ChEIs ; 77% vs. 78% pour la thérapie avec ChEIs interrompue). Pour les 
critères d’évaluation secondaires, la période jusqu’au décès était plus courte chez 
les patients avec la MCEREV que sans la MCEREV, mais la période jusqu’au 
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placement en hebergement n’était pas différente entre les deux groupes. Dans 
l'analyse primaire (non-biaisée), aucune association a été trouvée entre le type de 
ChEI et la mort ou le placement en maison d'hébergement. Cependant, après 
l'introduction du biais de temps-immortel, on a observé un fort effet différentiel. 
 
Limitations: Les résultats peuvent avoir été affectés par le biais de sélection 
(classification impropre), par les différences entre les groupes en termes de 
consommation de tabac et d’indice de masse corporelle (ces informations 
n’étaient pas disponibles dans les bases de données de la RAMQ) et de durée de 
la thérapie avec les ChEIs. 
 
Conclusions: Les associations entre la coexistence d’une MCEREV et la durée de 
la période jusqu’au placement en hebergement ou au décès apparaissent peu 
pertinentes cliniquement parmi les patients atteints de la MA traités avec des 
ChEIs. L’absence de différence entre les patients atteints de la MA souffrant ou 
non de la MCEREV suggère que la coexistence d’une MCEREV ne devrait pas 
être une raison de refuser aux patients atteints de la MA l’accès au traitement avec 
des ChEIs. Le calcul des « personne-temps » non exposés dans l'analyse élimine 
les estimations biaisées de l'efficacité des médicaments. 
 
Mots-clés : inhibiteurs de la cholinestérase ; démence ; maladie d’Alzheimer ; 
banque de données administrative 
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1.0   INTRODUCTION 
 
Dementia is a common, but complicated illness of aging that may currently affect 
over 24.3 million individuals worldwide 1, including more than 450,000 Canadian 
residents 2,3. As the elderly population grows over the next several decades, the 
global prevalence of dementia is projected to increase by 4.6 million new cases 
each year, such that 81.1 million patients may be diagnosed with dementia by 
2040 1. The anticipated surge in dementia cases is of particular concern, given that 
there is presently no cure for the illness and that the underlying causes of 
dementia are only beginning to be understood. Clearly, a more sophisticated 
understanding of dementia will be essential, given the increasing public health 
burden of this devastating disease.  
 
Although often construed by the public as a single disease entity, dementia is 
actually an umbrella term, used to describe a heterogeneous group of diseases 
associated with cognitive changes and functional impairment. Of the various 
dementia subtypes, the most commonly recognized is Alzheimer’s disease (AD), 
followed by vascular dementia (VaD). Historically, these subtypes have been 
construed as distinct entities, with AD attributed to the formation of plaques and 
tangles in the brain, and VaD related to various forms of cerebrovascular disease 
(CVD). However, researchers are now recognizing that AD and VaD frequently 
co-exist, and that “pure” forms of dementia (particularly VaD) may be relatively 
2 
 
rare. Such discoveries have led to a paradigm shift, which places more emphasis 
on mixed dementia 4. 
 
While some researchers are appreciating the overlap between the dementia 
disorders, others are focusing on the etiological heterogeneity within each 
dementia subtype 4. VaD, in particular, is being increasingly construed as a multi-
factorial disease, arising not only from stroke, but also from subcortical vascular 
changes. Importantly, the different causes of VaD seem to be associated with 
different clinical phenotypes, suggesting: (1) that specific criteria could be 
developed to identify VaD subtypes, and (2) that specific therapies could be 
developed for the various subpopulations of dementia patients 4. 
 
In Canada, the cholinesterase inhibitors (ChEIs) are the main class of medications 
approved by the health authorities (Santé Canada) to treat dementia associated 
with AD 5. These medications—donepezil (Aricept), galantamine (Reminyl) and 
rivastigmine (Exelon)—which until recently have been approved only for mild-to-
moderate AD, have not been shown to have disease-modifying effects, but may 
nevertheless exert cognitive benefits that prolong survival and delay admission to 
nursing home care 6.  
 
Currently, no medications are approved in Canada for therapy of VaD. Given that 
AD and VaD share pathological mechanisms, it has been speculated that drugs 
with efficacy in AD may be beneficial for VaD as well 7. Researchers have been 
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testing this hypothesis, with encouraging results, for a number of years. However, 
a recent meta-analysis of randomized, controlled trials of ChEIs in VaD 
concluded that while evidence suggests these agents produce small benefits in 
cognition in patients with mild-to-moderate VaD, insufficient data exist to support 
widespread use of ChEIs in this patient population 8.  
 
Definitive demonstration of the efficacy of ChEIs for treating dementia symptoms 
requires randomized, placebo-controlled clinical trials that include appropriate 
measures of cognition, functional ability, and global change 9. A more 
comprehensive assessment of clinical benefit would also include measures of 
behavioural alteration and caregiver burden 10. Unfortunately, instruments 
developed to assess these endpoints in AD trials may not be optimal for VaD 
clinical trials because of the subtle but distinct differences in the disease course, 
cognitive and functional deficits, and pattern of caregiver burden seen in patients 
with AD compared to those with VaD 10. Previous VaD clinical trials of ChEIs 
may have had limited ability to detect treatment effects since they used 
instruments developed for use in AD trials that may not have been sufficiently 
sensitive to the clinical changes associated with VaD 8. The 6-month follow-up 
period of these trials may also have been too short to assess overall benefit.  
 
Pending long-term, randomized, placebo-controlled trials of ChEIs in VaD and 
mixed dementia using disease-specific instruments, retrospective epidemiological 
analyses of administrative databases may provide valuable insight into the 
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effectiveness of dementia treatments and which populations may benefit most 
from them. Although such databases do not contain detailed clinical assessments 
of cognition, functional ability, and global change, they provide information on 
drug claims and medical services that can be used to construct other clinically 
relevant endpoints, such as time to survival and nursing home placement (NHP).  
 
Accordingly, the first of the two original studies contained in this thesis (see 
Chapter 5) is a retrospective cohort study undertaken using data from two of the 
Régie de l’Assurance Maladie du Québec (RAMQ) administrative databases: the 
prescription claims database and the medical services database in the Province of 
Québec, Canada. The main objective of this study was to determine whether co-
existing CVD is associated with survival or time to NHP among AD patients 
treated with ChEIs. A secondary objective was to identify predictors of death or 
NHP during and after ChEI treatment in AD patients with and without CVD. 
 
Despite their potential, the retrospective nature of epidemiological analyses of 
administrative databases subjects them to a variety of limitations potentially 
leading to bias, which need to be carefully considered in study design and 
interpretation of results. Bias in epidemiologic research is any systematic error 
that distorts an estimate of the relationship between exposure and outcome. Biases 
are generally categorized into three types. Selection bias refers to errors that occur 
in identifying the study population. Information bias, also known as observation 
bias, consists of error in ascertaining data on exposure or outcome. Immortal time 
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bias is a form of information bias in which a time-dependent exposure is treated 
as a time-invariant factor, and is of particular concern in retrospective cohort 
analyses. Confounding occurs when the relationship between exposure and 
outcome is affected by another factor 11. 
 
Minimization of bias is imperative for the design and interpretation of 
epidemiologic studies, given that its presence raises doubts about the quality and 
credibility of results. Key contributors to bias include the type of study design, 
which may be susceptible to particular forms of bias, and the conduct of 
investigators during study implementation. Whereas the effects of confounding 
may be controlled at the time study data are analyzed, it is critical to prevent 
selection bias and information bias at the design stage in order to avoid 
compromising study validity 12. Although quantitative analysis of the magnitude 
of potential bias is not always possible, the likely effect of the error on study 
findings can often be deduced either at the design or at the analysis phase of the 
study 11. 
 
Issues related to bias are addressed in the second of the two original studies 
contained in this thesis, reported in Chapter 6. This study is a methodological 
analysis of the RAMQ databases, conducted to demonstrate the importance of 
carefully considering study biases in retrospective cohort analyses. The primary 
objective of this study was to evaluate the impact of immortal time bias on the 
estimated risk of death or NHP among AD patients who took rivastigmine or 
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galantamine compared to those who were prescribed donepezil. A secondary 
objective was to examine whether immortal time bias would lead to erroneous 
conclusions about the effectiveness of treatment with the three ChEIs.  
 
Chapters 1 and 2 provide a broad overview of AD and vascular cognitive 
impairment, and the issue of bias in epidemiological research, respectively. 
Neither of these is intended to be a systematic or comprehensive literature review. 
Instead, the purpose of Chapter 2 is to introduce the disease states and therapeutic 
agents examined in both original studies (Chapters 5 and 6), while Chapter 3 
explains the issues related to bias in retrospective cohort analyses that are 
explored in the methodological analysis (Chapter 5). Chapter 4 provides the 
context for the objectives and hypotheses of the two original studies. 
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2.0   ALZHEIMER’S DISEASE AND VASCULAR COGNITIVE 
IMPAIRMENT: A REVIEW OF THE LITERATURE 
 
2.1   HISTORY 
 
Although the concept of dementia is centuries old, the history of AD can be 
directly traced to November 1901, when a German physician named Alois 
Alzheimer first described the case of Auguste D. to a group of his colleagues. 
Auguste D., according to reports, was a 51-year-old woman who exhibited a 
strange constellation of symptoms, including rapid memory loss, disorientation, 
aphasia, delusions, and disordered behavior. Because the patient’s symptoms were 
inconsistent with any known diagnosis, Alzheimer set out to determine their 
cause, eventually performing an autopsy after her death. The results of 
Alzheimer’s neuropathological studies suggested that Auguste’s illness was 
related to diffuse shrinkage of the brain, as well as widespread cell death and two 
types of microscopic deposits (beta-amyloid plaques and neurofibrillary tangles) 
that had not previously been seen. The disorder was soon recognized as a distinct 
disease entity, and given the name “Alzheimer’s disease” by Emil Kraeplin in the 
1910 edition of his textbook on mental disorders 13. 
 
Like AD, the concept of VaD also dates back approximately 100 years, when the 
neuropsychiatric community began to recognize that mental changes could occur 
when the blood supply to the brain was reduced. Over time, researchers such 
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Alzheimer, Otto Binswanger, and Pierre Marie determined that these cognitive 
changes could be caused either directly through arterial narrowing or indirectly 
via reactive inflammation in the brain. Formal subclasses of VaD were not 
recognized, however, until Binswanger provided a description of eight patients 
with subcortical arteriosclerotic encephalopathy, a phenomenon that would later 
be termed “Binswanger’s disease.” The term “multi-infarct dementia” was coined 
in 1970, when researchers found that dementia could be triggered by loss of brain 
tissue after stroke. Experts later identified a number of other VaD etiologies, 
including sustained hypoperfusion, incomplete white matter infarction, and single 
strategic infarcts 4,14.  
 
Research into the causes and consequences of VaD has been increasing since 1991, 
when the International Workshop on Vascular Dementia convened to developed 
standardized diagnostic criteria 14. Recent advances include the application of newer 
imaging modalities (e.g., diffusion-weighted imaging) in VaD research, and the 
discovery of pathophysiological interactions between cerebrovascular disease 
(CVD) and AD 15,16. Interestingly, it has been speculated that the symptoms 
exhibited by Alzheimer’s original patient, August D., were caused not by typical 
AD neurodegeneration, but rather by cerebrovascular causes 13.  
 
The relevance of dementia as a public health concern is increasing at a rapid pace, 
fueling a growing number of studies aimed at developing treatments to alleviate 
the effects of this debilitating disorder. Since the early 1990s, Canadian 
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population-based studies such as the Canadian Study of Health and Aging 
(CSHA), the Canadian Collaborative Cohort of Related Dementias (ACCORD), 
and the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) 
have contributed greatly to knowledge about the epidemiology and burden of 
dementing diseases. In addition, Canada has taken a leading role in developing 
clear consensus guidelines for the management, assessment, and treatment of 
dementia. The Canadian Consensus Conference on Dementia (CCCD), held in 
1998, represented a major effort toward using solid evidence to inform research 
methodology and clinical practice 17,18. 
 
2.2   DEFINITIONS 
 
2.2.1   Dementia 
 
The term dementia refers to a progressive loss of cognitive abilities that 
negatively impacts daily functioning. Most definitions of dementia specify that 
the condition must be associated with deficits in at least two of four essential 
cognitive domains, which include memory, language, executive performance 
(e.g., planning or organizing), and visual processing. In addition, dementia is 
defined by a marked interference in the ability to perform daily tasks, such as 
dressing, grooming, and preparing meals. These elements emphasize the breadth 
and magnitude of dementia’s impact on everyday life 14,19-21.  
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As stated, dementia is not a unitary construct, but rather an umbrella term used to 
describe numerous manifestations of cognitive decline. Historically, the various 
types of dementia have been distinguished using a categorical approach, with the 
presence of certain symptoms and brain abnormalities viewed as surrogates for 
discrete pathological changes. As research into dementia has advanced, however, 
it has become increasingly apparent that the symptoms and pathologies of 
different dementias frequently overlap, rendering distinctions between subtypes 
somewhat artificial. According to the emerging paradigm, dementia lies on a 
continuum from “pure” AD to “pure” VaD, with the majority of cases lying 
somewhere in between 4. Other, less common types of dementia include dementia 
with Lewy bodies, frontotemporal dementia, dementia from Parkinson’s disease, 
and normal pressure hydrocephalus. 
 
2.2.2   Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a diagnostic label given to patients whose cognitive 
decline is attributed to the formation of beta-amyloid (Aβ) plaques and 
neurofibrillary tangles (NFTs) within the brain 21. AD is the leading cause of 
dementia, with estimates of the proportion of dementia cases accounted for by AD 
ranging from 50% in a postmortem series 22 to 75% in the CSHA 23. The “classic” 
symptom presentation includes an initial loss of recent memory, followed by a 
gradual decline in language, organization, judgment, and other cognitive domains 
24. The two primary subcategories of AD are the early-onset familial type, which 
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is rare and manifests at ages 40-65 years, and late-onset sporadic AD, which is far 
more common and develops spontaneously at age 65 years or older 25. Early-onset 
familial AD has been associated with mutations in at least three genes: presenilin 
1, presenilin 2, and amyloid precursor protein 26-28. The type 4 allele of another 
gene, apolipoprotein E, has been identified as a risk factor for late-onset AD 29. 
Research is ongoing to test other candidate genes for a role in AD 30. 
 
2.2.3   Vascular Dementia  
 
The concept of vascular dementia (VaD) refers to a clinical syndrome of cognitive 
and functional impairment that occurs when blood flow is reduced to parts of the 
brain, often as a result of cerebrovascular disease (CVD). Like dementia, VaD is 
also used as an umbrella term, used to describe a range of clinical presentations 
that vary according to the type, location, and severity of cerebrovascular injury. 
Frequently recognized subcategories of VaD include multi-infarct dementia, 
strategic infarct dementia, and small vessel disease with dementia 4,15.  
 
Perhaps as a result of its heterogeneous nature, definitions of VaD are often 
frustratingly imprecise. For example, the terms multi-infarct dementia, post-stroke 
dementia, and atherosclerotic dementia are often used interchangeably with VaD, 
despite their failure to recognize small vessel disease and other vascular 
etiologies. In addition, VaD is sometimes referred to as VCI in the clinical 
literature, even though the general consensus is that VaD represents but one 
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subset of the larger VCI construct. Such imprecision in terminology is confusing, 
and may have hampered effective research in VaD populations 15. 
 
2.2.4   Mixed Dementia 
 
The term mixed dementia is usually used to describe a pattern of cognitive 
dysfunction that is characterized by both AD and VaD abnormalities, but may 
also refer to other combinations of dementia subtypes (e.g., AD plus vascular 
encephalopathy) 31. Due to a lack of diagnostic criteria, mixed dementia is often 
difficult to diagnose, and thus may not be recognized until autopsy. Many 
epidemiological studies group cases of mixed dementia together with VaD, or use 
the category of VCI to include both VaD and mixed dementia cases 32. Other 
experts dispense with the term mixed dementia entirely, advocating instead for the 
label “AD with CVD” to designate patients with possible AD accompanied by 
evidence of a vascular injury 14. 
 
2.2.5   Mild Cognitive Impairment 
 
Mild cognitive impairment (MCI) is a term that has been coined to describe 
cognitive changes that do not meet criteria for dementia. It is generally considered 
to be a transitional state between the cognitive decline of normal aging and the 
development of “full-blown” dementia 33. Its clinical significance derives from its 
ability to predict dementia in persons with subthreshold symptoms 34. MCI has 
been referred to by many terms, including benign senescent forgetfulness and 
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aging-associated cognitive decline. Recently, the concept of cognitive impairment 
no dementia (CIND) has come into the nomenclature, and is often used 
interchangeably with MCI. It has been argued, however, that MCI and CIND are 
not synonymous, as CIND encompasses a broader range of individuals, only some 
of whom have MCI 33.  
 
In most cases, MCI is associated with memory impairment, and thus assumed to 
be AD-related. The precise manifestations of MCI, however, can be quite 
heterogeneous, and may extend to non-memory domains. Subcategories of MCI 
have been proposed to differentiate between probable etiologies, with amnestic 
MCI used to describe memory-impaired cases and nonamnestic MCI reserved for 
cases with other cognitive deficits 33. The term vascular CIND (VCIND) is a 
related construct, used to describe patients with mild dysfunction in 
predominantly executive cognitive domains.  
 
2.2.6   Vascular Cognitive Impairment 
 
The construct of vascular cognitive impairment (VCI) is a relatively new 
phenomenon, having emerged in reaction to advances in the understanding of 
cognitive decline and the importance of early detection. Representing yet another 
umbrella term, VCI is used to reflect a spectrum of cerebovascular lesions and 
associated cognitive impairment, ranging from VCIND to VaD and mixed 
dementia. Although clearly a non-specific diagnosis, VCI may be advantageous in 
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identifying all cases in which vascular injury has contributed to cognitive 
changes, even if AD has also played a role or if symptoms have not yet led to 
functional deficits 4,35. Used in this way, the term VCI recognizes the difficulties 
inherent in differentiating VaD from mixed dementia, and also identifies patients 
with subthreshold symptoms who are nonetheless at increased risk of 
institutionalization and death 36. 
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2.3   PATHOPHYSIOLOGY 
 
2.3.1   Dementia – pathophysiology 
 
Dementia can arise due to a number of causes, many of which are reversible (see 
Figure A). For patients with non-reversible dementias, any of several pathological 
mechanisms may be at play, either in combination or isolation. At present, there is 
no definitive way to identify the underlying cause(s) with certainty until an 
autopsy is performed 21. Thus, clinicians must speculate about a patient’s 
pathology based on clinical, historical, and neuroimaging characteristics, and 
choose the most appropriate treatment accordingly. In cases attributed to 
reversible causes, such therapy will be targeted to the underlying etiology (e.g., 
depression or anemia), rather than the cognitive symptoms per se.  
 
Figure A. Potentially reversible causes of dementia 37 
 
D Drugs (any with anticholnergic activity) 
E Emotional (depression) 
M Metabolic (hypothyroidism 
E Eyes and ears declining 
N Normal pressure hydrocephalus 
T Tumor 
I Infection (AIDS or syphilis) 
A Anemia (deficiency in folate or vitamin 
B12) 
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2.3.2   Alzheimer’s Disease – pathophysiology 
 
As described by Alois Alzheimer in the early 1900s, the hallmark pathological 
features of AD are extracellular (senile) plaques composed of aggregated beta-
amyloid (Aβ) peptide and neurofibrillary tangles (NFTs) that are made up largely 
of tau protein. These pathologies, which have been identified in both early- and 
late-onset AD, seem to preferentially attack the memory centers of the brain (i.e., 
the hippocampus and entorhinal cortex), triggering the death of cholinergic 
neurons and related memory impairment. Although experts do not know for 
certain whether cell death triggered by amyloid plaques (the “amyloid 
hypothesis”) or NFTs represents the true underlying cause of AD or is merely a 
consequence of other processes, the general consensus is that neurodegeneration 
is caused by the combination of plaques and tangles, whereas cholinergic declines 
and other mechanisms (e.g., oxidative stress, inflammation, and apoptosis) lead to 
AD symptoms.  
 
2.3.2.1   Amyloid plaques 
 
The amyloid hypothesis of AD represents the reigning theory of AD development, 
and provides the foundation for nearly all current and emerging treatment 
strategies. According to the theory, AD is the consequence of an imbalance 
between Aβ clearance and production, which causes amyloid plaques to aggregate 
at the synapses between neurons, setting off a cascade of neurological and 
cognitive consequences (see Figure B) 34. One of the primary events in this 
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“amyloid cascade” is the blockade of impulses across the synaptic cleft, which 
interferes with cognitive processing. Of the various types of neurons in the brain, 
those in the cholinergic system seem particularly vulnerable to the effects of 
amyloid plaques, and are thus among the first to die in the presence of this 
pathology 38. 
 
As stated, the amyloid hypothesis of AD regards an imbalance between Aβ 
clearance and production as the central event in AD development. It is important 
to note, however, that there are two forms of the Aβ peptide (Aβ-40 and Aβ-42), 
both of which are produced from the amyloid precursor protein (APP), but only 
one of which (Aβ-42) is associated with plaque formation. In the case of familial 
AD, the production of Aβ-42 appears to be elevated, thereby increasing the 
likelihood of plaque development. With regard to late-onset AD, however, 
reduced clearance of Aβ-42 appears to be the primary contributor to plaque 
formation. Of note, there is also evidence that CVD inhibits Aβ clearance in the 
brain, which could explain how CVD exacerbates underlying AD pathology in 
patients with mixed dementia 34. Regardless of which mechanism is at play, 
strategies that correct the imbalance of Aβ clearance and production may have the 
potential to modify AD progression 39.  
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Figure B. Amyloid cascade hypothesis 34 
 
 
 
2.3.2.2.  Neurofibrillary tangles 
 
Neurofibrillary tangles (NFTs) represent the second hallmark AD pathology, but 
are thought to play a predominant role only at the later stages of disease. 
Composed of aggregated tau proteins, NFTs are thought to disrupt intracellular 
transport, rendering neurons unable to transport trophic factors from their 
synapses back to the cell body. Because trophic factors are essential for survival, 
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the intracellular disruptions induced by NFTs may cause neurons to die, thereby 
impairing a patient’s ability to process environmental stimuli and/or form or 
retrieve encoded memories. Experts are divided as to whether the NFTs represent 
a downstream event in the “amyloid cascade” or whether NFT formation is the 
initiator of AD pathogenesis 40,41.  
 
2.3.2.3   Cholinergic deficits 
 
A deficit in cholinergic neurons is a well-recognized consequence of AD 
pathology, as Aβ plaques appear to preferentially attack the cholinergic system. 
As a result of this cholinergic deficit, neurodegeneration may be triggered in the 
serotonergic and noradrenergic systems as well, thereby leading to depression, 
psychosis, and other behavioral sequelae 42. The currently available AD drugs 
strive to compensate for the loss of cholinergic neurons by reducing levels of an 
enzyme that destroys acetylcholine (ACh), which is depleted in the brains of AD 
patients. Unfortunately, it becomes impossible to achieve sufficient ACh levels 
once a certain number of cholinergic neurons have died. In addition, because the 
degree of cholinergic decline varies widely across patients, the benefits of 
elevating ACh levels are also highly variable 43. 
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2.3.2.4   Genetics 
 
Early-onset, familial AD, which accounts for only a small portion of all AD cases, 
has been linked to three genes, including the gene for APP and those for two 
presenilins (PS1 and PS2) that are involved in the cleavage of APP to produce the 
Aβ peptide. The finding that mutations in any of these genes can lead to an 
increase in Aβ-42 formation lends support to the amyloid hypothesis of AD. It 
also suggests that targeting the APP processing pathway and/or Aβ aggregation 
may have disease-modifying effects 34. 
 
2.3.2.5   NMDA receptors, glutamate, and oxidative stress 
 
Oxidative stress has been implicated in the pathogenesis of a number of diseases, 
including AD and other dementias. In AD, the increase in oxidative stress is 
attributed to an elevation in calcium concentrations between neurons, which is 
brought about by excessive glutamate release and an overactivation of N-methyl-
d-aspartate (NMDA) receptors. Under normal conditions, glutamate is transferred 
from presynaptic neurons to postsynaptic neurons, where it binds to NMDA 
receptors and allows calcium to pass. When the amount of glutamate released 
from presynaptic neurons is excessive, however, the NMDA receptors become 
overly excited, and the intraneuronal calcium levels rise to toxic concentrations. It 
is this process that occurs in the brains of AD patients, triggering mitochondrial 
damage, oxidative damage, and cell death. The NMDA receptor antagonist 
memantine was developed to prevent calcium toxicity by blocking overly active 
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NMDA receptors. Antioxidants represent another potential therapeutic strategy 
based on the role of oxidative damage in AD and other dementia disorders 44.  
 
2.3.3   Vascular Dementia – pathophysiology 
 
Among patients with VaD, cognitive impairments can be initiated by a variety of 
cerebrovascular events, including multiple large infarcts, single strategic infarcts, 
small vessel disease, and hypoperfusion. In rare cases, the dementia may arise 
solely as a result of a cerebrovascular injury. More frequently, however, it is a 
combination of vascular and AD pathologies that give rise to the cognitive 
deficits. Thus, there is often a degree of uncertainty as to whether the 
cerebrovascular insult is the root cause of a patient’s dementia, a contributor 
underlying degenerative decline, or an unrelated event. In addition, because 
several pathophysiological mechanisms may contribute to VaD, it can be difficult 
to tease out which is the primary etiology or whether the effects of various 
neuropathologic changes are additive 14,15. 
 
2.3.3.1   Multiple large infarcts 
 
The occurrence of multiple large-vessel occlusions, whether located in cortical or 
subcortical areas, almost inevitably triggers cognitive symptoms. While such 
symptoms are usually transitory, they may persist in a subset of patients, leading 
to constant or progressive cognitive decline. These cases, which are typically 
characterized by an abrupt onset, stepwise progression, and variable cognitive 
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deficits, are usually diagnosed as multi-infarct dementia, suggesting that the 
dementia is directly attributed to the index stroke 4. Importantly, the cognitive 
deficits in multi-infarct dementia patients appear to become more widespread with 
stroke recurrence, which reinforces the value of secondary prevention strategies in 
this population 15.  
 
The mechanism by which infarcts may lead to dementia is usually attributed to 
reduced blood flow (hypoperfusion) in the brain 45. According to this theory, the 
infarcts generate hypoperfusion, which can then trigger dementia either directly, 
by initiating neuronal cell death, or indirectly, by increasing Aβ peptide 
production and contributing to amyloid plaques 46. Related to these phenomena, it 
appears that stroke may cause significant changes in the cholinergic system, as 
cholinergic tracts are located in several brain regions (e.g., the hippocampus and 
subcortical white matter) that are particularly vulnerable to ischemic insult 47.  
 
2.3.3.2   Single strategic infarcts 
 
Like multiple large infarcts, small single infarcts may also lead to dementia, but 
only if the focal lesion is strategically localized in a functionally important brain 
region. The specific manifestations of VaD following strategic infarcts are highly 
variable, but may be predicted by the cognitive functions controlled at the site of 
ischemic damage (see Table 1). As with multi-infarct dementia, the onset of 
dementia following a strategic infarct is typically abrupt with a stepwise 
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progression. There is some evidence, however, that the cognitive deficits 
associated with strategic infarcts may be reversible, with less persistence over 
time 4,15. 
 
Table 1. Manifestations of dementia according to location of strategic infarct 14 
 
Location of Infarct Clinical Manifestations 
Angular gyrus • Acute onset of fluent aphasia 
• Alexia with agraphia 
• Memory deficit 
• Spatial disorientation 
• Constructional impairment 
Posterior cerebral artery • Amnesia 
• Psychomotor agitation 
• Visual hallucinations 
• Confusion 
• Visual impairment 
Anterior cerebral artery • Abulia 
• Transcortical motor aphasia 
• Memory deficit 
• Dyspraxia 
Basal forebrain • Severe amnesia 
• Behavioral changes 
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2.3.3.3   Small vessel disease 
 
Small vessel disease may cause both cortical and subcortical lesions, including 
lacunes and white matter insults commonly associated with aging. Given that 
small vessel disease often occurs in otherwise healthy individuals, this form of 
CVD has historically been considered benign, and in isolation, seems unlikely to 
trigger pervasive, severe dementia. A growing body of research, however, 
suggests that white matter abnormalities on MRI may signal more significant 
CVD (e.g., focal and diffuse lesions in cortical and subcortical areas; lacunes and 
microinfarcts in the central gray matter), which could lead to more widespread 
cognitive dysfunction and a two-fold increase in dementia risk 4,15.  
 
Because patients with small vessel disease do not often experience stroke, their 
cognitive decline is usually attributed to a disruption in the connections between 
subcortical structures and the frontal cortex. The resulting constellation of 
symptoms, which include deficits in memory and executive functioning, as well 
as psychomotor retardation, neurologic signs, speech problems, and 
mood/personality changes, is sometimes referred to as “subcortical dementia 
syndrome.” This subtype of VaD is typically characterized by an insidious onset 
and slow progression, which stands in stark contrast to the abrupt onset and step-
wise course associated with infarct-related VaD 4,14,15. 
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2.3.3.4   Lacunar strokes 
 
VaD attributed to lacunar stroke represents a sub-category of VaD with small 
vessel disease. In these cases, blood flow becomes cut off from the brain because 
of a blockage in the tiny blood vessels located in the deep white matter. As with 
strategic infarcts, the site of lacunar stroke is a major determinant of clinical 
presentation, with frontal white matter lacunes frequently leading to executive 
dysfunction and lacunes of the basal ganglia and pons often triggering 
pseudobulbar palsy. Unique characteristics of lacunar VaD include multifocal 
motor, reflex, and sensory disturbances 14,15 
 
2.3.3.5   Leukoaraiosis 
 
Leukoaraiosis is a cerebrovascular condition, recently identified as a cause of 
cognitive impairment. Based on research findings, the cognitive correlates of 
leukoaraiosis seem to resemble those of subcortical VaD, including frontal 
impairments and executive dysfunction. The speed at which leukoaraiosis 
progresses may be a major determinant of the rate of cognitive decline. Given that 
patients with more severe leukoaraiosis progress at faster speeds, researchers have 
suggested that the cognitive benefits of slowing leukoaraiosis progression may be 
greatest in the more severe subgroups 48. 
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2.3.3.6   CADASIL 
 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) is an inherited non-amyloid form of small-
vessel disease that has been linked to cognitive impairment and dementia 49. The 
clinical presentation of CADASIL, which has been identified as the first genetic 
form of VaD, is variable, but usually marked by recurrent subcortical strokes, 
which are accompanied by cognitive deficits and psychiatric symptoms 50. The 
mean age of symptom onset of CADASIL in a pooled analysis of 105 published 
cases was 37 years 51. Diagnoses are based on genetic testing and magnetic 
resonance imaging (MRI) findings 4.  
 
2.3.3.7   Hypertension 
 
Although the link between VaD and hypertension is somewhat controversial, some 
evidence suggests that cognitive impairment may be more frequent in hypertensive 
individuals. There are three mechanisms by which hypertension may contribute to 
cognitive decline. First, it has been suggested that hypertension induces a shift in 
the cerebral blood flow autoregulation curve, leading to tissue infarction and related 
cognitive deterioration. Second, hypertension has been shown to induce changes in 
the vessel wall, thereby triggering a cascade in which protein extravasion into brain 
parenchyma leads to brain edema and eventually, neuronal death and lacunae 
formation. Finally, myelin loss has been identified as potential mediator of the 
association between hypertension and cognitive decline 15. 
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2.3.3.8   Hemorrhagic lesions 
 
VaD may also arise from hemorrhagic lesions, such as chronic subdural 
hematoma, subarachnoid hemorrhage, and cerebral hematoma 14. 
 
2.3.3.9   Cerebral amyloid angiopathy 
 
Cerebral amyloid angiopathy (CAA) is a condition in which fibrillar amyloid 
replaces the normal wall of arterioles in the brain, thereby rendering the vessels 
vulnerable to rupture and subsequent cerebral hemorrhage. According to autopsy 
data, some degree of CAA is present in the vast majority of AD patients, 
suggesting that it has contributed to cognitive decline. Another, albeit rarer, 
consequence of CAA is vasculitis, which is often characterized by seizures and 
rapid cognitive deterioration. Given the association between CAA and cognitive 
decline, it has been speculated that severe CAA represents a subtype of VaD. 
Findings of severe CAA in 8-10% of persons at high risk for VaD have been used 
to support this hypothesis 4. 
 
2.3.3.10   Cholinergic deficits 
 
Loss of neurons in the cholinergic system has been reported in patients with VaD 52, 
and may be associated with VaD even in the absence of AD pathology 53. Evidence 
for an independent link between VaD and deficits in the cholinergic system have been 
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found in experimental, clinical, and pathologic studies 7. In addition, benefits of 
cholinesterase inhibitors have been found in VaD patients, providing even more 
support for a VaD-associated cholinergic deficit 15.   
 
2.3.4   Mixed Dementia – pathophysiology  
 
Mixed dementia reflects the co-occurrence of multiple dementia pathologies, but 
is most often used to describe patients in whom AD and VaD pathologies overlap 
(see Table 2) Because research into the mechanisms of mixed dementia is lacking, 
it is not currently known whether the condition stems from the additive effects of 
AD and VaD pathologies, or whether CVD interacts with AD pathology to 
exacerbate the underlying degenerative dementia 15.  
 
What is known is that rates of CVD and AD both increase with age, and that the 
two conditions frequently co-occur in patients aged ≥85 years. Thus, while it is 
possible that AD causes CVD, or vice versa, it is equally likely that AD and CVD 
are simply simultaneous consequences of the aging process. Regardless of which 
is true, the combination of vascular and degenerative components appears to 
trigger a substantial increase in the rate of cognitive decline. Beyond the speed of 
progression, however, the course of mixed dementia may be highly variable, 
depending on the type of contributing vascular pathology 4,54. 
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Table 2. Prevalence of AD- and VaD-associated pathologies in patients with 
clinical diagnoses of AD and VaD 55 
 
Pathologic feature AD VaD  
CAA 98% 30% 
Microvascular degeneration 100% 30% 
AD-associated 
pathologies 
Loss of cholinergic markers 70% 40% 
CAA-related intracerebral 
hemorrhage 
7% 15% 
Infarctions 36% 100% 
Microinfarcts 31% 65% 
VaD-
associated 
pathologies 
White matter pathology 35% 70% 
 
2.3.5   Vascular Cognitive Impairment – pathophysiology  
 
Because vascular cognitive impairment (VCI) encompasses both vascular 
dementia (VaD) and mixed dementia, its pathological features are essentially the 
same as those discussed above. The inclusion of subthreshold dementia in the 
definition of VCI, however, raises the question of how much vascular pathology 
is sufficient to cause cognitive impairment. In particular, research has shown that 
infarcts occur in fewer than 50% of VCI cases, suggesting that the presence of 
infarcts is not essential for VCI development. By contrast, extensive leukoaraiosis 
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has been documented in 30-65% of VaD cases, which raises the possibility that 
even minor leukoariaosis could contribute to VCI of lesser severity 54.  
 
2.3.6  Mild Cognitive Impairment – pathophysiology  
 
Conceptually, mild cognitive impairment (MCI) may represent either a benign 
consequence of aging or the earliest manifestation of a dementia syndrome. If 
attributed to the normal aging process, no specific pathological features would be 
expected. As an early sign of dementia, however, the potential etiology could be 
degenerative, vascular, psychiatric, or medical in nature, and it is the clinician’s 
responsibility to determine the most probable cause based on history or clinical 
features (see Table 3). If the features are consistent with a degenerative etiology, 
it is likely that AD pathology underlies the patient’s cognitive decline. In cases 
with a presumed vascular etiology, VaD is the most likely outcome, and CVD is 
the most probable cause. Autopsy data seem to confirm these hypotheses, as 
patients with MCI have shown intermediate levels of both AD and VaD 
pathology, relative to normal controls and dementia patients 33,56.  
 
 
Table 3. Features associated with potential etiologies of MCI 33 
 
Presumed Etiology Characteristic Features 
Degenerative (AD) Gradual onset 
Insidious progression 
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Presumed Etiology Characteristic Features 
Vascular (VaD) Abrupt onset 
Vascular risk factors 
History of strokes 
Transient ischemic attacks  
Psychiatric History of depression 
Depressed mood 
Anxiety 
Medical Congestive heart failure 
Diabetes 
Systemic cancer 
 
 
2.4   PATIENT ASSESSMENT 
 
2.4.1   Canadian Consensus Conference on Dementia (CCCD) guidelines 
  
Given the complexity and heterogeneity of the dementia disorders, a thorough 
assessment is required for proper diagnosis. In Canada, the assessment and 
diagnosis of dementia is guided by recommendations established at the 1998 
Canadian Consensus Conference on Dementia (CCCD), led by experts from the 
fields of family medicine, neurology, preventive healthcare, geriatric medicine, 
and psychiatry. The CCCD recommendations, which were based on research 
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evidence, specify that dementia diagnoses must be based on a detailed history and 
physical examination, combined with office-based tests (e.g., the Mini-Mental 
State Examination [MMSE]), measures of instrumental functioning (e.g., the 
Functional Assessment Questionnaire), and, in some cases, neuroimaging (see 
Table 4). In addition, the CCCD recommendations call for serial assessments to 
be conducted at intervals of three to six months, as these may be necessary to 
confirm progression and establish clinical prognosis 17.  
 
Table 4. CCCD consensus recommendations for assessment of dementia 17 
 
Topic Recommendations 
Laboratory 
Tests 
Basic laboratory work-up should be conducted, including: 
• complete blood count, 
• thyroid stimulating hormone 
• serum electrolytes 
• serum calcium 
• serum glucose 
Extensive laboratory testing not needed, except when 
presentation suggests delirium or a particular reversible cause. 
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Topic Recommendations 
Neuroimaging CT has a role in detecting certain causes of dementia (e.g., 
VaD) and should be performed when any of the following 
criteria are met: 
• age <60 years 
• rapid cognitive or functional decline 
• duration of dementia <2 years 
• recent/significant head injury 
• neurological symptoms of unknown origin 
• history of cancer 
• anticoagulant use or history of bleeding disorder 
• presence of urinary incontinence and gait disorder in the 
early stage of dementia 
• any new localizing sign 
• atypical features (e.g., progressive aphasia) 
• gait disturbance 
 
MRI offers no benefits over CT in most cases. 
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Topic Recommendations 
Ancillary 
Tests 
There is insufficient evidence to support routine use of ancillary 
tests such as: 
• PET, SPECT, or functional MRI 
• MRI hippocampal volumes 
• Reaction time measures 
• EEG with power spectral analysis 
• Sleep EEG 
• Cognitive evoked potentials 
• Genetic/neurochemical testing for ApoE genotype, CSF 
tau or beta-amyloid fragments 
 
 
2.4.2   Assessment Tools 
 
2.4.2.1   The Mini-Mental State Examination (MMSE) 
 
Among the various tools used in dementia assessment, the Mini-Mental State 
Examination (MMSE) 57,58 stands out as one of the most frequently used and 
important, particularly in Canada, where reimbursement for anti-dementia drugs 
is based on MMSE scores. Developed as a simple and practical alternative to 
lengthy cognitive batteries, the MMSE includes only 11 questions and requires 
only five to 10 minutes to administer and score. Its focus is on the cognitive 
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aspects of mental functioning, such as memory, orientation, attention, and 
language, which the clinician assesses by asking the examinee to vocally answer 
questions (e.g., “what is today’s date?”) or complete various tasks (e.g., write a 
sentence, copy a design, or spell “WORLD” backwards). Items addressing mood 
and thought processes, which are typically included in lengthier cognitive 
measures, are specifically excluded from the MMSE assessment 57. 
 
In clinical practice, the MMSE is typically used to assess dementia severity, as it 
provides a valid system for differentiating between different levels of impairment 
and tracking changes in cognition over time (see Table 5). In Quebec, clinicians 
must document an MMSE score of 10-26 on the 30-point scale, which 
corresponds to mild or moderate cognitive impairment, in order to obtain 
reimbursement for approved AD treatments. The rationale for categorizing 
dementia as mild, moderate, or severe stems from the observation that certain 
therapies may only be effective at certain disease stages. Once a patient has 
reached severe dementia, as evidenced by an MMSE score of <10, many drugs 
are considered to be ineffective, and thus not reimbursable under Quebec’s 
healthcare system. 
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Table 5. Stages of dementia progression, by MMSE score and corresponding 
disability level 19,21,59 
 
Stage MMSE Range Level of Disability 
Mild 18-26 Minimal impairment in work or social activities 
Relatively intact judgment 
Appropriate personal hygiene 
Capacity for independent living despite some 
cognitive problems 
Possible depression 
No psychotic symptoms 
Moderate 10-17 Independent living is hazardous 
Need for assistance with self care 
Possible wandering 
Difficulty recognizing family and friends 
Apparent agitation and psychotic behavioral 
symptoms 
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Stage MMSE Range Level of Disability 
Severe 0-9 Need for assistance with almost all daily activities 
Increased frequency and severity of behavioral 
symptoms 
Possibility of being bed-ridden, mute, and/or 
unaware of surroundings 
Frequently fatal accidents and infections 
 
2.4.2.2   Alternatives to the MMSE 
 
Although the MMSE has proven to be valid and reliable for testing general 
cognitive function 57, it has been criticized for being insensitive to executive 
dysfunction and failing to identify subclinical cognitive deficits 60,61. The 
Canadian Study of Health and Aging (CSHA) attempted to address the limitations 
of the MMSE by using the Modified Mental Status (3MS) as a screen for 
dementia, but ultimately failed to establish the usefulness of either measure for 
identifying early cognitive decline 61. Other researchers have proposed that the St. 
Louis University Mental Status Examination may be a better alternative for 
detecting dementia in its earliest stages 37. In addition, the Montreal Cognitive 
Assessment (MoCA) tool was developed specifically to detect mild cognitive 
impairment that may progress to dementia, and has been shown to have greater 
sensitivity to detect mild cognitive impairment than the MMSE 62. 
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In addition to the MMSE and 3MS, a number of other measures are commonly 
used to assess the impact of dementia on various aspects of functioning, and to 
track changes over time (see Table 6). For detecting cognitive change, the 
Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) 63,64 is 
frequently used in clinical trials, whereas the Clinician’s Interview-Based 
Impression of Change-Plus caregiver input (CIBIC-Plus) 65 has become a popular 
tool for evaluating overall response to treatment. Another frequently used 
instrument is the Clinical Dementia Rating (CDR), which provides a global score 
and a summary rating (sum of box score: CDR-SB) for the domains of memory, 
orientation, judgment, community affairs, home/hobbies, and personal care 66,67. 
More detailed neuropsychological evaluations may include specific tests for 
memory, abstract thinking, judgment, aphasia, apraxia, agnosia, and construction 
2. Finally, evaluations of behavioral changes and psychiatric symptoms may be 
indicated to identify related areas of impairment.  
 
The assessment of activities of daily living (ADLs) usually relies on caregiver 
input regarding the patient’s ability to perform basic tasks (e.g., dressing, 
washing, and personal grooming), as well as instrumental activities (e.g., 
shopping, preparing food, using the telephone, and housekeeping). Instruments 
such as the Alzheimer’s Disease Functional Assessment and Change Scale 
(ADFACS) 68 and the Disability Assessment for Dementia (DAD) 69 provide 
valuable scoring systems for both basic and instrumental ADLs. Measures of 
39 
 
instrumental ADLs are often considered to be reliable surrogates for the 
assessment of executive function 16.  
 
 
Table 6. Commonly used instruments in the assessment of dementia 
 
Domain of 
Assessment 
Popular Instrument Citation(s) 
Mini-Mental State Examination (MMSE) 57,58 
Alzheimer’s Disease Assessment Scale – 
cognitive subscale (ADAS-cog) 
63,64 
Cognition 
Modified Mental Status Examination 
(3MS) 
70 
Clinician’s Interview-Based Impression of 
Change-Plus caregiver input (CIBIC-Plus) 
65 
Functional Assessment Questionnaire 
(FAQ) 
71,72 
Blessed Dementia Scale 73 
Clinical Dementia Rating – Sum of the 
Boxes (CDR-SB) 
66,67 
Functional Rating Scale 74 
Global functioning 
Global Deterioration Scale 75 
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Domain of 
Assessment 
Popular Instrument Citation(s) 
Hamilton Rating Scale for Depression 
(HAM-D) 
76 
 
Neuropsychiatric Inventory (NPI) 77 
Cornell Scale for Depression 78 
Geriatric Depression Scale 79 
Psychiatric 
symptoms 
Present State Examination 80 
Alzheimer’s Disease Functional 
Assessment and Change Scale (ADFACS) 
68 Activities of Daily 
Living (ADLs) 
Disability Assessment for Dementia 69 
 
 
2.4.3   Neuroimaging Tests 
 
The role of neuroimaging in the assessment and diagnosis of dementia has been 
extensively debated, with the general consensus being that neuroimaging should 
play an ancillary role in the evaluation process. Magnetic resonance imaging 
(MRI) and computerized tomography (CT) represent two frequently used 
instruments for identifying infarcts and other brain abnormalities that may 
contribute to cognitive impairment. Other potentially useful strategies include 
positron emission tomography (PET), single-photon emission computer 
technology (SPECT), and magnetic resonance spectrometry, each of which has 
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demonstrated an ability to distinguish AD from VaD patients. Within the VaD 
population, diffusion weighted imaging (DWI) and diffusion tensor imaging 
(DTI) have exhibited promise in tracking longitudinal changes. With DWI in 
particular, researchers may be able to detect recent small infarcts associated with 
small vessel disease, even before patients begin to exhibit cognitive decline 15. 
 
2.5   CLINICAL DIAGNOSIS 
 
2.5.1   Dementia – diagnosis  
  
The diagnosis of dementia is a complex process, beginning with the identification 
of cognitive decline and ending with a hypothesis about its probable cause. The 
first step is usually to determine that cognitive impairment exists, and to establish 
that the impairment represents a deterioration from previous functioning. Once 
cognitive impairment has been established, it is important to assess the severity of 
the dementia, to specify which cognitive domains and areas of functioning have 
been most affected, and to rule out potentially reversible causes (e.g., AIDS or 
hypothyroidism). The pattern of symptoms and course of decline must be assessed 
both retrospectively and prospectively over time, as features of disease 
progression may be helpful in differential diagnosis (e.g., AD vs. VaD vs. 
frontotemporal dementia). Ultimately, however, the accuracy of a clinical 
diagnosis cannot be confirmed while a patient is still alive, as the detection of 
pathological features (e.g., amyloid plaques and NFTs) requires autopsy 
examination. Because of this limitation, it is essential to collect as much 
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information as possible to support a specific diagnosis. Tools such as 
neuroimaging and laboratory tests may be useful in this process 34. 
 
2.5.1.1   The problem of underdiagnosis  
 
Given the clinical and pathophysiological heterogeneity of dementing diseases, it 
is perhaps not surprising that diagnoses are often missed in community settings. 
Family members rarely recognize memory impairments before the dementia 
reaches moderate severity, often dismissing subtle declines as part of the natural 
aging process and/or denying symptoms due to fear of an AD diagnosis. 
Compounding the problem, community physicians may fail to render a correct 
diagnosis in as many as 50% of patients who meet standard dementia criteria, 
which suggests that greater education is needed at both the public and 
professional levels regarding dementia and its proper diagnosis 37. 
 
2.5.1.3   Potential biomarkers 
 
Although diagnoses of dementia are currently behaviorally based, researchers are 
actively searching for biomarkers that may facilitate early detection. Among such 
potential surrogates, cerebrospinal fluid (CSF) levels of total tau, phosphorylated 
tau, and Aβ42 have all shown accuracy in differentiating AD from normal aging, 
but appear to be far less useful in distinguishing AD from other forms of 
dementia. A more promising alternative involves the use of Aβ plaque imaging 
techniques, such as Pittsburgh Compound B, which would allow researchers to 
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view AD pathology in the living human brain 34. Experts are hopeful that this 
strategy may allow AD to be detected at earlier stages, thereby promoting more 
effective therapeutic intervention 81.  
 
2.5.2   Alzheimer’s Disease – diagnosis  
 
As stated, the second step of dementia diagnosis involves reaching an informed 
conclusion about its most probable cause. In this process, all of the data collected 
during clinical, neurological, and psychiatric examinations are analyzed and 
compared with standard diagnostic criteria.  
 
2.5.2.1   NINCDS-ADRDA Criteria for AD 
 
The most commonly used system for diagnosing AD is that set forth in 1984 by 
the National Institute of Neurological and Communicative Diseases and Stroke 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA), which provides guidelines for identifying possible, probable, and 
definite AD (see Table 7). Noteworthy features of this diagnostic system include 
the emphasis placed on course variables (e.g., insidious onset and progressive 
decline), as well as the importance given to ruling out other identifiable causes 21.  
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Table 7. NINCDS-ADRDA criteria for diagnosis of probable AD 21 
 
Criteria 
required for 
diagnosis 
• Dementia, established by clinical examination and 
neuropsychological tests 
• Deficits in ≥2 cognitive domains 
• Progressive decline in memory and other cognitive functions 
• No disturbance of consciousness 
• Onset at age 40-90 years (usually at age >65 years) 
• No evidence of systemic disease or other brain disorders that 
could be sole cause of cognitive impairment 
Criteria that 
support 
diagnosis 
• Progressive decline in specific cognitive domains: language, 
motor skills, and perception 
• Impairments in behavior and daily functioning 
• Family history of cognitive impairment 
• Laboratory results: normal lumbar puncture, normal or 
nonspecific EEG findings, CT evidence of cerebral atrophy 
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Features 
consistent 
with 
diagnosis 
(after 
exclusion of 
other causes) 
• Plateaus in disease progression 
• Associated behavioral and psychiatric symptoms (e.g., 
depression, delusions, insomnia) 
• Motor signs (e.g., increased muscle tone, myoclonus, gait 
disorder) in advanced disease 
• Seizures in advanced disease 
• Normal CT for age  
Features that 
make 
diagnosis 
uncertain or 
improbable 
• Sudden onset 
• Focal neurologic signs (e.g., hemiparesis, sensory loss, visual 
field deficits, incoordination) in early disease 
• Seizures or gait disturbance in early disease 
 
Although the NINCDS-ADRDA criteria are widely used in clinical and research 
settings 82,83, they have been criticized for having a relatively low diagnostic 
accuracy, as well as imprecise specifications for evidence of mixed dementia. To 
some extent, the low accuracy rates may be inevitable, as there will always be 
some degree of uncertainty in diagnoses made prior to death. At the same time, 
however, the failure of the NINCDS-ADRDA to address the impact of 
concomitant CVD is a noteworthy weakness, as it may hamper accurate 
differential diagnosis. Because no thresholds for vascular pathology have been 
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set, there has been little consistency in how clinicians and researchers distinguish 
between AD and mixed dementia 34.  
 
To address such shortcomings in the original NINCDS-ADRDA criteria, a 
working group at the Second Congress of the International Society for Vascular 
Behavioural and Cognitive Disorders (Vas-Cog) developed revised diagnostic 
criteria 81. The revised criteria, published in 2007, no longer refer to a dementia 
threshold, and instead attempt to identify AD on the basis of clinical, biochemical, 
structural, and metabolic features (see Table 8). Using these criteria, AD can be 
diagnosed even in its early, predementia stages following objective evidence of 
significantly impaired memory, presence of hippocampal atrophy on MRI, an 
abnormal pattern of CSF biomarkers, or a specific pattern on PET neuroimaging. 
 
 
Table 8. Revised Vas-Cog diagnostic criteria for AD 81 
 
Probable AD A plus one or more supportive features B, C, D, or E 
Core diagnostic 
criteria 
A. Presence of an early and significant episodic memory 
impairment that includes the following features: 
1. Gradual and progressive change in memory function 
reported by patients or informants over >6 months 
2. Objective evidence of significantly impaired episodic 
memory on testing 
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3. Episodic memory impairment can be isolated or 
associated with other cognitive changes at the onset of AD or 
as AD advances 
B. Presence of medial temporal lobe atrophy 
• Volume loss of hippocampi, entorhinal cortex, amygdala 
evidenced on MRI 
C. Abnormal cerebrospinal fluid biomarker 
• Low amyloid β1–42 concentrations, increased total tau 
concentrations, increased phospho-tau concentrations, or 
combinations of the three 
• Other well validated markers to be discovered in the 
future 
D. Specific pattern on functional neuroimaging with PET 
• Reduced glucose metabolism in bilateral temporal 
parietal regions 
• Other well validated ligands, including those that 
foreseeably will emerge 
Supportive 
features 
E. Proven AD autosomal dominant mutation within the 
immediate family 
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History 
• Sudden onset 
• Early occurrence of gait disturbances, seizures, 
behavioral changes 
Clinical features 
• Focal neurological features including hemiparesis, 
sensory loss, visual field deficits 
• Early extrapyramidal signs 
Exclusion criteria 
Other medical disorders severe enough to account for 
memory and related symptoms 
• Non-AD dementia 
• Major depression 
• Cerebrovascular disease 
• Toxic and metabolic abnormalities 
• MRI FLAIR or T2 signal abnormalities in the medial 
temporal lobe consistent with infectious or vascular 
insults 
Definite AD • Both clinical and histopathological (brain biopsy or 
autopsy) evidence of the disease, as required by the NIA-
Reagan criteria for the post-mortem diagnosis of AD 84 
• Both clinical and genetic evidence (mutation on 
chromosome 1, 14, or 21) of AD 
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2.5.2.2   DSM-IV Criteria for AD 
 
The Diagnostic and Statistics Manual-Fourth Edition (DSM-IV) provides an 
alternative approach to diagnosing AD, and was actually used in combination 
with the NINCDS-ADRDA in the second wave of the Canadian Study of Health 
and Aging (CSHA) 83. Like the NINCDS-ADRDA, the DSM-IV requires 
evidence of memory impairment as well as progressive cognitive decline. The 
primary difference between the two systems seems to lie in the DSM-IV’s failure 
to differentiate between criteria that are definitive vs. supportive of an AD 
diagnosis. For example, while the NINCDS-ADRDA considers functional 
impairment to be supportive of AD, the DSM-IV makes this an essential feature 
of the disease 19.  
 
2.5.2.3   ICD-10 Criteria for AD 
 
The International Statistical Classification of Diseases, 10th Revision (ICD-10) 
criteria for AD resemble those of the DSM-IV in that they do not outline levels of 
evidence supporting diagnosis. According to the ICD-10, a definite diagnosis of 
AD can made in all cases with an insidious onset and slow deterioration of 
dementia, provided that evidence of focal neurological signs and systemic causes 
(e.g., hypothyroidism) are absent. The ICD-10 definition of dementia includes 
deficits in both memory and “thinking,” as well as functional impairment and a 
duration of illness of at least six months 20. 
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2.5.2.4   Neuropathologic criteria 
 
Because the presence of AD can be validated only after death, criteria for 
establishing definitive neuropathologic diagnoses are of utmost importance. 
Among the most commonly used neuropathologic systems, the Consortium to 
Establish a Registry for AD (CERAD) recommends that diagnoses of possible, 
probable, and definite AD be based on semiquantitative estimates of amyloid 
plaques. By contrast, recommendations from the National Institute of Aging 
(NIA)-Reagan Institute Working Group suggest that estimates of plaques are not 
enough, and thus specify that the estimated NFT burden must also be considered 
to establish an AD diagnosis 84.  
  
2.5.3   Vascular Dementia – diagnosis  
  
Diagnostic criteria for VaD have been evolving over the past 20 years, and 
continue to generate controversy in the clinical and research communities. When 
first recognized, definitions of VaD resembled those of AD, and thus may have 
over-emphasized the importance of memory and learning deficits. In more recent 
years, experts have begun to recognize that VaD is often characterized by declines 
in non-memory cognitive domains, and that a lack of memory impairment may 
not preclude a VaD diagnosis. As a result of such discoveries, the methods 
conventionally used to identify VaD are being re-evaluated.  
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As with AD, strategies for VaD diagnosis have historically relied on a two-stage 
process of first identifying dementia and then differentiating between subtypes. 
Because the initial detection of dementia was based primarily on AD features, 
only VaD patients with AD characteristics (i.e., memory impairment) were 
considered for diagnosis. Use of this strategy in research settings may have 
artificially magnified the similarities between VaD and AD patients, while 
simultaneously creating VaD populations with a disproportionately high number 
of mixed dementia cases. Clinically, many VaD cases may have been missed 
because they did not resemble AD dementia, thereby precluding opportunities for 
optimal treatment. The newer methods for diagnosing VaD, including the 
popularization of the VCI concept, reflect an increased awareness of the co-
occurrence of AD and VaD, as well as an attempt to identify VaD patients with 
non-AD presentations 4,54. 
 
Clinically, patients with VaD and AD may have similar presentations, supporting 
an overlap between VaD and AD pathologies. The “classic” VaD syndrome, 
however, is marked by several differences from AD (see Table 9), including a 
relative preservation of memory function, a more abrupt onset of illness, and 
higher frequencies of mood changes and gait impairment early in the disease. In 
addition, the course of cognitive decline in VaD may be stepwise or fluctuating, 
in contrast to the characteristically progressive decline seen in AD patients. These 
features are often cited in diagnostic criteria as supporting a VaD diagnosis 
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Table 9. Distinguishing characteristics of VaD and AD 15 
 
Feature VaD AD 
Onset Sudden or gradual Gradual 
Progression Slow, step-wise Insidious, progressive 
Focal neurological 
signs/symptoms 
Present Usually absent 
Memory Mild deficits Early and severe 
impairment 
Executive function Early and severe 
impairment 
Late deficits 
Vascular risk factors Strokes, transient 
ischemic attacks (TIAs) 
Less common 
Modified Hachinski 
score 
>7 <4 
Neuroimaging Infarcts, white matter 
lesions 
Normal, hippocampal 
atrophy 
 
 
At present, several systems exist for diagnosing VaD patients, all of which are 
based on a presumed link between co-existing CVD and dementia. While the 
importance of this link is not debated, questions remain regarding how it should 
be established. For example, even though most systems require that the onset of 
dementia occur within a certain time period after cerebrovascuar injury, others 
regard this temporal association as too restrictive, particularly in cases arising 
from non-infarct-related injury. Related to this debate, controversy exists over 
neuroimaging criteria for CVD, as some experts worry that cases of non-infarct-
related VaD will be overlooked if neuroimaging evidence is required. Proponents 
of VCI favor broadening the concept of VaD to include more types of vascular 
pathology. Others advocate the development of separate, more specific criteria 
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that may be tailored to either infarct-related VaD or VaD secondary to other 
vascular causes 4. 
 
2.5.3.1   Hachinski Ischemic Scale  
 
The Hachinski Ischemic Scale (HIS) represents one of the first attempts to 
distinguish VaD from AD. Geared toward the diagnosis of multi-infarct dementia, 
the original version of HIS asked clinicians to rate patients’ conformity with 13 
features thought to be associated with VaD. A newer, modified version retains 8 
of the 13 original criteria (see Table 10), with the resulting score intended to 
reflect the likelihood that a patient’s dementia has a vascular origin 15.  
 
Table 10. Modified Hachinski Ischemic Scale* 15 
 
Feature Score 
Abrupt onset 0 or 1 or 2 
Stepwise deterioration 0 or 1 
Somatic complaints 0 or 1 
Emotional lability 0 or 1 
History of hypertension 0 or 1 
History of stroke 0 or 1 or 2 
Focal neurological symptoms 0 or 1 or 2 
Focal neurological signs 0 or 1 or 2 
*A score of ≥4 indicates that CVD is a likely contributor to dementia 
54 
 
Although the HIS has exhibited sensitivity and specificity values of 70-80% for 
distinguishing VaD from AD, it has been less reliable for identifying cases of 
mixed dementia, and provides no context for integrating neuroimaging data into 
the diagnostic process. These drawbacks, combined with its failure to recognize 
characteristics of non-infarct-related VaD, have limited the use of the HIS as a 
primary diagnostic tool 15.  
 
 
2.5.3.2   DSM-IV Criteria for VaD 
 
The DSM-IV approach to diagnosing VaD is noteworthy in several respects, 
particularly as it requires a memory deficit as evidence of cognitive impairment. 
According to the DSM-IV, the presence of a CVD component must be established 
either by focal neurological signs and symptoms (e.g., pseudobulbar palsy, gait 
abnormalities, and extensor plantar response) or laboratory evidence (e.g., 
multiple cortical or subcortical infarctions), but a temporal link between CVD and 
dementia is not required. No specifications are made regarding the onset or 
progression of VaD, which stands in contrast to the insidious onset and 
progressive course required for a DSM-IV diagnosis of AD 19. Because of these 
features, the DSM-IV may be among the most inclusive but least specific methods 
for VaD diagnosis 85.  
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2.5.3.3   ICD-10 Criteria for VaD 
 
The World Health Organization’s ICD-10 offers an alternative approach to VaD 
diagnosis, and outlines the features of VaD subtypes such as multi-infarct 
dementia, subcortical VaD, and VaD with mixed cortical and subcortical 
components. Like the DSM-IV, the ICD-10 requires memory impairment for a 
VaD diagnosis, and considers an abrupt onset, stepwise deterioration, and focal 
neurological signs to be supportive of a vascular etiology. No specifications are 
made regarding the temporal relationship between CVD and dementia, but a 
number of associated features are listed, including hypertension, emotional 
lability, transient delirium, apathy, and other mood and personality changes 20. 
 
2.5.3.4   NINDS-AIREN Criteria for VaD 
 
In 1991, the Neuroepidemiology Branch of the National Institute of Neurological 
Disorders and Stroke (NINDS) organized an International Workshop of Vascular 
Dementia, which was held at the National Institutes of Health in Bethesda, 
Maryland. With the support of the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (AIREN), the Workshop aimed to develop a 
consensus definition of VaD to be used in research settings, as well as a set of 
specific diagnostic criteria for use in epidemiologic studies. The results of their 
efforts highlight the complexity of VaD, and offer a strategy for diagnosing 
probable, possible, and definite VaD (see Table 11). In addition, these criteria 
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specify that VaD can be sub-categorized into cortical VaD, subcortical VaD, 
Binswanger’s disease, and thalamic dementia for research purposes 14.  
 
Of the current diagnostic criteria for VaD, those developed by the NINDS-AIREN 
are considered to be the most specific, as they have very restrictive requirements 
for a temporal relationship and neuroimaging evidence of  
CVD 85. The NINDS-AIREN system is very commonly used in epidemiological 
and clinical studies, including the CSHA, which based VaD diagnoses on both 
NINDS-AIREN and ICD-10 criteria 83. 
 
Table 11. NINDS-AIREN Diagnostic Criteria for Probable, Possible, and 
Definite VaD 14 
 
Diagnostic 
Category 
Criteria Comments 
Probable VaD Dementia • Decline in memory and ≥2 other 
cognitive domains 
• Preferably established by clinical 
exam and neuropsychological testing 
• Deficits must interfere with daily 
functioning 
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Diagnostic 
Category 
Criteria Comments 
CVD • Presence of focal signs on neurologic 
exam* AND 
• Neuroimaging evidence of CVD**  
A 
relationship 
between 
dementia 
and CVD 
• Onset of dementia at <3 months post-
stroke, OR 
• Abrupt cognitive deterioration and 
fluctuating, stepwise progression of 
cognitive deficits 
Features 
consistent 
with 
diagnosis 
• Early gait disturbance 
• History of unsteadiness and falls 
• Early urinary symptoms not explained 
by urologic disease 
• Pseudobulbar palsy 
• Mood and personality changes 
Possible VaD Dementia • Defined as a decline in memory and 
≥2 other cognitive domains 
• Preferably established by clinical 
exam and neuropsychological testing 
• Deficits must interfere with daily 
functioning 
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Diagnostic 
Category 
Criteria Comments 
Focal 
neurologic 
signs 
• In patients with missing neuroimaging 
data, OR 
• In the absence of a clear temporal 
relationship, OR 
• In patients with an insidious onset and 
variable course of cognitive decline + 
evidence of cerebrovascular disease 
Clinical 
criteria for 
Probable 
VaD 
 
• Dementia 
• CVD 
• Relationship between dementia and 
CVD 
Histopathic 
evidence of 
CVD 
• Obtained from biopsy or autopsy 
Definite VaD 
Absence of 
other causes 
of cognitive 
decline 
• No NFTs or senile plaques in excess 
of what is expected for age 
• No clinical or pathologic disorder 
associated with dementia 
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* Focal signs include hemiparesis, lower facial weakness, Babinski sign, sensory 
deficit, hemianopia, and dysarthria consistent with stroke. 
** Neuroimaging evidence includes multiple large-vessel infarcts, a single 
strategic infarct, multiple basal ganglia, white matter lacunes, and/or extensive 
periventricular white matter lesions. 
 
2.5.3.5   ADDTC Criteria for VaD 
 
As an alternative to the NINDS-AIREN criteria, the State of California 
Alzheimer’s Disease Diagnostic and Treatment Centers (ADDTC) developed its 
own recommendations for diagnosing VaD in clinical and research settings. The 
structure of the ADDTC system is quite similar to that of the NINDS-AIREN, as 
both differentiate between probable, possible, and definite forms of the disease. 
The primary difference between two systems lies in the scope of pathology 
addressed by the criteria, as the ADDTC is limited to only ischemic forms of 
VaD, while the NINDS-AIREN includes both ischemic and non-ischemic VaD 
subtypes. In addition, the ADDTC is unique in its inclusion of specific criteria for 
mixed dementia and its recognition that mixed dementia may include the co-
occurrence of CVD with dementias other than AD (e.g., dementia with Lewy 
bodies).  
 
Beyond these obvious differences, the ADDTC system differs from the NINDS-
AIREN in a number of subtler (but no less noteworthy) ways, including its 
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definition of dementia, criteria for functional impairment, and specifications for a 
temporal relationship between CVD and dementia. With regard to dementia 
definition, the ADDTC places more emphasis on clinical judgment, and rejects 
the NINDS-AIREN contention that dementia is defined by a certain type, number, 
or pattern of cognitive deficits. In terms of functional impairment, the ADDTC 
de-emphasizes the importance of deficits in social and occupational functioning, 
viewing these as relatively common consequences of normal aging. In line with 
these more inclusive criteria, the ADDTC does not cite any specific type of course 
or require disease progression for a VaD diagnosis. In addition, the ADDTC 
requires evidence of a temporal relationship between CVD and dementia only in 
cases of isolated infarcts. This stands in contrast to the NINDS-AIREN criteria, 
which call for a temporal relationship even among patients who have experienced 
multiple strokes 86.  
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Table 12. ADDTC diagnostic criteria for probable, possible, and definite 
ischemic VaD 86 
 
Diagnostic 
Category 
Criteria Comments 
Dementia • Decline in more than one area of 
intellectual performance  
• Deficits must broadly interfere with 
daily living 
• Deficits must be independent of level of 
consciousness 
Probable VaD 
Stroke • Historical, neurologic, or neuroimaging 
evidence of ≥2 ischemic strokes OR a 
single stroke with a temporal 
relationship to dementia onset  
• Neuroimaging evidence of ≥1 infarct 
outside of the cerebellum 
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Features that 
support 
diagnosis 
• Evidence of multiple infarcts in brain 
areas associated with cognition 
• History of multiple transient ischemic 
attacks 
• History of vascular risk factors (e.g., 
hypertension, diabetes, heart disease) 
• Elevated score on the Hachinski 
Ischemia Scale 
Features 
consistent with 
diagnosis, but 
await further 
research 
• Early gait disturbance or urinary 
incontinence 
• Neuroimaging evidence of 
periventricular and deep white matter 
changes that are excessive for age 
• Focal changes on electrophysiologic or 
physiologic neuroimaging studies 
Features 
inconsistent 
with diagnosis 
• Transcortical sensory aphasia without 
neuroimaging evidence of 
corresponding focal lesions 
• Absence of central neurological 
symptoms and signs other than 
cognitive impairment 
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Dementia • Decline in more than one area of 
intellectual performance  
• Supported by historical evidence 
• Documented by bedside mental status 
exam or ideally, by neuropsychological 
assessment 
• Deficits must broadly interfere with 
daily living 
• Deficits must be independent of level of 
consciousness 
Possible VaD 
Cerebrovascular 
Disease 
• A history of a single stroke without a 
temporal relationship to dementia onset 
OR Binswanger’s syndrome*  
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Dementia 
 
• Decline in more than one area of 
intellectual performance  
• Supported by historical evidence 
• Documented by bedside mental status 
exam or ideally, by neuropsychological 
assessment 
• Deficits must broadly interfere with 
daily living 
• Deficits must be independent of level of 
consciousness 
Definite VaD 
Histopathic 
evidence of 
cerebrovascular 
disease 
• Confirmation of multiple infarcts, 
including some outside the cerebellum 
 
* Binswanger’s syndrome is diagnosed based on the presence of: (1) early-onset 
urinary incontinence or gait disturbance; (2) vascular risk factors; and (3) 
extensive white matter changes on neuroimaging. 
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2.5.4   Mixed Dementia – diagnosis  
 
Although most diagnostic guidelines address the possibility that dementia 
subtypes may overlap, none provide specific, comprehensive guidance for making 
a mixed diagnosis. Perhaps because of this limitation, diagnoses of “pure” AD 
and VaD may often be assigned inappropriately in clinical practice, and cases of 
mixed dementia may frequently be lumped into the VaD category for research 
purposes 54.  
 
Table 13. Perspectives on mixed dementia, as outlined by major diagnostic 
criteria 
 
Guideline Handling of Mixed Dementia  
NINDS-AIREN  A diagnosis of AD with CVD should be assigned to 
patients who fulfill clinical criteria for possible AD, while 
also exhibiting clinical or neuroimaging evidence of CVD 
14 
ADDTC A diagnosis of mixed dementia should be made when 
stroke co-exists with a second systemic or brain disorder 
(e.g., AD or Parkinson’s disease) that is thought to be 
causally related to dementia 86 
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NINCDS-ADRDA Cases of mixed dementia are categorized as possible AD 
if AD is considered to be the principal cause 21 
DSM-IV There is no diagnostic code for mixed dementia. When 
there is evidence that dementia is due to multiple 
etiologies (e.g., AD and VaD), both diagnoses should be 
recorded 19.  
ICD-10 A diagnosis of mixed dementia should be made when 
evidence of CVD co-occurs with a clinical presentation 
and history suggestive of AD 20.  
 
In its monograph on ischemic VaD, the ADDTC specifies that a diagnosis of 
mixed dementia should be made when stroke co-exists with a second systemic or 
brain disorder that is thought to be causally related to dementia 86. This definition 
is similar to that set forth by the NINDS-AIREN, which assigns a diagnosis of 
“AD with CVD” to patients who fulfill clinical criteria for possible AD, while 
also exhibiting clinical or neuroimaging evidence of CVD 14. It differs, however, 
from the criteria proposed by the NINCDS-ADRDA, which assigns the category 
of possible AD to all cases of mixed etiology in which AD is considered to be the 
principal cause 21.  
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2.5.5  Vascular Cognitive Impairment – diagnosis  
 
Current criteria for VaD have poor sensitivity for identifying cases at early stages, 
when treatment for dementia is most likely to be successful. In an effort to 
improve the detection of mild cases and increase the potential for treatment 
success, researchers have proposed the concept of VCI, which would presumably 
be diagnosed by very sensitive, rather than very specific, instruments. Although 
such instruments have yet to be developed, it has been suggested that methods 
used to identify VCI should place equal emphasis on all cognitive domains 54. 
 
2.5.5.1   NINDS-CNS recommendations  
 
To address the lack of diagnostic criteria for VCI, the NINDS and Canadian 
Stroke Network (CSN) recently convened a group of experts to formulate 
recommendations for the clinical diagnosis and research of this disease construct. 
From the outset of the workshop, it was recognized that existing data were 
insufficient to develop a definitive set of diagnostic criteria. Thus, the overarching 
goal of the workshop was to determine which data elements should be collected in 
studies that would aim to flesh out the definition of VCI. A basic assumption was 
that VCI would encompass a broad spectrum of cognitive deficits, ranging from 
VCIND to VaD to mixed dementia.  
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Among the results of the NINDS-CNS workshop, recommendations were made 
for 5-, 30-, and 60-minute neuropsychological test protocols that could be used to 
identify patients for VCI studies. These protocols were selected based on their 
ability to assess a wide range of cognitive domains, while simultaneously 
focusing on the evaluation of executive function. The 60-minute protocol was 
composed of numerous tests for executive/activation, visuospatial, language, 
memory/learning, and neuropsychiatric functioning. A subset of these tests was 
retained for the 30-minute protocol, with a selection of subtests from the MoCA 62 
recommended for use in 5-minute screening evaluations. However, due to its 
insufficient sensitivity in detecting executive dysfunction and mild memory 
impairment, the MMSE was considered inappropriate for use in VCI 
assessment 60.  
 
In addition to setting forth neuropsychological criteria, the NINDS-CNS 
participants also addressed the role of neuroimaging in VCI studies. Their 
conclusions emphasize the important descriptive function of neuroimaging in VCI, 
as it can provide vital information on the severity and location of brain atrophy, 
white matter hyperintensities, infarction, hemorrhage, and other manifestations of 
vascular disease. At the same time, however, the NINDS-CNS working group 
maintained that neuroimaging has limited value in VCI diagnosis, due to the lack of 
pathogomonic radiological features of VCI and the frequent overlap between 
vascular and degenerative pathologies. The experts recommended magnetic 
resonance imaging (MRI) as the optimal instrument for VCI assessment, and 
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cautioned against the use of computerized tomography (CT) due to the dangers of 
radiation exposure and limitations in measuring mild disease 60. 
 
2.5.5.3   Potential biomarkers 
 
As in AD and VaD, the diagnosis of VCI could be improved by the identification 
of biomarkers that differentiate between AD and vascular pathology. However, 
the heterogeneity of VCI subtypes and the prevalence of mixed dementia have 
hampered research in this area, such that only one test (the CSF Albumin Index) 
is currently clinically available for this purpose. Markers with potential utility in 
VCI, according to the NINDS-CNS Working Group, are listed in below (see 
Table 14). All are found in the cerebral spinal fluid (CSF), as no blood biomarkers 
have yet been identified.  
 
Table 14. Candidate CSF biomarkers for VCI 60 
 
Marker Related Pathology  
Serum albumin ratio Blood-brain barrier damage to intracerebral vessels 
Sulfatide White matter demyelination 
Neurofilament Axonal degeneration 
Matrix 
Metalloproteases 
Vascular disease with inflammation 
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2.5.6   Mild Cognitive Impairment – diagnosis  
 
When individuals exhibit cognitive deficits that do not meet dementia criteria, 
they may be classified as having MCI or cognitive impairment no dementia 
(CIND). The rationale behind such classification is that MCI and CIND represent 
the early stages of dementia syndromes, and could thus be used to identify 
patients who are likely to progress to dementia over time. The construct of MCI, 
however, is still evolving, and according to the Canadian Consensus Conference 
on Dementia (CCCN), there is insufficient evidence to support widespread 
screening for MCI/CIND in unselected older people or individuals who lack 
dementia symptoms. Until more evidence is available, clinicians are generally 
advised only to maintain a high level of suspicion for dementia, and to follow-up 
on concerns of functional decline or memory loss reported by patients and 
caregivers 17. Even in research settings, diagnoses of MCI or CIND may be made 
by clinical judgment after exclusion of dementia. This strategy was employed by 
both the CSHA and ACCORD studies, despite the fact that specific criteria for 
MCI have been developed 33. 
 
2.5.6.1   Suggested diagnostic algorithms  
 
Historically, diagnostic criteria for MCI called for the existence of subjective 
memory complaints and objective memory impairment in the absence of general 
cognitive dysfunction or interference with daily functioning. Although the 
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relevance of these criteria have held up over time, there has been increasing 
recognition that not all memory impaired individuals progress to dementia, and 
that dementia can develop from other clinical phenotypes. Such observations led 
to the identification of amnestic and nonamnestic MCI subtypes, for which 
criteria were developed at a 2003 international conference. The most current 
diagnostic algorithm breaks down the diagnosis of MCI even further, specifying 
not only the presence or absence of memory impairment, but also the number of 
domains with some degree of dysfunction (see Figure C). Still greater precision 
can be made by classifying MCI according to whether the etiology is presumed to 
be degenerative, vascular, psychiatric, or medical in nature 33. Whether or not 
such diagnostic precision is clinically relevant, however, remains unclear, as data 
from the Canadian Study of Health and Aging (CSHA) indicated that use of 
specific diagnostic sets did not improve the prediction of dementia progression, 
relative to broader, more inclusive criteria 87.  
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Figure C. Current algorithm for diagnosing MCI and its subtypes 33 
 
 
 
2.7.6.2   Neuroimaging and potential biomarkers 
  
An important issue in the diagnosis of MCI/CIND is the differentiation between 
patients whose deficits are precursors of dementia and those whose memory loss 
is more benign. In an attempt to address this issue (and more appropriately select 
patients for early treatment intervention), researchers have been looking for 
biomarkers that will predict which MCI patients will progress to AD and which 
will remain cognitively stable over time. To this end, urinary neural thread protein 
(NTP) has been targeted by a new diagnostic test (Nymox’s AlzheimAlert) that 
has shown efficacy in detecting early AD 88. Other promising diagnostic tools 
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include MRI measurements of hippocampal volumes, positron emission 
tomography (PET) imaging of glucose metabolism, and CSF measurements of 
total tau, phosphorylated tau, and Aβ42 33,34,37. In future, the novel PET tracer 
Pittsburgh Compound-B, which has been demonstrated to bind to cortical amyloid 
deposits in patients with AD 89, may facilitate diagnoses of AD at even earlier 
stages by identifying patients with Aβ plaques before the development of 
cognitive impairment. Another novel compound, 2-(1-(6-[(2-[F-
18]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene) malononitrile (FDDNP), 
allows neuritic plaques and NFTs to be visualized by molecular imaging at 
preclinical stages 90. 
 
2.6   EPIDEMIOLOGY 
 
2.6.1  Dementia – epidemiology 
 
2.6.1.1   Incidence and prevalence in Canada 
 
The prevalence of dementia in 1991 was estimated at 8% among Canadians aged 
≥65 years, with roughly half of dementia patients living in the community and 
half residing in institutional settings. As expected, the prevalence of dementia in 
Canada increased dramatically with age (see Table 15), exceeding 34% among 
persons aged ≥85 years 2 and reaching 58% by ages 95 years and older 23. The 
percentage of females with dementia was generally similar to the percentage 
among men (8.6% vs. 6.9%), although the longer lifespan among Canadian 
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women translated into a far higher number of female vs. male dementia patients 
(171,400 vs. 81,200) 83. When stratified by disease stage, prevalence rates were 
2.3% for mild dementia, 3.1% for moderate dementia, and 2.6% for severe 
disease. The difference between males and females seemed to be particularly 
pronounced at moderate and severe dementia stages (see Table 16) 3.  
 
Table 15. Age-standardized prevalence of dementia (all types) in Canada, by 
age and gender, 1991 2 
 
Age Group Men Women Total 
65-74 years 1.9% 2.8% 2.4% 
75-84 years 10.4% 11.6% 11.1% 
85+ years 28.7% 37.1% 34.5% 
Total 6.9% 8.6% 8.0% 
 
 
Table 16. Prevalence of dementia (all types) in Canada, by gender and 
disease severity, 1991 3 
 
Gender Mild  Moderate  Severe 
Men 2.1% 2.6% 1.4% 
Women 2.4% 3.6% 3.5% 
Total 2.3% 3.1% 2.6% 
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Between 1991 and 1996, the annual incidence of dementia in Canada was 
estimated at 2%, which translated into 60,150 new cases of dementia per year. As 
seen with prevalence rates, the incidence of dementia in Canada increased 
dramatically with age, but did not vary significantly according to gender (2.18% 
vs. 1.91%) 91. When these figures were extrapolated to the population, researchers 
estimated that approximately 252,600 Canadians had some form of dementia in 
1991, and that the prevalence would triple to reach an estimated 778,000 
individuals over a 40-year period 2. The most recent estimates provided by the 
Alzheimer Society of Canada 92 place the prevalence of dementia at 450,000 in 
2006, with an additional 97,000 individuals expected to develop the condition in 
2007. This rapid rise in dementia prevalence has exceeded the growth of general 
population, highlighting the need for more effective intervention 2. 
 
2.6.2   Alzheimer’s Disease – epidemiology  
 
2.8.2.1   AD commonality and prevalence 
 
Epidemiologists generally agree that AD represents the most common form of 
dementia, accounting for up to 75% of all dementia cases 93. In Canada, AD was 
identified as a cause of dementia in 64% of cases identified by the CSHA, and in 
77.9% of patients diagnosed in specialized referral centers 2,82. The total age-
standardized AD prevalence rate was calculated at 5.1%, indicating that 161,000 
Canadian individuals had AD in 1991 2. Applying this rate to population 
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estimates, the prevalence of AD in Canada was reported at 279,000 in 2005 and 
projected to reach 509,000 by the year 2031 2,94. A substantial percentage of 
Canadians either know someone with AD (20-32%) or have a family member 
affected with the disease (21-26%) 92,95.  
 
2.6.2.2   Rates of AD increase with age and female gender 
 
As with dementia overall, the prevalence of AD increases substantially with age, 
with estimates ranging from 1% among Canadians aged 65-74 years to 26% 
among those aged 85 and older (see Table 17). In addition, there seems to be a 
marked variation in prevalence by gender, such that women are disproportionately 
affected 55. In Canada, AD was estimated to affect 5.8% women aged ≥65 years, 
compared with 3.8% of men. This gender difference, which has also been 
observed in other nations, seems to be particularly pronounced at older ages, and 
stands in contrast to trends in VaD, which seems to predominate among men 2.  
 
Table 17. Age-standardized prevalence of AD in Canada, by age and gender, 
1991 2 
 
Age Group Men Women Total 
65-74 years 0.5% 1.4% 1.0% 
75-84 years 5.5% 7.8% 6.9% 
85+ years 19.6% 28.8% 26.0% 
Total 3.8% 5.8% 5.1% 
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2.6.2.3   Prevalence of AD in Canada and other countries 
 
Prevalence rates of AD in the United States, Europe, and Asia are generally 
similar to rates reported in Canada. Pooled age-specific prevalence rates from 36 
studies in these regions were as follows: 0.5% in people aged 60-65 years, 1.5% 
in those aged 65-69 years, 3% in those aged 70-74 years, 6% in thosee aged 75-79 
years, and 12% in those aged 80-84 years 93.  
 
There is some evidence, however, that the burden of AD in the US exceeds that in 
Canada, with figures indicating that AD affects 13% of US residents aged ≥65 years 
and 50% of those aged 85 years and older 96. A study based on estimates among 
residents of Chicago, Illinois placed the US prevalence of AD at 4.5 million people 
in 2000, with a projected increase to 13.2 million by 2050 97.  
 
The fact that the prevalence of AD in Canada is roughly similar to or lower than 
that in other nations is interesting in light of the observed excess of dementia 
among Canadians. It has been speculated that this apparent discrepancy may be 
related to “an unusual balance” between AD and other dementia subtypes in the 
CSHA study. Worldwide, there appears to be a preponderance of AD in 
Caucasian populations (AD to VaD ratios = 3.3 in Canada, 3.0 in the UK, 2.0 in 
Italy, and 1.3 in Scandinavia), whereas VaD predominates in Asian nations (AD 
to VaD ratio = 0.6 in both Japan and China) 2. 
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2.6.3   Vascular Dementia – epidemiology  
  
In comparison with AD, VaD has been the subject of far less epidemiological 
research. In fact, the CSHA is one of the few North American studies to publish 
population-based data specifically on VaD, yielding an age-standardized prevalence 
rate of 1.5% in the older Canadian population. Based on this rate, researchers 
estimated that 49,000 older Canadians had VaD in 1991, and that by 2031, VaD 
could affect as many as 144,000 Canadian residents 2.  
 
Of all dementia cases identified in the 1991 CSHA, only 19% were attributed to 
VaD, indicating that VaD was 3.3 times less common than AD in the Canadian 
population 2. Although not addressed specifically by this study, it has been 
suggested that “pure” VaD (i.e., VaD with no co-existing AD pathology) is even 
rarer than reported, perhaps accounting for less than 3% of all dementia cases 98. 
Findings from the Canadian Collaborative Cohort of Related Dementias 
(ACCORD) study seem to support this contention, as a diagnosis of “pure” VaD 
was given to only 8.7% of Canadians presenting to a dementia clinic, whereas 
18.7% were diagnosed with mixed dementia 82. 
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2.6.3.1   Rates of VaD  
 
Like AD, the prevalence of VaD in Canada appears to increase with age, 
approaching 5% in the oldest subgroups. Unlike AD, however, VaD appears to be 
disproportionately common among men, despite the higher number of females in 
the elderly population. In the CSHA, age-standardized prevalence rates were 
calculated at 1.9% among men, compared with 1.2% among women. The greatest 
gender discrepancy was observed in the subgroup aged 75-84 years, where VaD 
was estimated to affect 3.1% of men, but only 1.9% of women (see Table 18) 2.  
 
Table 18. Age-standardized prevalence of VaD in Canada, by age and 
gender, 1991 2 
 
Age Group Men Women Total 
65-74 years 0.8% 0.4% 0.6% 
75-84 years 3.1% 1.9% 2.4% 
85+ years 5.2% 4.6% 4.8% 
Total 1.9% 1.2% 1.5% 
 
2.8.3.2   Incidence of VaD 
 
Between 1991 and 1996, the CSHA identified 97 new cases of VaD among 8,623 
Canadian residents, yielding an annual incidence rate of 0.25% when only 
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survivors were taken into account, and 0.38% when deaths during follow-up were 
also considered. The overall incidence of VaD was slightly higher in men than in 
women, and increased with age in persons of both genders (see Table 19). 
Extrapolating these data to the general population, it was estimated that 7,355 to 
11,062 new cases of VaD developed during the five-year period 99. 
 
Table 19. Annual incidence of VaD by age and gender, as estimated among 
survivors only and both survivors and decedents 99 
 
Women Men Age 
Group Survivors Deaths 
included 
Survivors Deaths 
included 
65-69 
years 
0.07% 0.14% 0.12% 0.22% 
70-74 
years 
0.07% 0.11% 0.31% 0.46% 
75-79 
years 
0.38% 0.70% 0.35% 0.66% 
80-84 
years 
0.53% 0.73% 0.53% 0.71% 
85+ years 0.68% 0.93% 0.66% 0.83% 
TOTAL 0.23% 0.35% 0.28% 0.42% 
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The 1.5% prevalence reported in Canada appears to fall at the lower end of the 
range reported in other countries 15, including the US, where prevalence of VaD 
among individuals aged 71 years and older has recently been estimated at 2.48% 
100. With regard to incidence, however, Canadian rates appear to fall in the middle 
range, exceeding those reported in France, Sweden, and the Netherlands, but 
lower than those found in the UK, Germany, Taiwan, and Japan (see Table 20) 
101.  
 
At present, it is unclear whether the apparent geographical variation in VaD 
incidence is result of genetic and/or environmental influences, or whether it 
reflects differences in study methodology and diagnostic criteria 101. The fact that 
VaD appears to represent 50% of all dementias in Japan (compared with 4-20% in 
the Western world), however, has led to speculation that the excess of 
hypertension and stroke in Asia may lead to a disproportionately high occurrence 
of VaD in the Japanese population 15. Alternately, researchers have pointed to 
increased rates of small vessel disease as contributing to the higher frequency of 
VaD observed in Blacks, Hispanics, and Asians 55. 
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Table 20. Age-standardized incidence ratios (SIRs) for VaD in Canada vs. 
other countries, as calculated from studies that did and did not include 
deaths during follow-up 101 
 
Methodology Country SIR 
Canada Reference 
Taiwan 1.79 
China 1.40 
UK 2.68 
France 0.83 
Survivors only* 
Japan 1.58 
Canada Reference 
Sweden 0.71 to 0.82 
The Netherlands 0.42 
Germany 1.23 
Deaths included** 
China 0.87 
 
 
2.6.4   Mixed Dementia – epidemiology  
 
While AD is widely accepted as the most common form of dementia, there is 
increasing consensus that AD often overlaps with other dementia subtypes, 
including VaD and frontotemporal dementia. According to autopsy studies, nearly 
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half of all dementia patients in the US and Europe have more than one form of the 
disease, with 11% of dementia cases attributed to a combination of AD and VaD 
(see Table 21) (Barker et al, 2002). Moreover roughly 50% of AD patients exhibit 
CVD on neuropathological assessment, and the majority of VaD patients show 
some degree of degenerative pathology 4,34. The relatively common categorization 
of mixed dementia as VaD in epidemiological studies may have resulted in 
inflated estimates of VaD prevalence and a reduced appreciation for the 
concurrent influence of AD pathology.  
 
Table 21. Distribution of “pure” and mixed dementia subtypes among 382 
dementia patients in the State of Florida Brain Bank, 2004 (Barker et al, 2002) 
 
Subtype Percentage of All 
Dementia Cases 
AD 42% 
VaD 3% 
“Pure” Dementia (58%) 
Other subtypes 13% 
AD + VaD 11% 
AD + other subtype(s) 21% 
VaD + other subtype(s) 1% 
AD + VaD + other 
subtype 
2% 
Mixed Dementia (42%) 
Other combinations 7% 
 
2.8.4.1   Lack of data on mixed dementia in Canada 
 
Although the exact frequency of mixed dementia in Canada has not been 
established, estimates from an autopsy study in the US place the prevalence of 
mixed AD/VaD at 23% of dementia patients 102. In Canada, it is noteworthy that 
18.7% of patients presenting to a dementia clinic in the ACCORD study were 
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diagnosed with mixed AD/VaD, and that the prevalence of mixed AD/VaD was 
almost three times higher in subjects aged >70 years than in younger patients. The 
relatively high estimates of mixed AD/VaD in the ACCORD study suggest not 
only that AD and VaD pathologies are more likely to exert a combined influence 
at older ages, but also that the process of referral to a dementia clinic may 
facilitate the often challenging mixed diagnoses 82.  
 
2.6.5   Mild Cognitive Impairment– epidemiology   
 
2.6.5.1   Prevalence  
 
Although there are presently no data on the epidemiology of MCI in Canada, the 
CSHA investigated the prevalence of a related construct, CIND, and found that 
16.8% of Canadians aged ≥65 years (21.3% of males; 13.5% of females) had 
cognitive dysfunction that did not meet dementia criteria 3,61. In the ACCORD 
study, an even higher rate of CIND was found, such that 30.1% of Canadians 
presenting to a dementia clinic received a CIND diagnosis. The difference in 
CIND prevalence across the two studies suggests that CIND is more likely to be 
detected at a specialty center than in general practice 82.  
 
Of note, the relative prevalence of CIND and dementia in the ACCORD sample 
varied markedly by age, such that rates of CIND exceeded those of dementia until 
the age of 60 years. The decreasing prevalence of CIND with age suggests that 
older individuals may tolerate a higher level of cognitive impairment before 
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seeking referral to a specialty clinic. Thus, public education may be needed to 
increase the likelihood that older persons will seek treatment at an early stage of 
cognitive decline, when treatment is most likely to be effective 82. 
 
2.6.5.2   Variation in estimates of prevalence and progression 
 
Although CIND and MCI are not synonymous constructs, the rates of CIND 
reported in the Canadian studies are in line with those reported for MCI in other 
populations. Across studies, estimates of MCI prevalence have varied widely, 
ranging from 5% to 25% among community dwelling individuals and from 6% to 
85% in clinical settings 37. A similar variation has been found in rates of 
conversion from MCI to dementia, which range from 5% to over 35% per year, 
depending on the criteria used to define MCI. Although progression to dementia 
is more common among MCI patients than in cognitively normal controls (1% to 
7% annually), it is important to note that not all patients with MCI exhibit further 
decline. In fact, within the CSHA cohort, roughly 33% of subjects classified with 
CIND showed an improvement in cognitive status after five years of follow-up. 
Still, the rate of incident dementia among Canadians with CIND was more than 
three times higher than that of other individuals, suggesting that CIND is a 
precursor to more serious cognitive dysfunction (Linsday et al, 2004).  
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2.7   RISK FACTORS 
 
The risk of dementia is generally thought to stem from the combined effects of 
many factors, including age, genetics, lifestyle, and medical and environmental 
features, many of which have been associated with both degenerative and vascular 
pathology. Because of its multifactorial nature, the task of identifying risk factors 
for dementia is a complicated one, with relative risks varying in accordance with 
the criteria used for study inclusion. To the extent that researchers aim to identify 
predictors of discrete dementia subtypes, it is imperative to select homogeneous 
samples for case-control studies. Given that many studies misclassify mixed 
dementia as either pure AD or VaD, caution must be used in assuming that the 
influence of a particular risk factor is on AD, VaD, or both (Alzheimer’s Society 
of Canada, 2006).  
 
Beyond these concerns, research on dementia risk is hampered by the fact that 
cognitively impaired individuals, almost by definition, have difficulty 
remembering and reporting accurate historical information. Because traditional 
interview-based approaches to obtaining history will not be useful in this 
population, alternative strategies are clearly needed. In the CSHA, researchers 
addressed this problem in two ways: first, by conducting baseline case-control 
analyses using retrospective data provided by informants; and secondly, by 
prospectively following non-demented subjects over five years to identify 
baseline predictors of incident dementia. Among the variables assessed by the 
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CSHA were medical history, family history, and health behaviors, as well as 
exposures to a range of substances 83.  
 
Findings from the CSHA point to a number of factors that may influence the risk 
of VaD as defined by ICD-10 and NINDS-AIREN criteria (see Table 22 and 
Table 23). In many cases, the identified variables were similar to established risk 
factors for AD, including low education, ApoE genotype, heart disease, 
hypertension, and exposure to fertilizers and pesticides 2,99,103.  
 
Although not specifically supported by CSHA findings, a number of other risk 
factors have been identified as common to AD and CVD (e.g., hypertension 104-
106, hyperhomocysteinemia 107, systemic inflammation 108, smoking 109, diabetes 
110,111, obesity 112,113, and the metabolic syndrome 114,115), thus supporting the 
overlap between degenerative and vascular pathologies. While it is possible that 
these vascular factors play a causal role in the development of AD pathology, it is 
equally likely that they induce cerebrovascular pathology, thereby lowering the 
threshold at which plaques and NFTs will lead to dementia 34.  
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Table 22. Risk factors for prevalent VaD, as identified in a baseline case-
control analysis of CSHA subjects 103 
 
Risk Factor Odds Ratio 
High systolic 0.58 
High systolic + diastolic 1.42 
High blood pressure 
Normal reference 
Orthostatic hypotension 1.29 
History of arterial hypertension 2.08*† 
Cardiac symptoms 1.35 
<20 2.02 
20-<25 reference 
25-<27 1.02 
Body mass index 
27+ 1.12 
Head trauma 1.50 
Alcohol abuse 2.45* 
Smoking 0.78 
Diabetes 1.67 
Arthritis 0.67† 
Heart condition 1.71* 
Medical history 
Migraine 1.45 
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Risk Factor Odds Ratio 
Aspirin 3.10* Current drug use 
NSAIDs 0.71† 
Pesticides and fertilizers 2.60*† Occupational exposure 
Liquid plastics or rubbers 2.59* 
0-6 years 4.06*† 
7-9 years 1.28 
Education 
10+ years reference 
 
*Denotes statistical significance  
†Designates those variables that were significantly associated with AD in either 
the CSHA case-control or prospective risk factor analysis 2,83 
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Table 23. Risk factors for incident VaD, as identified in a prospective case-
control analysis of CSHA subjects 99 
 
Risk Factor Odds Ratio 
Sex (male) 1.02 
Rural residence 2.03* 
Living in an institution 2.33* 
ApoE4 allele 2.34*† 
Diabetes 2.14* 
Depression 2.41* 
Men 0.86 High blood pressure 
Women 2.05* 
Men 2.52* Heart condition 
Women 0.71 
Current or previous aspirin use 2.33* 
Estrogen replacement therapy 0.25 
Shellfish consumption (at least once per month) 0.46* 
Men 1.24† Regular exercise 
Women 0.46*† 
Cigarettes 0.83 Smoking (nearly every day) 
Cigars 
 
0.20* 
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Beer 0.66 
Wine 0.72† 
Alcohol use (at least once a 
week) 
Spirits 0.88 
Pesticides or fertilizers 2.05*† Occupational exposure 
Plastic or rubbers 1.75 
*Denotes statistical significance 
†Designates those variables that were significantly associated with AD in either 
the CSHA case-control or prospective risk factor analysis 2,83. 
 
2.7.1   Demographic Factors 
 
2.7.1.1   Age 
 
Of all the proposed risk factors for cognitive decline, age is almost universally 
regarded as the most important, with significant effects seen across all dementia 
disorders 34,37. For each increasing year of age, the risk of VaD may increase by a 
factor of 5%, with an additional 18% increase observed in AD risk 99,116. Given 
the rapid aging of the population, the risks conferred by advancing age could lead 
to a tremendous increase in dementia prevalence.  
 
Although the association between age and dementia is largely undisputed, 
findings from the third wave of the CSHA indicate that this is not a simple 
relationship, and that cognitive decline is by no means a universal consequence of 
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aging. In fact, of the elderly non-demented individuals who participated in the 
CSHA, nearly 50% showed almost no change in cognitive status over a 10-year 
period. In addition, the CSHA found no impact of age on cognitive decline among 
subjects who had already developed dementia, indicating that older dementia 
patients do not progress more rapidly than do younger subjects. Although this 
finding of the CSHA has been replicated in some studies, it has been contradicted 
by others, leaving the question of how age impacts cognition after onset of 
dementia open to further research 83. 
 
2.7.1.2   Gender 
 
The impact of gender on dementia risk remains controversial, with some (but not 
all) studies pointing to an increased risk of AD among females and a 
preponderance of VaD among men 37. In Canada, the risks associated with AD 
and VaD appear to be similar in men and women, and while the CSHA provided 
some evidence of faster cognitive decline in female subjects, the association 
between sex and cognitive decline was only seen in the institutionalized subgroup 
83,99,116. 
 
2.7.1.3   Low education 
 
Low educational attainment has been identified as a risk factor for dementia in 
numerous studies, including the CSHA 2 and a case-control study conducted in 
Manitoba, Canada 116. Such findings provide evidence that educational or 
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occupational attainment may provide a “cognitive reserve” against the clinical 
manifestation of the neuropathologic changes of AD 117. Although most of the 
literature focuses on the link between education and AD 118, an association with 
VaD has also been documented, suggesting that education may lead to increased 
brain density and a subsequently higher threshold for brain injury-induced 
cognitive impairment in this condition as well 119.  
 
2.7.2   Genetic Factors 
 
2.7.2.1   Family history 
 
Family history is often cited as a major risk factor for AD, with some evidence 
suggesting a two- to four-fold increase in AD risk among individuals with a family 
history of the disease 37. Not all research, however, supports this conclusion, as an 
association between AD and a family history of dementia was found in the CSHA 
baseline analysis, but not in the prospective incidence study 83. 
 
2.7.2.2   Apolipoprotein E4 genotype 
 
A polymorphism in the apolipoprotein (ApoE) gene is an established risk factor 
for sporadic, late-onset AD, with up to 50% of cases attributed to the presence of 
the ApoE ε4 allele 120. Given the strength of the association between AD and this 
polymorphism, recent research has focused on determining: (1) whether the ApoE 
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ε4 allele can be used to predict the development of non-AD dementias, and (2) 
whether ApoE ε4 genotype is a predictor of MCI-to-dementia progression.  
 
Over the past few years, researchers from the CSHA have attempted to answer 
these questions, finding that the risk of VaD (but not VCI) is increased in ApoE 
ε4 allele carriers and that the ApoE genotype can predict progression from CIND 
to AD (but not VaD) dementia (see Table 24) 121,122.  
 
In line with the CSHA analyses, the ACCORD study also investigated the impact 
of the ApoE4 genotype and found significantly increased risks of AD (odds ratio 
6.3), VaD (odds ratio 7.4), amnestic CIND (odds ratio 3.2) and VCIND (odds 
ratio 3.4) among ApoE ε4 allele carriers. Notably, ACCORD data indicate that the 
proportion of ApoE ε4 alleles increases across the spectrum of normal cognition 
to CIND to dementia, supporting CIND as an intermediate stage between normal 
aging and significant cognitive deterioration 82 
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Table 24. The impact of ApoE ε4 genotype on the 5-year incidence of AD and 
VaD among older Canadians with normal cognition (n = 1173) or CIND (n = 
296) at baseline 122 
 
Baseline Status 
 
Incident Diagnosis Adjusted OR 
AD 2.89 Normal 
VaD 3.13 
AD 2.69 CIND 
VaD NS 
 
Overall, the data strongly support a link between the ApoE polymorphism and 
dementia development, suggesting that genetic testing could be used to identify 
individuals at increased risk of not only AD, but VaD as well. According to the 
CCCD, however, more information is needed before widespread ApoE screening 
can be recommended for either symptomatic or asymptomatic individuals. As 
such, the CCCD currently advocates that genetic testing be performed only when 
a patient’s family history is consistent with autosomal dominant disease, or when 
an individual without such a history requires further reassurance or assistance. 
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2.7.3   Vascular Risk Factors 
 
Among the most important risk factors for dementia development are those that 
also confer an increased risk of future vascular events. The influence of such 
vascular risk factors, which include hypertension, dyslipidemia, and smoking, has 
been studied both individually and cumulatively, with varying results. Logically, 
theories regarding the etiologies of AD and VaD would suggest that vascular risk 
factors would be more important in VaD development. On the other hand, the 
frequent co-occurrence of AD and VaD pathologies would anticipate a substantial 
overlap in vascular risk profiles across dementia subtypes. Support for both 
hypotheses may be found in a secondary analysis of the CSHA, which 
investigated the influence of a “vascularity index score” (i.e., the cumulative 
number of vascular risk factors present) on the risks of AD and VCI, which by 
definition included mixed dementia cases. According to this analysis, higher 
scores on the vascularity index conferred an increased risk of VCI, but not AD, 
suggesting that the influence of vascular factors may be reduced in AD when 
there is no vascular component 121.  
 
2.7.3.1   Stroke 
 
Data from epidemiological, clinical, and neuropathologic research all support a 
link between stroke and dementia or cognitive impairment, which might be 
expected given that stroke is an etiological cause of some VaD subtypes. 
According to experts, approximately 76% of patients with VaD and 56% of those 
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with VCI have experienced at least one infarction. This rate is far higher than the 
5-7% incidence reported in AD patients, supporting stroke as an important 
predictor in differential diagnosis 15.  
 
The likelihood of developing dementia within one year of index stroke may vary 
by age, ranging from 5.4% in patients aged >60 years to 10.4% in those aged >90 
years. In the case of lacunar stroke, the risk of dementia may be even more 
pronounced, occurring at a rate of up to 23% within four years 119. Other potential 
predictors of dementia among stroke patients include lower education, cortical 
atrophy, diabetes mellitus, African American race, comorbid disorders associated 
with hypoxemia (e.g., seizures and cardiac arrhythmia), ApoE ε4 genotype, and 
previous atherosclerosis or vascular disease 15. 
 
2.7.3.2   Dyslipidemia 
 
The term dyslipidemia refers to abnormalities in serum lipid levels, such as elevated 
low-density lipoprotein (LDL) cholesterol, reduced high-density lipoprotein (HDL) 
cholesterol, and elevated triglycerides, any of which can trigger the development of 
atherosclerosis and vascular disease. As with other vascular conditions, 
dyslipidemia appears to be a risk factor for both AD and VaD 15, with one study 
showing a three-fold increase in the risk of either “pure” VaD or mixed AD/VaD 
among elderly persons with elevated total or LDL cholesterol 119.  
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Although the mechanism linking dyslipidemia to dementia remains unclear, the 
impact of cholesterol on Aβ deposition is a prime suspect, with in vitro studies 
showing a marked inhibition of Aβ production following reduction of cholesterol 
levels 123,124. Such research, as well as a meta-analysis of seven observational 
studies that documented reduced risks of cognitive impairment among statin users 
125, suggests that lipid-lowering medications may be useful in dementia 
prevention 126. However, no significant benefits of statins on cognitive endpoints 
were found in the recently reported LEADe trial of atorvastatin 127 or the 
PROSPER trial of pravastatin 128. The impact of other statins on dementia risk is 
currently the subject of several major research projects 129. 
 
2.7.3.3   Hypertension 
 
Hypertension is an important risk factor for CVD and may also play a role in 
dementia development. The impact of hypertension, however, may vary according 
to dementia subtype, with the risks of AD or mixed dementia appearing to be 
most greatly affected 119. With regard to “pure” VaD, the role of hypertension has 
been described as controversial, as not all studies have shown a connection 15. In 
the CSHA, hypertension predicted an increased risk of VaD among women (odds 
ratio 2.05), but had no such effect in men 99. In addition, several studies have 
shown a decline in blood pressure before dementia onset in AD patients, whereas 
no such change was observed prior to VaD onset 119.  
 
99 
 
According to some researchers, the association between hypertension and 
dementia may be a result of a hypertension-induced development of white matter 
lesions 130, which are common in age-related dementias 131. Protection against 
dementia development has been found with some antihypertensive drugs, but 
there is currently disagreement over which class of antihypertensive is most 
effective for reducing dementia risk 132.  
 
2.7.3.4   Heart disease 
 
Coronary artery disease and myocardial infarction represent two additional 
vascular factors that have been linked to dementia risk in some studies. For 
example, among residents of Manitoba, Canada, neither heart attack nor other 
heart conditions was significantly associated with AD 116. Moreover, with regard 
to VaD, the CSHA found the effects of heart disease to be gender-specific, 
reaching significance only in male subjects (odds ratio 2.52) 83,99.  
 
2.7.3.5   Diabetes 
 
Diabetes is not only an established risk factor for heart disease and stroke, but 
may also lead to the development of AD, VaD, and VCI 99,133. In the CSHA, 
diabetes was associated with relative risks of 1.62 for VCI, 2.03 for VaD, and 
1.68 for VCIND, but appeared to have no impact on the incidence of AD, mixed 
AD/VaD, or all dementias 133. Further support for a link between diabetes and 
dementia was found in a 24-week treatment study in which the diabetes drug 
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rosiglitazone appeared to prevent cognitive decline among patients diagnosed 
with MCI or very mild AD.  Although the mechanism behind the drug’s 
neuroprotective benefits is unclear, it is possible that the rosiglitazone alters Aβ 
processing, either by reducing inflammation 134 or by modulating insulin activity 
135.  
 
Several hypotheses have been put forth to explain the link between diabetes and 
dementia. First, it has been suggested that diabetes induces micro- and 
macrovascular changes that trigger a reduction in cerebral blood flow and 
subsequent cognitive decline. Second, hyperglycemia has been implicated as 
having either direct effects on neuronal death or indirect effects through increased 
production of a substance associated with amyloid deposition, tau formation and 
oxidative stress. Finally, it has been speculated that insulin is essential for 
neuronal growth, and that the insulin changes associated with diabetes disrupt the 
normal neurogenesis process 119 
 
2.7.3.6   Systemic inflammation 
 
A role for systemic inflammation in dementia development is supported by 
several lines of evidence, including epidemiological studies linking inflammatory 
biomarkers (e.g., C-reactive protein) to both CVD and AD 136,137, as well as 
experimental data indicating that AD pathology can trigger inflammatory 
processes that lead to neuronal damage 138. Based on such findings, some 
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researchers believe that CRP and other markers of inflammation may be useful in 
predicting dementia risk 139. Support for this theory was provided by the Honolulu 
Heart Disease Study, which found increased risks of both AD and VaD among 
Japanese-American men with elevated high-sensitivity CRP in mid-life 140. Of 
note, the association between CRP and dementia was found to be independent of 
cardiovascular disease, as well as other vascular risk factors 140. 
 
2.7.3.7   Metabolic syndrome 
 
The term “metabolic syndrome” refers to a constellation of symptoms—obesity, 
low serum HDL cholesterol, higher serum triglycerides, hypertension, and 
elevated blood glucose—that appear to directly promote the development of 
atherosclerotic disease 141. Given that many of the symptoms of this syndrome are 
known risk factors for dementia 132 and vascular diseases 141, it is not surprising 
that the metabolic syndrome represents an important predictor of not only AD 
114,115, but also silent infarctions 142,143, which are associated with an increased risk 
of dementia and a decline in cognitive function 144. Recognition that chronic 
inflammation is an integral component of the metabolic syndrome 145 provides 
further support for inflammation as a treatable target for dementia prevention. 
 
2.7.3.8   Smoking 
 
Although smoking is frequently cited as a predictor of VaD risk, the evidence 
supporting this association comes primarily from retrospective studies, and cannot 
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be considered conclusive 15,119. When prospective data are considered, the impact 
of smoking on VaD appears to be minimal at best, with CSHA findings showing 
no correlation at all between smoking and the risk of VaD 83. With regard to AD, 
an analysis of three additional Canadian datasets failed to find an effect of 
smoking after adjustment for confounding variables. It has thus been suggested 
that any association between smoking and AD may be limited to specific 
subtypes 146. 
 
2.7.3.9   Head injury/Brain atrophy 
 
Head injury and reduced brain size have also been cited as independent risk 
factors for AD, although the impact of head injury on AD risk failed to reach 
statistical significance in either the CSHA (odds ratio 1.66) or another population-
based Canadian study (relative risk 1.59) 116,147. With regard to brain size, it has 
been speculated that people with larger brains have a reduced risk of AD because 
they have more neurons to lose before symptoms occur. This hypothesis may also 
explain the putative link between AD and early cognitive ability, as individuals 
with lower intelligence may have smaller brains, fewer synaptic connections, and 
slower neurotransmission. 34,37.  
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2.8   PSYCHOSOCIAL BURDEN 
 
By definition, the cognitive impairments associated with dementia are not benign, 
but rather carry a vast range of negative consequences, including functional 
disability, psychiatric disturbances, and ultimately death. As the cognitive 
symptoms of dementia increase, so too does the burden of illness, such that 
patients in the later stages of disease may require assistance for even the most 
basic everyday activities, including bathing, dressing, eating, and use of the toilet. 
Importantly, the burden associated with dementia may begin long before full 
symptom development, when patients are exhibiting only minor cognitive deficits 
87. By the time the final stages of dementia are reached, which may occur only a 
few years after symptom onset, individuals are often bedridden, having 
completely lost the ability to communicate and/or recognize loved ones 96. 
Clearly, such deficits place tremendous financial and emotional strain on family 
members, who are often called upon to provide informal care and/or pay for 
residential treatment. The costs of dementia are thus far-ranging, impacting not 
only patients, but also family, friends, and society at large. 
 
2.8.1   Disease progression 
 
Although the course of dementia may vary according to patient characteristics and 
pathological subtypes, none of the dementia disorders can presently be considered 
curable, and no effective strategies currently exist for stopping or slowing long-
term decline. This means that even though some patients may lead active and 
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fulfilling lives long after a dementia diagnosis, the ultimate prognosis is poor, 
regardless of disease subtype. For most patients, the duration of dementia ranges 
from three to ten years 37,96, with VaD portending a shorter survival 148.  
 
For individuals with a diagnosis of MCI or CIND, outcomes are only slightly 
improved, and the likelihood of a progressive deterioration in cognitive and 
functional status is high. For example, even though a diagnosis of VCIND was 
associated with less progression in the CIVIC study, relative to VaD or mixed 
dementia, VCIND patients still exhibited an increased risk of progression, 
compared with matched controls 35. Similar trends were observed in the CSHA, in 
which 47% of CIND patients who survived five years progressed to dementia 
during this time. The rate of progression in the CIND subgroup represented a 5.3-
fold increase over that observed in cognitively normal controls 87. 
 
2.8.2   Mortality 
 
2.8.2.1   Dementia as a leading cause of death 
 
Dementia is associated with a shortened life expectancy, and is cited as one of the 
leading causes of death in Canada, the US and worldwide. With regard to AD 
specifically, data from the Centers for Disease Control and Prevention (CDC) in 
the US place AD as the 7th leading cause of death for Americans of all ages, and 
the 5th leading cause for Americans aged 65 years and older. Importantly, the 
impact of AD on mortality appears to be on the rise, as the number of AD-
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associated deaths in the US increased by 32.8% between 2000 and 2004, and may 
actually have been underestimated, given that many AD patients have co-existing 
medical conditions. Regardless of actual numbers, survival among AD patients 
appears to be reduced in all age groups, compared with the general population 96. 
 
2.8.2.2   Mortality risks 
 
According to data from the CSHA, the median survival among Canadians with 
dementia was only 3.3 years, with VaD conferring a 16% increase in the risk of 
death, relative to an AD diagnosis 148. In comparison with cognitively normal 
individuals, mortality risks were increased not only among dementia patients, but 
also in those with a CIND diagnosis 87. When stratified by residence and gender, the 
risks associated with CIND and dementia appeared even greater in institutional 
settings, particularly among female subjects (see Table 25). These findings from the 
CSHA are in line with other data suggesting that MCI-related mortality may be 
double that of the population having no cognitive impairment 37. 
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Table 25. Age-adjusted mortality ratios among CSHA subjects by residence, 
gender, and cognitive status 149 
 
Mortality Ratio Residence  Cognitive Status 
Men Women 
Normal 1.0 1.0 
CIND 1.95 2.17 
Community 
Dementia 2.84 2.64 
Normal 1.0 1.0 
CIND 3.09 3.52 
Institution 
Dementia 5.02 6.03 
 
2.8.2.3   Risk of mortality after stroke 
 
The association between mortality and cognitive decline appears to apply not only 
to the general elderly population, but also to patients with a history of stroke. As 
seen in a US study, individuals who exhibited cognitive decline after stroke had 
increased risks of death, relative to cognitively stable stroke patients, regardless of 
whether cognitive decline was defined as low MMSE scores (relative risk 3.99), 
“post-stroke dementia” (relative risk 3.11), or either “post-stroke dementia” or 
AD with CVD (relative risk 3.22) 150. Given that these categories all resemble 
VCI subtypes, such data suggest that the construct of VCI may be an important 
predictor of mortality following an index stroke.  
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2.8.3   Nursing home placement (NHP) 
 
Because dementia by definition is associated with functional impairment, the risk 
for dependency is high, particularly at later disease stages. When the amount of 
assistance required by a dementia patient exceeds that available in the community, 
placement in a nursing home or other institutional facility becomes inevitable. In 
the US, an estimated 25-50% of all elderly users of hospitals, nursing homes, 
assisted living, home care, and adult day services carry a dementia diagnosis. 
Given that most US dementia patients do not have the financial assets to pay for 
even one month of nursing home care, Medicaid costs for nursing home residents 
with dementia are projected to rise from $21 billion in 2005 to $38 billion by 
2025 96. 
 
2.8.3.1   NHP risks  
 
The association between dementia and institutionalization is a well-recognized 
phenomenon, with increased risks of nursing home placement (NHP) seen in 
nearly all dementia subtypes and at all levels of disease severity. In the CSHA, the 
presence of any cognitive impairment was associated with a 29-fold increase in 
NHP risk, relative to normal cognition, while a diagnosis of AD increased the risk 
of institutionalization by a factor approaching 15 151. Among Canadians with VCI, 
the percentage of patients requiring long-term residential care ranged from 41.4% 
to 92.8% in the most severe stages, with increased risks of institutionalization 
seen in all VCI subgroups, including VCIND 35,152. In the CSHA, rates of NHP 
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over five years of follow-up were 29% among patients with baseline CIND versus 
14% in cognitive normal individuals 87. The 2.5-fold increased risk observed in 
this analysis was in line with the two- to three-fold risk increase reported in MCI 
patients 37.  
 
With regard to differences in NHP across dementia subtypes, there is some 
indication that risks may be increased in AD 61 and reduced in acute-onset 
patients who have a higher likelihood of vascular risk factors and/or a VaD 
diagnosis 153.  
 
2.8.4   Disability 
 
Related to the need for institutional care, the inability to attend to ADLs and 
instrumental ADLs (IADLs) is a common consequence of cognitive decline. 
According to a study conducted in the US, more than 69% of patients with 
probable AD may no longer be able to dress, groom, or wash themselves within 5 
years of diagnosis, and roughly 68% may require care equivalent to that provided 
in long-term residential settings (Holtzer et al, 2003).  
 
In another study of Medicare beneficiaries, 81% of all patients with AD or other 
dementia were found to be dependent in at least one ADL, with 32% exhibiting 
impairment in all activities. Importantly, the degree of functional impairment 
corresponded with both healthcare costs and risks of NHP in this population, 
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indicating that functional decline is a particularly important consequence of 
dementia 154.   
 
2.8.5   Depression 
 
Symptoms of depression may be present in as many as 63% of AD patients, with 
up to 20% exhibiting major depressive disorder 17. In the CSHA, the prevalence 
of major depression was 3.2% for AD and 21.2% for VaD, indicating that 
depression is over eight times more common among VaD patients 155. Data from 
the CIVIC study support these findings, indicating the progression of depressive 
symptoms over time may be significantly more frequent in patients with VCI 
(30%) than in those with AD (15%) or normal cognitive functioning (12%). The 
likelihood of progression of depressive symptoms does not appear to differ 
according to VCI subtype 35.  
 
2.10.6   Behavioral disturbances 
 
Behavioral signs and symptoms are a common manifestation of dementia, 
occurring in up to 90% of dementia patients and frequently contributing to 
increased caregiver distress 17. In the CIVIC study, behavioral problems were 
identified in 55% of patients with VCI or AD, compared with 33% of those with 
normal cognitive functioning. Disturbances in judgment were common in both 
VCI (31%) and AD (22%), as were disruptions in other executive domains (39% 
for both subtypes), which contradicts the assumption that executive dysfunction is 
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a hallmark of VCI. Of the VCI subtypes, VCIND was associated with a lower 
incidence of behavior symptoms (43%), relative to patients with VaD or mixed 
dementia (64%) 35. 
 
2.8.7   Comorbidities 
 
Given that dementia is an illness of aging, the co-occurrence of other aging-
related medical conditions among dementia patients is high, leading to increased 
costs and service utilization. In a sample of 25,109 Medicare beneficiaries aged 
≥65 years with an AD diagnosis or at least one claim for an AD-specific drug, 
almost 95% had at least one medical comorbidity, with 35.4% exhibiting six to10 
comorbid conditions, and 28.8% carrying 11 or more comorbid diagnoses 156,157. 
Notably, comorbidity rates were higher for AD patients versus controls in almost 
all medical categories, including diabetes (odds ratio 1.21), heart conditions (odds 
ratio 1.16), and cerebrovascular (odds ratio 2.60), neurological (odds ratio 2.32), 
mental (odds ratio 5.08), and cognitive disorders (odds ratio 155.72) 156,157. Such 
increased comorbidity rates may contribute to more frequent hospitalizations and 
increased rates of NHP among dementia patients 157-159.  
 
2.8.8   Caregiver Burden  
 
One of the most important issues associated with dementia is the burden that it 
places on caregivers. In Canada, family members and friends are the primary 
source of care for community-dwelling AD patients, and may also provide 
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significant assistance to AD patients living in institutional settings. In most cases, 
one person (typically a spouse or adult child) assumes the majority of caretaking 
responsibilities, which may include assisting the patient with basic activities, 
providing emotional and financial support, and mediating with other service 
providers. Primary caregivers in Canada provide an average of 19 more hours of 
informal support to AD patients than to nondemented elderly individuals 160.  
 
2.8.8.2   Physical and psychological consequences of caregiving 
 
Beyond the financial burden associated with caregiving, persons who provide care to 
dementia patients may also experience declines in physical and psychological health. 
Depression is reported by as many as 30% of AD caregivers, and may be particularly 
prevalent in caregivers with low social support. Because of the consuming nature of 
caretaking, many caregivers have little time or energy for social interactions and 
recreational activities, leading to a reduction in quality of life. In the US, providing 
care to dementia patients has been shown to be more stressful than caring for 
nondemented elderly persons 96, and in Canada, health problems have been 
identified more frequently among persons caring for dementia patients than among 
caregivers of healthy elders 83. Key predictors of negative caregiver outcomes 
include the frequency of behavioral problems (e.g., aimlessness and aggression) 
exhibited by the care recipient, as well as the certain personality traits and a lack of 
social support 151,160. 
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2.9   ECONOMIC BURDEN 
 
2.9.1   Canadian Cost Estimates 
 
Beyond the clinical burden to patients, AD and other dementias impose 
tremendous financial strain on caregivers, as well as federal and state budgets. In 
Canada, the annual net economic cost of dementia was estimated at over $3.9 
billion (or $13,900 per patient) in 1991 161, with projections totaling $5.5 billion 
by the year 2000 92. These figures, which reflect the difference in costs incurred 
by CSHA subjects with and without dementia, represent the sum total of direct 
expenditures for drugs, hospitalization, institutional care, and research, combined 
with indirect cost estimates for unpaid services provided by informal caregivers 
(see Table 26). What is not reflected, however, are the indirect costs associated 
with missed work or the unquantifiable burden associated with emotional distress. 
In addition, because conservative cost values were used in categories that 
precluded direct measurement, it is likely that this research underestimates the 
true costs of dementia, and that Canadian society actually spends far more on 
dementia each year 161. In fact, the Alzheimer Society of Canada predicts that AD 
and related dementias “may prove to have the highest economic, social, and 
health cost burden of all diseases” over the next 25 years 92 
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Table 26. Net annual costs of dementia in Canada, 1991 161 
 
Population Source of Costs Net cost per 
patient 
Total 
annual net 
cost  
Paid services $4,970 $615 
million 
Unpaid 
services 
$5,130 $635 
million 
Community-
based 
services 
Subtotal $10,100 $1.25 
billion 
Long-term care $19,100 $2,180 
million 
Drugs $240 $60.6 
million 
Hospitalization* $0 $0 
Diagnosis $250 $13.5 
million 
Elderly dementia 
patients 
Subtotal $13,900 $3.5 billion 
Younger dementia patients** $389 
million 
Research*** $9.8 
million 
Total $3.9 billion 
 
* There was no significant difference in hospitalization days between dementia 
patients and controls.  
** Based on the assumptions that 9-25% of AD patients are aged <65 years, and 
that costs for younger and older dementia patients are equivalent. 
*** Based on the actual costs of dementia-related research conducted in Canada 
during 1991-1992 
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2.9.1.2   Cost variations by subtype and disease severity 
 
Whereas the analysis set forth above focused on the net costs of any dementia 
(without consideration for cost differences across disease subtypes), a subsequent 
study investigated the costs associated specifically with VCI in the Canadian 
population. Once again using data from the CSHA, researchers found that the 
societal costs of VCI exceeded those of AD at the mild stage of disease, but were 
lower than those of AD among patients who had mild-to-moderate, moderate, or 
severe dementia (see Table 27) 152. The generally higher costs observed in 
Canadian AD patients are line with reports from the US, which rank AD (but not 
VCI) among the top 10 most expensive illnesses 37. 
 
Table 27. Mean annual per patient costs of VCI and AD by disease severity 
152 
 
Disease Severity Dementia 
subtype 
 
Source of costs
Mild Mild-to-
Moderate  
Moderate  Severe 
Long-term care $6,708 $7,944 $13,728 $31,104 
Community 
services 
$2,184 $1,125 $1,728 $580 
VCI 
Medications, 
physician fees 
$310 $299 $299 $287 
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Disease Severity Dementia 
subtype 
 
Source of costs
Mild Mild-to-
Moderate  
Moderate  Severe 
Unpaid net 
supervision 
time 
$1,584 $468 $792 $948 
Unpaid direct 
care time 
$4,236 $4,632 $3,516 $1,596 
TOTAL $15,022 $14,468 $20,063 $34,515 
AD TOTAL $9,451 $16,052 $25,724 $36,794 
 
As reflected in the table above, the costs of VCI increase in direct proportion to 
disease severity, ranging from an annual $15,022 per Canadian with mild VCI to 
$34,515 per patient with severe cognitive deficits 152. Similar trends have been 
found in studies of patients with AD and any dementia, with data from the 
multicenter Predictors study demonstrating a 13% annual increase in the direct 
costs of caring for an AD patient 96,162.  
 
2.9.1.3   Nursing home placement (NHP) is a significant cost driver 
 
Data from the CSHA indicate that long-term institutionalization is the most 
significant cost driver for both dementia in general and VCI in particular. With 
regard to overall dementia, the costs of NHP in Canada in 1991 were estimated at 
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$2.18 billion, or $19,100 per elderly dementia patient, which was roughly double 
the costs reported for community-based services (see Table 26). The costs 
attributed to NHP in this study accounted for almost two-thirds of total 
expenditures among elderly patients, suggesting that strategies to delay NHP may 
have tremendous cost-savings potential 161.   
 
Among Canadians with VCI, long-term residential care was found to be the most 
significant cost driver at all levels of disease severity, indicating that even mild 
cases incur substantial institutionalization costs. Of note, however, the relative 
contribution of NHP to total costs appeared to increase as cognitive functioning 
declined, such that annual costs of NHP were only three times higher than those 
of community services among mild cases ($6,708 vs. $2,184), but nearly 54 times 
higher than those of community services among patients with severe disease 
($31,104 vs. $580) (see Table 27). Such trends indicate that as spending increases 
for institutional placement, the costs of community services and unpaid direct care 
decline. Thus, the focus of costs appears to shift from informal to formal 
providers as VCI progresses 152.  
 
2.10   PHARMACOTHERAPY  
 
The currently available anti-dementia drugs in Canada include donepezil (Aricept), 
rivastigmine (Exelon) and galantamine (Reminyl), all of which act as cholinesterase 
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inhibitors (ChEIs). While these drugs are all approved for mild-to-moderate AD, only 
donepezil has received additional approval for treating more severe cases.  
 
Recently available in Canada, the NMDA receptor antagonist memantine 
represents an alternative to ChEIs, but is generally used as second-line therapy for 
moderate-to-severe cases 163. Other, less commonly used treatments include 
antioxidants (e.g., ginkgo biloba and vitamin E), nootropics (e.g., piracetam and 
aniracetam) and calcium-channel antagonists (e.g., nimodipine), all of which have 
demonstrated some modest efficacy in AD patients. Importantly, while all of the 
drugs mentioned above have symptomatic benefits, none have been found to 
prevent or reverse dementia progression.  
 
2.10.1   Goals and Recommendations for Dementia Treatment 
 
At the 1998 meeting of the CCCD, a group of experts outlined “reasonable” goals 
for dementia treatment, and set forth guidelines for the use of anti-dementia drugs 
(see Table 28). Among their most noteworthy recommendations, the CCCD 
participants placed great emphasis on the need for routinely monitoring 
medication response. Their guidelines indicate that drug-treated patients should be 
formally assessed every three months, and that observations of stabilization, 
improvement, and deterioration should be used to guide subsequent treatment 
decisions 17. 
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Table 28. CCCD Goals and Recommendations for Anti-Dementia 
Pharmacotherapy 17 
 
Goals • To halt or slow cognitive and functional declines 
• To improve memory and other cognitive functions 
• To maintain or improve a patient’s self-care abilities 
• To improve behavior, mood, quality of life, and 
general well-being in patients and caregivers  
Guidelines • Physicians should pursue continuing education on the 
administration and interpretation of functional and 
cognitive tests. 
• Patients should be monitored every 3 months after 
starting therapy. 
• Records should be kept to document stabilization, 
improvement, or deterioration over time. 
• Caregivers should keep written logs about patient’s 
condition. 
• Primary care physicians who are unable to perform 
routine assessment should make appropriate referrals. 
• Physicians should be able to educate patients and 
families about dementia and treatment expectations. 
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Medication 
Recommendations 
• Donepezil and rivastigmine are appropriate treatment 
options for mild to moderate dementia. 
• Neither donepezil nor rivastigmine should be used for 
AD prevention. 
• Vitamin E is not recommended for AD treatment or 
prevention. 
• Ginkgo biloba is not recommended for AD treatment 
or prevention. 
 
2.10.2   Cholinesterase Inhibitors 
 
The use of ChEIs in the treatment of AD can be traced back to 1986, when the 
ChEI tacrine hydrochloride became the first anti-dementia drug to demonstrate 
efficacy in a controlled clinical trial 164. Although tacrine is no longer in use due 
to tolerability concerns, its approval by US regulators in 1993 heralded a wave of 
research into the effects of “second-generation” ChEIs, which were found to 
provide superior safety profiles. The benefits of the ChEIs donepezil, 
rivastigmine, and galantamine have since been demonstrated in several 
randomized, double-blind trials, leading this class to become the mainstay of AD 
therapy 165.  
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2.10.2.1   Mechanism of action of ChEIs 
 
The rationale for using ChEIs in AD treatment derives from the cholinergic 
hypothesis, which posits: (1) that the cognitive symptoms of AD are caused by a 
loss of cholinergic neurons; (2) that the loss of cholinergic neurons is 
accompanied by a reduction in the neurotransmitter acetylcholine (ACh), which is 
required for memory formation; (3) that levels of ACh are further reduced by the 
enzyme acetylcholinesterase (AChE); and (4) that ChEIs can block the effects of 
AChE, thereby increasing the amount of ACh available for cholinergic 
neurotransmission 166. The end result of this process is enhanced cognitive 
functioning—an effect that is supported by a growing body of clinical research 34.  
 
2.10.2.3   Potential utility of ChEIs in VaD 
 
Although the use of ChEIs in mild-to-moderate AD has been recommended by 
numerous guidelines (e.g., the CCCD), the general consensus among physicians is 
that the efficacy for these treatments is low 167, and the lack of approved 
medications for patients with non-AD dementias means that this population is 
greatly underserved. To address the latter concern, the developers of donepezil, 
rivastigmine, and galantamine have been actively testing these drugs in the 
treatment of VaD, with some promising results. In terms of development, 
donepezil appears to be farthest along, having been pre-registered for VaD as of 
2005, and having exhibited benefits in cognition, behavior, and ADLs among 
VaD patients 7. While the other two ChEIs have been less extensively tested, 
121 
 
some evidence suggests that these drugs may have efficacy in certain vascular 
subpopulations, which might be expected based on the presence of cholinergic 
dysfunction in VaD patients 7. 
 
However, in a recently published, independently funded, review and meta-
analysis of 6 trials of ChEIs and 2 of memantine, investigators concluded that the 
widespread use of ChEIs in patients with vascular dementia could not be 
supported because the drugs produced only “small benefits in cognition of 
uncertain clinical significance” in patients with mild to moderate VaD. Both 
published and unpublished data were included in the review. Trials were 6 months 
in duration with similar criteria for vascular dementia and outcome measures, and 
included a total of 3,093 drug-treated patients and 2,090 patients who were given 
a placebo. Some efficacy was found in terms of an increase in ADAS-cog (about 
the same in magnitude as has been found in AD trials) and MMSE measures. 
However, in the absence of a corresponding effect on global impression, 
functional, or behavioral outcomes, the clinical significance of the positive 
measures were undermined. Only donepezil showed both cognitive and global 
effects, but the data across studies were inconsistent 8. 
 
To further clarify their findings with respect to the efficacy of ChEIs in VaD, 
Kavirajan and Schneider point out that their review illustrates the challenges 
inherent in designing clinical trials for VaD, including differences in diagnostic 
imaging techniques and the presence of coexisting AD. In addition, they 
122 
 
acknowledge the possibility that the small benefits found in VaD trials may 
actually be reflective of the effects on comorbid AD 8. 
 
2.10.2.5   Reimbursement and utilization of ChEIs in Quebec 
 
Under criteria set forth by the Régie de l'assurance maladie du Québec (RAMQ), 
reimbursement for ChEIs in Quebec requires a special authorization process, 
during which clinicians must justify both the initiation and continuation of 
treatment (see Figure D). Under most circumstances, authorization for an initial 
request is granted only for patients with an MMSE score indicative of mild-to-
moderate dementia (10-26), although patients with higher scores may be 
considered with appropriate justification. After a 6-month initial prescription, the 
physician must provide proof that the medication has been of benefit to the 
patient, as evidenced by stabilization or improvement in symptoms, and a decline 
of no more than 3 points on the MMSE. At present, the maximum duration of 
RAMQ authorization for ChEIs is 12 months.  
 
Figure D. RAMQ reiumbursement criteria for ChEIs 168 
 
 
For initiation of treatment: 
 
• MMSE score must be between 10 and 26, or up to 27 or 28 with appropriate 
justification 
• Medical documentation must be provided regarding degree of impairment in: 
o Cognitive function, including memory 
o Mood 
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o Behavior 
o ADLs and IALDs 
o Social interaction, including ability to participate in conversation 
• Up to 6 months of therapy may by reimbursed 
For continuation of treatment: 
 
• MMSE score must be between 10 and 26, or higher or lower with appropriate 
justification 
• No more than a 3-point decline on the MMSE over 6 months, or a greater 
decline with appropriate justification 
• Stabilization or improvement in at least one of the following areas: 
o Cognitive function, including memory 
o Mood 
o Behavior 
o ADLs and IALDs 
o Social interaction, including ability to participate in conversation 
• Up to 12 months of therapy may be reimbursed 
 
According to a review of the RAMQ database, a total of 18,748 patients received 
at least one dispensation for a ChEI between January 1, 2000 and June 30, 2003. 
The majority of these patients (68%) were women, and the mean age was 79.2. In 
74% of cases, ChEIs were prescribed by a general practitioner, and in 50%, 
treatment was discontinued within 216 days after initiation. Older patients and 
those who were dispensed <20 prescriptions during the year prior to the index 
ChEI prescription were at increased risk of treatment discontinuation. Other risk 
factors for discontinuing therapy included receiving the index prescription from a 
GP rather than a specialist (rate ratio 1.10) and being prescribed donepezil rather 
than galantamine (rate ratio 1.13) 169. 
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2.10.3   Donepezil in mild-to-severe AD 
 
In Canada, donepezil is approved for use at two doses (5 and 10 mg daily) and in 
two forms (tablets and rapidly disintegrating tablets) 170. Donepezil is indicated 
for mild, moderate and severe Alzheimer’s dementia. Its approval in mild-to-
moderate AD was based primarily on two 24-week trials and one 54-week 
placebo-controlled trial. Overall, data from these controlled clinical trials showed 
beneficial symptomatic effects of donepezil vs. placebo (see Table 29). Donepezil 
was also approval by Health Canada in June 2007 for severe AD 171, based on two 
24-week placebo-controlled trials. According to the drug’s product monograph, 
the most common adverse events associated with donepezil are nausea, diarrhea, 
insomnia, vomiting, muscle cramp, fatigue and anorexia. These adverse events 
were often of mild intensity and transient, and resolved during continued 
treatment without the need for dose modification. An open-label study suggested 
that the frequency of these common adverse events was lower in patients who 
received an initial 5-mg daily dose for 6 weeks prior to increasing the dose to 10 
mg/day than in patients who received the initial 5-mg daily dose for only 1 week 
before receiving 10 mg/day 170.  
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Table 29. Phase III trials supporting the use of donepezil for the treatment of 
mild-to-moderate AD 170 
 
Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
ADAS-cog 
Rates of improvement and 
stabilization were greater with 
donepezil 5 mg and 10 mg, 
compared with placebo. 
CIBIC-Plus  Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
24 weeks 473 
CDR-SB Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
ADAS-cog Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Effects were not sustained after 6 
weeks of placebo washout. 
CIBIC-Plus Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Effects were not sustained after 6 
weeks of placebo washout. 
CDR-SB Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
24 weeks 818 
Interview for 
Deterioration 
in Daily 
Functioning 
Significant drug-placebo differences 
favored donepezil 10 mg, but not 
donepezil 5 mg, at week 24-LOCF. 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
54 weeks  432 Clinically 
evident 
functional 
decline 
Survival times were significantly 
longer with donepezil vs. placebo.  
Overall risks were 38% lower with 
donepezil vs. placebo.  
LOCF = last observation carried forward 
 
2.10.4   Donepezil in VaD and VCI 
 
Beyond AD, donepezil has also been studied in patients with VaD/VCI, and is 
among the compounds farthest in development for a VaD indication. In 2004, the 
evidence regarding donepezil’s effects in VCI was investigated in a Cochrane 
review, which concluded that the drug has both cognitive and functional benefits 
in patients with mild to moderate forms of VaD or mixed dementia. The review, 
which was based primarily on two 24-week, randomized, double-blind trials, 
emphasizes the potential value of donepezil as a short-term symptomatic therapy, 
but suggests that the drug may be effective in the longer-term as well. 
Importantly, donepezil was well tolerated at daily doses of 5 or 10 mg in these 
study patients (n = 1,216), and had a low incidence of adverse events 172.   
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2.10.5   Rivastigmine in mild-to-moderate AD 
 
Like the other ChEIs, rivastigmine is an inhibitor of AChE, and has been 
approved for the treatment of mild-to-moderate AD in Canada 173,174. Unlike the 
other ChEIs, however, rivastigmine’s effects are not specific to AChE, but rather 
extend to butyrylcholinesterase (BuChE), which is thought to play a role in 
attentional processes. Perhaps because of this unique mechanism of action, the 
clinical profile of rivastigmine in mild-to-moderate AD includes not only benefits 
on cognition and daily functioning, but also efficacy in behavioral and 
neuropsychiatric disturbances 175. 
 
In Canada, rivastigmine is available in capsule form (1.5 mg, 3 mg, 4.5 mg and 6 
mg), as an oral solution (2 mg/mL), and as a transdermal patch (5 cm2 and 10 cm2 
containing 9 mg and 18 mg rivastigmine base, respectively) for the symptomatic 
treatment of mild-to-moderate AD 173,174. Its approval was based primarily on two 
studies, both of which were 26 weeks in duration and incorporated flexible 
maintenance-dose regimens. Outcomes on the ADAS-cog, CIBIC-Plus, and 
Progressive Deterioration Scale (PDS) all favored rivastigmine over placebo, with 
6-12-mg doses providing superior results compared with lower dosing strategies. 
Common adverse events included nausea, vomiting, dizziness, diarrhea, anorexia, 
abdominal pain, fatigue, asthenia, and somnolence. These adverse events were 
generally mild in intensity, more frequent at higher doses, of short duration, and 
attenuated with continued dosing or discontinuation of rivastigmine. Common 
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adverse events in the single clinical trial with the patch formulation were nausea, 
vomiting, diarrhea, decreased weight, and dizziness. The overall incidence of 
adverse events in patients treated with the 10 cm2 patch was lower than the rate in 
patients who received a 20 cm2 patch (not a marketed dose) or the capsule 
formulation. 173,174.  
 
Table 30. Phase III trials supporting the use of rivastigmine for the treatment 
of mild-to-moderate AD 173,174 
 
Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. A greater 
treatment effect was noted for 
rivastigmine 6-12 mg than for 1-4 
mg. 
26 weeks 699 ADAS-cog 
Rates of improvement and 
stabilization were greater with 
rivastigmine 6-12 mg compared with 
placebo. 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
CIBIC-Plus  Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. 
PDS Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF. 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF.  
ADAS-cog 
Rates of improvement and 
stabilization were greater with 
rivastigmine 6-12 mg compared with 
placebo. 
CIBIC-Plus Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF. 
26 weeks 725 
PDS Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF. 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
ADAS-cog Significant drug-placebo differences 
favored rivastigmine 10-cm2 and 20-
cm2 patch and 12-mg/day capsules at 
week 24-LOCF. 
ADCS-
CGIC 
Significant drug-placebo differences 
favored rivastigmine 10-cm2 patch 
and 12-mg/day capsules, but not 20-
cm2 patch, at week 24-LOCF. 
24 weeks 1053 
ADCS-ADL Significant drug-placebo differences 
favored rivastigmine 10-cm2 and 20-
cm2 patch and 12-mg/day capsules at 
week 24-LOCF. 
Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
26 weeks 699 ADAS-cog Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. A greater 
treatment effect was noted for 
rivastigmine 6-12 mg than for 1-4 
mg. 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
Rates of improvement and 
stabilization were greater with 
rivastigmine 6-12 mg compared with 
placebo. 
CIBIC-Plus  Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. 
PDS Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF. 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF.  
ADAS-cog 
 
26 weeks 725 
CIBIC-Plus Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Effects were not sustained after 6 
weeks of placebo washout. 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
CDR-SB Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Interview for 
Deterioration 
in Daily 
Functioning 
Significant drug-placebo differences 
favored donepezil 10 mg, but not 
donepezil 5 mg, at week 24-LOCF. 
54 weeks  432 Clinically 
evident 
functional 
decline 
Survival times were significantly 
longer with donepezil vs. placebo.  
Overall risks were 38% lower with 
donepezil vs. placebo.  
Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. A greater 
treatment effect was noted for 
rivastigmine 6-12 mg than for 1-4 
mg. 
26 weeks 699 ADAS-cog 
Rates of improvement and 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
stabilization were greater with 
rivastigmine 6-12 mg compared with 
placebo. 
CIBIC-Plus  Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. 
PDS Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF. 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF.  
ADAS-cog 
 
CIBIC-Plus Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Effects were not sustained after 6 
weeks of placebo washout. 
26 weeks 725 
CDR-SB Significant drug-placebo differences 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Interview for 
Deterioration 
in Daily 
Functioning 
Significant drug-placebo differences 
favored donepezil 10 mg, but not 
donepezil 5 mg, at week 24-LOCF. 
54 weeks  432 Clinically 
evident 
functional 
decline 
Survival times were significantly 
longer with donepezil vs. placebo.  
Overall risks were 38% lower with 
donepezil vs. placebo.  
Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. A greater 
treatment effect was noted for 
rivastigmine 6-12 mg than for 1-4 
mg. 
26 weeks 699 ADAS-cog 
Rates of improvement and 
stabilization were greater with 
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Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
rivastigmine 6-12 mg compared with 
placebo. 
CIBIC-Plus  Significant drug-placebo differences 
favored rivastigmine 6-12 mg and 1-
4 mg at week 26-LOCF. 
PDS Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF. 
Significant drug-placebo differences 
favored rivastigmine 6-12 mg but 
not 1-4 mg at week 26-LOCF.  
ADAS-cog 
 
CIBIC-Plus Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
week 24-LOCF. 
Effects were not sustained after 6 
weeks of placebo washout. 
26 weeks 725 
CDR-SB Significant drug-placebo differences 
favored donepezil 5 mg and 10 mg at 
137 
 
Duration of 
Treatment 
Number 
of Patients
Endpoint Results 
week 24-LOCF. 
Interview for 
Deterioration 
in Daily 
Functioning 
Significant drug-placebo differences 
favored donepezil 10 mg, but not 
donepezil 5 mg, at week 24-LOCF. 
54 weeks  432 Clinically 
evident 
functional 
decline 
Survival times were significantly 
longer with donepezil vs. placebo.  
Overall risks were 38% lower with 
donepezil vs. placebo.  
ADCS-ADL = AD Cooperative Study Activities of Daily Living Inventory; 
ADCS-CGIC = AD Cooperative Study Clinical Global Impression of Change 
 
2.10.6   Rivastigmine in VaD and VCI 
 
The question of rivastigmine’s efficacy in patients with VCI was addressed in a 
recent Cochrane Review 176, but remains unresolved due to a paucity of clinical 
data and a lack of unconfounded, randomized, placebo-controlled trials. At 
present, the most robust evidence supporting rivastigmine’s use in VCI comes 
from small, open-label studies showing a range of benefits in patients with 
subcortical VaD, and from subgroup analyses of larger trials, which document the 
drug’s efficacy in AD patients with hypertension or other vascular risk factors. 
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Although these findings clearly suggest that rivastigmine has potential in treating 
VCI or subcortical VaD, experts agree that further research is needed before any 
recommendations can be made 175,176.  
 
2.10.7   Galantamine in mild-to-moderate AD 
 
Galantamine represents a third option for the treatment of mild-to-moderate AD 
in Canada, where it has been approved in both tablet (4 mg, 8 mg, and 12 mg) and 
extended-release capsule (8 mg, 16 mg, and 24 mg) forms 177. Support for 
galantamine’s use in mild-to-moderate AD can be found in four randomized 
double-blind, placebo-controlled trials, including one which compared 
immediate-release galantamine to the extended-release formulation (see Table 
31). Results showed significant benefits of galantamine over placebo on measures 
of cognition, functioning, and caregiver-rated ADLs, when given at doses of 16-
32 mg/day for up to six months. In general, there appeared to be few efficacy 
differences between immediate- and extended-release galantamine, although the 
extended-release formulation did not differentiate from placebo on the CIBIC-
Plus after 24 weeks of administration. The most common adverse events in the 
dose-escalation trial were nausea, vomiting, diarrhea, and anorexia. These events 
tended to occur at a lower rate with 16 mg/day, the initial recommended 
maintenance dose. Administration of galantamine with food, the use of anti-
emetic medication and ensuring adequate fluid intake may reduce the impact of 
these events 177. 
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Table 31. Phase III trials supporting the use of galantamine for the treatment 
of mild-to-moderate AD 177 
 
Duration of 
Treatment/ 
Formulations/ 
Dosages  
Number of 
Patients 
Endpoint Results 
Significant drug-placebo 
differences favored galantamine 
16 mg and 24 mg daily (but not 
galantamine 8 mg daily) at week 
21. 
ADAS-cog 
Rates of improvement and 
stabilization were greater with 
galantamine 16 mg and 24 mg 
daily (but not galantamine 8 mg 
daily), compared with placebo. 
CIBIC-Plus Significant drug-placebo 
differences favored galantamine 
16 mg and 24 mg daily (but not 
galantamine 8 mg daily) at week 
21. 
21 weeks 
 
Immediate-
release 
galantamine 
 
8 mg, 16 mg, 
and 24 mg, 
given in twice 
daily doses 
978 
ADCS-
ADL 
Significant drug-placebo 
differences favored galantamine 
16 mg and 24 mg daily (but not 
galantamine 8 mg daily) at week 
21. 
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Duration of 
Treatment/ 
Formulations/ 
Dosages  
Number of 
Patients 
Endpoint Results 
Significant drug-placebo 
differences favored galantamine 
24 mg and 32 mg daily at week 
21. 
ADAS-cog 
Rates of improvement and 
stabilization were greater with 
galantamine 24 mg and 32 mg 
daily, compared with placebo. 
26 weeks 
 
Immediate-
release 
galantamine 
 
24 mg and 32 
mg, given in 
twice daily 
doses 
636 
CIBIC-Plus Significant drug-placebo 
differences favored galantamine 
24 mg and 32 mg daily at week 
21. 
ADAS-cog Significant drug-placebo 
differences favored galantamine 
extended-release at week 24. 
CIBIC-Plus The effects of galantamine 
extended-release did not differ 
significantly from placebo. 
24 weeks 
 
Extended-
release  
galantamine 
 
16 mg or 24 
mg, given 
once daily 
(number of 
patients not 
included in 
the Ortho 
publication)
ADCS-
ADL 
Significant drug-placebo 
differences favored galantamine 
extended-release 24 at week 24. 
ADCS-ADL = AD Cooperative Study Activities of Daily Living Inventory 
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2.10.5.2   Galantamine in VaD and VCI 
 
Beyond these pivotal trials, galantamine has also been investigated in two 
randomized, placebo-controlled studies of patients who could be classified as 
having VCI. In the first trial, galantamine was assessed in patients who met 
criteria for either VaD or AD plus CVD, with results indicating that the drug had 
cognitive, functional, and behavioral benefits in the entire cohort and the AD plus 
CVD subgroup, but not among patients with “pure” VaD. By contrast, the second 
trial investigated only patients who met VaD criteria, and documented benefits of 
the drug on measures of both cognition and executive functioning. Although 
Health Canada did not find sufficient evidence for a VCI indication (Janssen 
Ortho Inc, 2007), the authors of a recent Cochrane Review considered 
galantamine to be possibly beneficial in the VCI population. Regardless of its 
potential benefits, however, the risks associated with galantamine are of concern, 
as the drug has been associated with increased rates of adverse events and 
withdrawal, compared with placebo 32. 
2.11   CONCLUSIONS 
 
The field of dementia research is evolving at a rapid pace, and significant progress 
has been made in unraveling the complexities of this devastating disorder. Over 
the past few decades, a number of important discoveries have been made, 
including the recognition that VaD may arise from a wide range of 
cerebrovascular injuries (e.g., subcortical white matter changes), the finding that 
AD and VaD may share common pathogenic pathways (e.g., a cholinergic 
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deficit), and the observation that patients with milder forms of cognitive 
impairment may also have poor outcomes (e.g., institutionalization and death). As 
a result of such advances, researchers are learning to better differentiate between 
the dementia subtypes while appreciating the etiological overlaps across dementia 
disorders. In addition, they are recognizing the importance of early detection, and 
identifying risk factors not only for the onset of cognitive impairment, but also for 
the risk of progression to dementia after initial decline. 
 
Based on recent findings, a new paradigm is emerging in which AD and VaD are 
no longer viewed as dichotomous entities, but rather as opposite ends of a 
spectrum of dementia disorders. The concept of VCI, which encompasses VaD, 
VCIND, and mixed dementia, represents an important outgrowth of this emerging 
paradigm, recognizing that AD and VaD often co-exist and that it is often difficult 
(if not impossible) to identify which is the primary contributor to cognitive 
decline. Although VCI is a nonspecific construct and may overlook the subtle 
distinctions between vascular etiologies, it nonetheless serves to identify a 
population of patients whose cognitive decline has a vascular component, and 
who may benefit from similar treatment interventions. 
 
Regardless of subtype, dementia is clearly a debilitating disease, affecting not 
only cognition, but also the ability to perform everyday tasks. Many patients with 
AD, VaD, and even milder forms of cognitive dysfunction are at increased risk of 
disability and nursing home placement, which is extremely costly to both 
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individuals and society. It is thus promising that in some studies the currently 
available AD drugs (i.e., the cholinesterase inhibitors) have been shown to delay 
institutionalization and reduce the accompanying costs in both AD and VCI 
patients. Such benefits point to possible cost benefits of the cholinesterase 
inhibitors, which may extend beyond AD patients.  
 
With regard to the future of dementia research, investigators have called for a 
better characterization of non-AD dementias, a clearer understanding of the 
convergence between AD and CVD, and more sensitive tools for identifying early 
cognitive impairment 4,15. It is hoped that advances in these areas will facilitate 
the development of disease-modifying drugs, while improving the detection of 
patients who are most likely to benefit from either preventive or treatment 
interventions. Given the aging of the population and the anticipated surge in 
dementia patients, the importance of continued research cannot be 
underestimated.  
 
Retrospective epidemiological analyses of administrative databases containing 
information on drug claims and medical services may provide valuable insight 
into the effectiveness of AD treatments and which populations may benefit most 
from such treatments. However, the retrospective nature of these studies subjects 
them to a variety of potential limitations which need to be carefully considered in 
study design and interpretation of results. The most important biases that may 
occur in epidemiological studies are discussed in the next chapter. 
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3.0   BIAS IN EPIDEMIOLOGIC RESEARCH 
 
3.1   OVERVIEW 
 
Scientific evidence regarding factors that increase the risk of Alzheimer’s 
disease or prevent its occurrence is primarily based on observational studies of 
human populations. Due to their non-experimental nature, these 
epidemiological studies are subject to a variety of study limitations potentially 
leading to bias. Bias in epidemiologic research is any systematic error that 
distorts an estimate of the relationship between exposure and outcome. Biases 
are generally categorized into three types. Selection bias refers to errors that 
occur in identifying the study population. Information bias, also known as 
observation bias, consists of error in ascertaining data on exposure or outcome. 
Immortal time bias is a form of information bias in which a time-dependent 
exposure is treated as a time-invariant factor, and is of particular concern in 
retrospective cohort analyses. Confounding occurs when the relationship 
between exposure and outcome is affected by another factor 11. 
 
Minimization of bias is imperative for the design of epidemiologic studies, 
given that its presence raises doubts about the quality and credibility of results. 
Whereas the effects of confounding may be controlled at the time study data are 
analyzed, it is critical to prevent selection bias and information bias at the 
design stage in order to avoid compromising study validity 12. 
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The interpretation of epidemiologic data should take into account the possibility 
of bias. Key contributors to bias include the type of study design, which may be 
susceptible to particular forms of bias, and the conduct of investigators during 
study implementation. Although quantitative analysis of the magnitude of 
potential bias is not always possible, the likely effect of the error on study 
findings can often be deduced either at the design or at the analysis phase of the 
study 11. 
 
This chapter discusses common types of bias in pharmacoepidemiologic 
research and provides examples to illustrate them. Methods for preventing or 
correcting bias during the design, conduct, and analysis of epidemiologic 
research are also described. Given the large number of possible biases 178, the 
three main categories and frequently encountered subtypes are covered here: 
selection bias (i.e., referral bias, self-selection, prevalence bias, protopathic 
bias, publication bias), information bias (i.e., misclassification bias, detection 
bias, recall bias, immortal time bias, loss to follow-up), and confounding. 
 
3.2   SELECTION BIAS 
 
Selection bias occurs when a patient sample is identified that has a different 
relationship between drug exposure and outcome than the target population. This 
type of error can be introduced during the design or implementation stages of a 
study 178. Case-control and retrospective cohort designs are particularly 
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vulnerable to selection bias, due to the fact that both exposure and outcome have 
already occurred at the time the investigation is conducted. Thus, exposure 
status may influence the selection of cases and controls in case-control studies, 
and outcome may affect the identification of exposed and non-exposed subjects 
in retrospective cohort studies. Selection bias is less likely in prospective cohort 
studies, in which exposure is determined prior to outcome 11. The inclusion of 
patients in a study sample in a way that is systematically different from the 
actual distribution in the target population is very difficult to take into account in 
the data analysis, and therefore must be avoided as far as possible at the design 
and implementation stages 12. 
 
Several common forms of selection bias are presented below and illustrated 
with examples from the epidemiologic literature. Methods for preventing and, 
when possible, correcting for selection bias are discussed at the end of the 
section. 
 
3.2.1   Referral bias 
 
The use of healthcare databases to obtain epidemiologic data poses a risk of 
introducing referral bias. This error arises when patients referred to a healthcare 
institution (e.g., a hospital) are not representative of cases that originate in the 
community 178.  
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Women who experience leg pain, for example, may be more likely to receive a 
referral for in-hospital testing for venous thrombosis if they report the use of 
oral contraceptives to their primary care physicians. Awareness among 
healthcare providers of a possible contraceptive-related risk of thrombotic 
disease would thus result in the diagnosis of more cases of venous thrombosis 
in contraceptive users than non-users, and hospital databases would show a 
biased association between exposure and adverse outcome. After the 
publication of study data suggesting a positive association between a drug and a 
disease, the behavior of healthcare providers may change, increasing the risk of 
referral bias in subsequent studies. In such instances, the referral bias is termed 
popularity bias or publicity bias 12. 
 
Referral bias may be demonstrable even when the reasons for it are not 
apparent. Sorenson and colleagues evaluated the claim, made in previous case-
control and cohort studies, that supportive care at a tertiary medical center 
improves survival in patients with amyotrophic lateral sclerosis (ALS), a 
devastating neurological disease with a poor prognosis. The authors examined 
data on 132 patients treated at a tertiary ALS center within a general hospital. 
Forty-two of these subjects were local residents who received ALS care at the 
hospital as the sole inpatient facility in the area. The other 90 subjects were 
referred to the ALS center from more distant geographic regions.  
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Although both groups of patients had similar demographic characteristics, 
experienced a similar disease course, and received the same medical care for 
ALS, the referral patients had a significantly (p=0.007) longer median survival 
time after diagnosis than the local patients (29 months versus 18 months). In the 
absence of an obvious explanation, Sorenson and colleagues attributed the gap 
to “as yet unknown prognostic factors” that differed between the local and 
referral populations. They concluded that the apparent benefits of ALS 
treatment at a tertiary care center, as suggested by previous research, are likely 
attributable to referral bias, although no likely source for such bias has yet been 
identified. Regarding the results of their own study, Sorenson and colleagues 
speculated that the difference in survival rates may have been due to the fact 
that the referral patients were delayed in their first clinic visit until several 
months after diagnosis, which may have excluded patients with an especially 
short survival from this group 179. 
 
3.2.2   Self-selection 
 
Self- selection bias refers to the selective participation of certain subsets of 
individuals, and is primarily of concern when a large percentage of individuals 
asked to participate in a study decline to participate. If factors related to non-
participation (for example, younger, more educated people and women have 
been found to be more likely to participate) are also correlated with exposure or 
disease occurrence, this would result in a bias that may either mask or enhance 
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true associations. Self-selection of study participants presents a particular risk 
of bias for retrospective, interview-based case-control studies. In such 
investigations, exposure and outcome have already occurred at the time of 
recruitment, and decisions to participate may therefore be related to both 
exposure and outcome.  
 
In a typical example, mothers of children with birth defects are approached to 
participate in an interview-based study of potential associations between 
adverse pregnancy outcomes and medication use 12. It is plausible to assume 
that mothers who smoked during pregnancy are less likely to participate. This 
would result in a biased association of medication use and birth defects, for 
example, if mothers who smoked were less likely to use medications during 
pregnancy and more likely to give birth to children with adverse outcomes. 
Consequently, medication use among mothers of children with birth defects 
would be underestimated, resulting in a biased association of medication use 
and adverse outcome. 
 
In contrast, the use of databases on active workers may result in the 
underestimation of disease and mortality rates associated with exposures of 
interest. Self-selection occurs prior to the study, given that the actively 
employed are generally healthier than the overall population, which includes 
the retired and disabled. Such bias is termed the healthy worker effect 180. 
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Study investigators can avoid self-selection bias by employing methods to 
capture all cases in a population, such as using registry data. Approaches for 
minimizing selection bias in general are described in section 3.2.6. 
 
3.2.3   Prevalence bias 
 
The use of prevalent cases of disease in case-control and cross-sectional studies 
raises a potential for prevalence bias, also known as incidence-prevalence bias 
or Neyman’s bias. Prevalence bias arises when mortality from a disease is 
affected by the exposure under study. In an investigation of a potential link 
between smoking and the occurrence of acute myocardial infarction (AMI), for 
example, the investigators might interview AMI patients one week following 
the event to obtain their smoking status. If smoking increases mortality in the 
first days after AMI, however, the interviews would miss a disproportionate 
number of smokers who had already died from their AMI, and the study would 
thereby underestimate the association between AMI and smoking 178. The use 
of incident cases avoids the potential for prevalence bias, although incidence 
data may be difficult to obtain for conditions that have a gradual onset, such as 
Alzheimer’s disease 181. 
 
A similar error of particular interest for observational pharmacoepidemiologic 
studies is survivor treatment selection bias. Patients who live longer are more 
likely to try different medications than those who die sooner from an illness. A 
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correlation in a patient database between longer survival and use of a 
medication may lead to the erroneous conclusion that an ineffective treatment 
increased survival, whereas longer life in fact caused use of the treatment. 
Glesby and Hoover discuss this problem in relation to studies of AIDS 
therapies, and suggest statistical methods to mitigate the bias. Multivariate 
regression techniques, for example, may be used to adjust for prognostic factors 
and time of treatment initiation, thereby eliminating the effects of variables 
other than medication use. Better statistical approaches to the problem, 
however, are needed 182. 
 
3.2.4  Protopathic bias 
 
Protopathic bias arises when drug exposure is affected by the early signs and 
symptoms of the disease of interest, resulting in confusion of cause and effect. 
Such error is attributable to the fact that many diseases are not diagnosed until 
late after the first manifestations of illness. The appearance of bloody stools, for 
example, may lead individuals to discontinue taking aspirin. Patients later 
diagnosed with colon cancer would not be listed as aspirin users at the time of 
diagnosis, and the potential association between drug and outcome would be 
underestimated 12. 
 
Conversely, early symptoms of an illness may cause patients to start taking a 
drug, leading to the biased conclusion that use of the medication is positively 
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associated with the disease. Patients are likely to be prescribed a proton pump 
inhibitor for the relief of gastrointestinal symptoms, which may be the first 
indicator of as yet undetectable gastric cancer 183. 
 
The use of lag time provides one way to control for protopathic bias in the 
analysis of postmarketing pharmacoepidemiologic data. In this method, a 
specific period of time prior to disease diagnosis is excluded from the 
assessment of drug exposure in order to account for the possibility of a disease-
induced increase in drug use. Tamim and colleagues recently pointed out that 
no scientific criteria to determine the appropriate length of lag time have been 
developed. Using data from a previous case-control study of proton pump 
inhibitors and gastric cancer, they proposed a method for ascertaining the 
optimal amount of lag time to be used in an exposure assessment. A range of 
different lag times were applied to the study data, and commonly used 
statistical techniques were employed to select the lag time at which the 
association between proton pump inhibitor use and gastric cancer stabilized. 
According to the authors, this approach can be easily implemented and 
incorporated into future study manuscripts 183. 
 
3.2.5   Publication bias 
 
Selection bias can also occur after a study has been conducted, in the form of 
publication bias. Studies that produce statistically significant results are more 
153 
 
likely to be published in peer-reviewed journals, whereas null results are less 
likely to be communicated. Publication bias is attributable to both study 
investigators and journal editorial boards; authors may be less enthusiastic 
about pursuing publication of statistically nonsignificant findings, and editorial 
boards may be more prone to reject such articles. Publication bias can create the 
erroneous impression that a drug is more efficacious than is actually the case, 
by causing a disproportionate number of statistically significant studies to be 
available. Similarly, the risk of adverse events may be exaggerated as a 
consequence of publication bias against data that do not support a significant 
association between exposure and adverse outcome 184. 
 
In order to explore factors relevant to publication bias, Timmer and colleagues 
examined a random sample of abstracts submitted to Digestive Diseases Week, 
an important annual event in the field of gastroenterology. The sample included 
abstracts on 326 controlled clinical trials, 336 other clinical research reports, and 
174 basic science studies. Subsequent publication of findings in a medical journal 
was ascertained by a database search and a mailed questionnaire to the authors of 
each abstract. Significant predictors of publication in a peer-reviewed journal 
were acceptance of the abstract for publication at the meeting and multicenter 
status of the research (i.e., the abstract had authors from >3 research centers). 
Studies that did not produce statistically significant results were significantly less 
likely to appear in journals deemed to be “high impact” publications in the field 
185. 
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A related form of bias is reference bias, also known as citation bias, in which 
the authors of an article selectively cite statistically significant studies and omit 
non-significant findings. Even in the absence of reference bias on the part of 
their authors, meta-analyses are vulnerable to the effects of pre-existing 
publication bias, as only published studies can be included 184. 
 
Gøtzsche evaluated the presence of reference bias in articles that reported 
double-blind trials of non-steroidal anti-inflammatory drugs in rheumatoid 
arthritis. A total of 111 study reports were examined. For each article, Gøtzsche 
determined which drug was under evaluation in the trial, and counted the 
number of previous studies of the drug that were cited in the article. He then 
ascertained the total number of previous studies of the drug that were available 
to the authors at the time the article was written, and determined whether the 
outcome in each was positive or negative. In 22 of the 111 articles, the authors 
had cited a disproportionate number of studies with a negative outcome for the 
drug, compared to the total number of studies that were available at the time. 
The authors of 44 studies, however, had cited a disproportionate number of 
studies with a positive outcome, indicating a significant citation bias in favor of 
drug efficacy 186. 
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3.2.6   Avoiding selection bias 
 
Selection bias is difficult to control for during data analysis and must be 
prevented as far as possible in the design of the study. In addition to the 
strategies mentioned above for avoiding specific types of selection bias, the 
application of a few general principles can maximize the probability of 
obtaining a study sample representative of the target population. Random 
sampling of both cases and controls (or of exposed and non-exposed patients in 
cohort studies) is desirable. Well-codified accrual procedures that can be 
followed in the same way by different study investigators should be established. 
Recruitment of consecutive patients provides a way to avoid self-selection, and 
using a geographic definition of incident cases can reduce referral bias 12. 
 
Selection bias is in principle fairly easy to correct mathematically, but this is 
rarely achievable in practice. Two necessary preconditions for such a procedure 
are that the factors affecting subject selection have been measured and that the 
joint distribution of these factors in the entire source population is known. Such 
conditions rarely obtain in retrospective studies, and thus selection bias does 
not “lend itself readily to quantitative resolution.” 187 
 
3.3   INFORMATION/OBSERVATION BIAS 
 
Information bias, also known as observation bias, refers to systematic error in 
the collection of data on exposure or outcome. As with selection bias, 
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information bias can be introduced during the design or implementation of a 
study, and is more difficult than confounding to correct at the analysis stage. 
Information bias can occur in retrospective case-control or cohort studies, but 
may also compromise data collection in prospective investigations. Several 
common subtypes of information bias are discussed below, followed by a brief 
overview of methods for preventing or adjusting for such errors. 
 
3.3.1   Misclassification 
 
Misclassification of exposure occurs when study subjects are assigned the 
wrong exposure status. Given that some inaccuracy in data collection is 
inevitable, misclassification has the potential to arise in almost all 
epidemiological studies. If such error applies to both study groups equally, it is 
termed random or nondifferential misclassification. In a case-control study of 
spermicide use and adverse pregnancy outcomes, for example, exposure was 
defined as use of the agent within 600 days prior to birth. This definition would 
misclassify the exposure status of subjects who used spermicide before that 
period, and the error would apply to both cases and controls. Random 
misclassification increases the statistical similarity of the two study groups and 
therefore tends to produce an underestimation of the actual association of 
disease and exposure 11. 
 
157 
 
When misclassification of exposure applies to one study group more than the 
other, the error is said to be nonrandom or differential. For example, this type 
of error may occur in case-control studies in which knowledge of disease status 
affects the quality of information sought for previous exposure. (See more on 
this in the subsequent section “Detection bias.”) Depending on the source of 
nonrandom misclassification, the actual relationship between exposure and 
outcome may be either exaggerated or underestimated 12. 
 
In addition to bias due to systematic error in the measurement of exposure or 
covariates, epidemiological studies can be biased due to incorrect classification 
of disease status, or disease misclassification 178,188-191. For mortality studies, 
death certificates are commonly used to assess outcomes but the quality of the 
cause of death may be variable 192. In studies of non-fatal outcomes, sources 
include disease registries (e.g., cancer, congenital malformations, occupational 
disease notifications), health system records (e.g., hospital admissions, general 
practice records), health insurance claims, standardized questionnaires (e.g., by 
asking the question: “have you ever been told by a doctor that you had…”), and 
physiological measurements. The potential for error is present in all methods 
for assessing outcomes.  
 
In a mortality study, a specific cancer recorded on the death certificate as the 
underlying cause of death may instead have been metastatic disease for which the 
exposure of interest would not be etiologically relevant, or the underlying death 
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cause may differ entirely. Medical records, although an important source of 
clinical data for study participants, are intended for patient care and not 
systematically recorded for research purposes. The quality of clinical information 
from medical records is variable; incorrect information may be supplied by 
patients or it may be incorrectly recorded, medical records may be incomplete, 
the physician’s handwriting may be illegible, or the abstractor’s interpretation of 
the data in the medical record may be incorrect 193-195. The increased utilization of 
electronic health records is believed to improve quality of care and patient safety 
196 and may benefit clinical research as well. In United States studies using 
hospital discharge data, the phenomenon known as “DRG creep” may affect the 
accuracy of diagnosis data collected. DRG creep arises in United States studies 
when a patient’s illness is upcoded into the highest treatment category possible in 
order to increase hospital income by obtaining more reimbursement than would 
otherwise be due 197. Subjects’ self-report of past illness is affected by the type of 
medical condition, with recall being more accurate for well-defined and relatively 
easily-diagnosed diseases and less accurate for diseases characterized by complex 
non-specific symptoms. Physiological measurements may be affected by the use 
of inaccurate instrumentation, such as using only one size blood pressure cuff to 
take measurements on all adults regardless of body type 191.  
 
In a discussion of antibiotic resistance studies, Harris and colleagues illustrate 
the complexity of the challenges posed by misclassification bias. The authors 
describe two case-control studies designed to identify factors associated with 
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the emergence of antibiotic-resistant Pseudomonas aeruginosa in a single 
hospital. In the first investigation, cases were patients with positive cultures for 
the resistant organism, and controls were randomly selected from all patients 
admitted to the institution. Harris and colleagues note that control patients were 
subject to misclassification, however, as some were not administered bacterial 
cultures and thus may actually have been cases infected with resistant P. 
aeruginosa. This nonrandom misclassification bias would be expected to result 
in the underestimation of associations between risk factors and outcome. 
A second study was designed to avoid the misclassification bias. As in the 
previous study, control group patients were selected randomly from all hospital 
patients, but also had to have received at least one bacterial culture, which would 
confirm the absence of resistant P. aeruginosa in this group. As Harris and 
colleagues note, however, elimination of the misclassification bias introduced the 
potential for selection bias. Specifically, patients who receive bacterial cultures 
tend to be sicker than those who do not. The control group in the second study, 
therefore, had more severe illness than the control group in the first study and 
presumably also had a disproportionately higher share of risk factors. As a 
consequence, estimates of the associations between risk factors and antibiotic 
resistance were even lower in study two than in study one 198. 
 
Information on the sensitivity and specificity of the method employed to 
determine diagnosis may be used to assess potential bias due to disease 
misclassification. Estimates of positive and negative predictive values may also be 
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informative for this purpose, and are commonly used for treatment decisions and 
communication of disease risk to patients 199-202. These measures of diagnostic 
accuracy assume that a gold standard for diagnosing illness exists. For example, 
one study determined the validity of hospital discharge data on acute myocardial 
infarction by using a gold standard diagnosis which considered symptoms, cardiac 
biomarkers, and electrocardiographic evidence 203. Another study assessed the 
validity of dementia status in a disease registry using a well-established two-stage 
diagnostic process as the gold standard, and found that about half of the dementia 
patients were not recognized as such in the disease registry 204. 
 
Sensitivity represents the probability that a test is positive for disease (or, in 
record linkage studies, that a medical record or death certificate noted the disease) 
given that someone truly has disease. Conversely, specificity is the probability 
that a test is negative for disease when someone truly is without disease. The 
most helpful methods for classifying disease are those with high sensitivity and 
specificity. Predictive values measure the usefulness of a diagnostic test, sign or 
symptom. The positive predictive value (PPV) represents the probability that 
someone with a positive test truly has disease or will develop it in the future, 
whereas the negative predictive value (NPV) indicates the probability that an 
individual with a negative test does not have disease or remains disease-free 200-
202. While predictive values have a more intuitive clinical interpretation than 
sensitivity and specificity, they are influenced by the prevalence of disease in the 
population in which the test was administered. As the population prevalence 
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increases, the PPV will increase and the NPV will decrease. Therefore, it is not 
appropriate to apply the predictive values from one study population to another if 
they differ in underlying disease prevalence. Sensitivity and specificity are not 
affected by disease prevalence in the source population. 
 
Identification of outcomes should be consistent between the exposed and 
unexposed to avoid information bias. If errors in classification of disease status 
are made, the rate of such errors should be the same for exposed and unexposed 
participants, i.e., disease misclassification should be non-differential. This is 
best accomplished by blinding those who are responsible for determining 
outcomes to the exposure status of participants. For non-differential 
misclassification to be present, the sensitivity and specificity of determining 
outcome should be exactly the same in the exposed and unexposed group. With 
this type of bias, measures of association in epidemiological studies will on 
average be underestimated, i.e., there will be bias towards the null 189,200,201. 
However, a measure of association will be unbiased in the presence of non-
differential misclassification when specificity for detecting the outcome is 100 
percent (i.e., everyone without disease is correctly classified as such) and 
sensitivity is less than perfect 189. These observations apply to case-control 
studies or during follow-up in cohort studies, but not to the measurement of 
disease at baseline in cohort studies excluding people with prevalent disease 
from follow-up (because they are not at risk of disease). In this situation, non-
differential misclassification of disease at baseline can lead to over- or 
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underestimation of measurements of association, which highlights the need for 
highly sensitive tests for disease at baseline to excluded all diseased subjects 
from follow-up 205.  
 
The impact of non-differential error in disease classification was illustrated in a 
case-control study of prostate cancer 206. Large autopsy studies have found that 
about 30 percent of men have been found to have unsuspected prostate cancer, 
which would result in recruiting these men with indolent disease as controls for 
prostate cancer cases. Assuming non-differential disease misclassification, 
Godley and Schell reported that statistical power drastically reduced with an 
increasing error rate necessitating the need to increase the size of the study 
population by as much as three-fold to detect the hypothesized difference 206. 
The authors speculated that this methodological limitation is partially 
responsible for the lack of evidence for protective or harmful risk factors for 
prostate cancer.  
 
When errors in outcome assessment are more or less common among exposed 
as compared to unexposed participants, the misclassification of disease is said 
to be differential by exposure status. If disease misclassification is only 
approximately non-differential or more obviously differential, the impact on 
measures of association is less predictable. Jurek and colleagues found that 
small deviations from non-differential error in exposure measurement (and, by 
extension, in outcome measurement) could inflate measures of association by 
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four-fold or reduce them by half 200. In another simulation study, Chyou found 
that differential misclassification likely overestimates an exposure effect. The 
magnitude of bias appeared to depend not only on exposure status but also on 
the true magnitude of association and the proportion of misclassification 207. 
 
Disease misclassification is best avoided through proper study design as it is 
seldom possible to fully control for bias in the statistical analysis. Outcomes 
should be clearly defined, specific, and measurable 192,208. The diagnostic 
accuracy of methods employed should be determined in validation studies prior 
to initiating the epidemiological investigation. Investigators assessing outcomes 
should be unaware of participants’ exposure status to reduce the possibility of 
false-positive associations. 
 
3.3.2   Detection bias 
 
Detection bias describes a situation in which procedures for assessing exposure 
or outcome are dissimilar between study groups. Like recall bias (see below), 
detection bias is considered to be a source of differential misclassification bias, 
but may be conceptualized as a distinct topic due to its importance for study 
design and conduct. 
 
Both retrospective and prospective studies are vulnerable to detection bias. 
Awareness of disease status in a case-control study may influence data collection, 
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in that the investigators search more thoroughly for evidence of exposure among 
the cases. In cohort studies, follow-up may be more extensive for exposed 
patients. For example, women who take postmenopausal hormone therapy are 
likely to see their physicians more frequently than other women, and thus to 
receive a greater number of assessments for cancer or cardiovascular disease. 
Alternately, use of a drug associated with adverse gastric effects may result in 
more frequent diagnostic imaging in the exposed patients, leading to greater 
detection of other prevalent conditions (e.g., gallstones) in this group. If exposure 
or disease is systematically detected more accurately in one of the study groups, 
differential misclassification will result 12. 
 
Interviewer bias closely resembles detection bias but refers specifically to 
investigator error during the conduct of patient interviews. In case control or 
cohort studies, knowledge of the hypothesized relation between exposure and 
outcome may lead the interviewer to prompt study subjects in subtle ways. 
Verbal cues and gestures may elicit anticipated responses 178. 
 
3.3.3   Recall bias 
 
Retrospective studies are especially susceptible to the recall bias of study 
participants. Patients who have experienced an illness may reflect more 
thoroughly on possible causes of their condition, and subjects who were 
exposed to a possible risk may report subsequent symptoms with a greater 
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degree of accuracy. Family members or other caregivers display similar 
tendencies when interviewing on behalf of study subjects 11. 
 
In a recent study, Andrews and colleagues reviewed case notes on children 
diagnosed with autism in two different periods. The first set of notes was drawn 
from the years before mid-1998, when a widespread media discussion took 
place on a possible association between measles, mumps, and rubella (MMR) 
vaccination and risk of autism. The second set was taken from the years 
following this debate. At the time of diagnosis, parents were asked when they 
first noticed possible symptoms of autistic regression. Parents interviewed after 
the 1998 event recalled the first regressive symptoms shortly after MMR 
vaccination more often than those interviewed before widespread concern over 
this possible association 209. 
 
3.3.4   Immortal time bias 
 
Epidemiological cohort studies are frequently used to evaluate the efficacy, 
effectiveness and safety of medical interventions in specific patient populations. 
Randomized controlled trials are considered the gold standard for assessing 
treatment effects, but these studies are limited in their ability to generalize their 
findings to populations beyond the specific patient population studied and lack 
sufficient sample size to examine long-term outcomes beyond those of primary 
interest. Observational cohort studies, in particular those utilizing administrative 
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databases with routinely collected information on exposure such as medications or 
occupational toxins, address these limitations but need to be designed carefully 
because they are themselves subject to a variety of biases that may hamper 
interpretation. Specifically, immortal time bias has recently been suggested as an 
important source of systematic error in observational studies of inhaled 
corticosteroid treatment in patients with chronic obstructive pulmonary disease 
and asthma 210-216, multidisciplinary care and mortality among patients with 
chronic kidney disease 217, interferon-β treatment in multiple sclerosis 218, and 
statin therapy and the risk of dementia 219,220. 
 
Immortal time bias, also referred to as survival bias 221 or survivor treatment 
bias 182, is a form of information bias and refers to an error in the statistical 
analysis of cohort data in which a time-dependent exposure is treated as a time-
invariant factor 222,223. In its basic form, cohort members who are first exposed 
toward the end of follow-up would be classified as exposed for the entire 
follow-up period. In studies of therapeutic effects, this approach ignores the fact 
that patients who live longer have more probability to receive a certain 
treatment. That is, many patients who received treatment are healthier than 
those who did not, because inherent to the design of the study they are required 
to survive to the date of treatment whereas patients who die sooner have less 
time to select treatment and are therefore more likely to remain untreated 182. 
Thus, the rate of disease among patients who did not receive treatment may be 
artificially greater than among those who were treated. If the statistical analysis 
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does not account for a difference in treatment probability, immortal time bias 
will make the treatment appear more effective than it truly is 222 or in some 
cases suggest a health benefit when in truth the treatment may actually be 
harmful 216. Another form of immortal time bias, which we call “follow-up 
bias” (not to be confused with “bias due to loss to follow-up”), may occur when 
patients are followed for different study durations due to differences in the time 
specific medications were available for prescription. That is, patients who are 
prescribed drugs that were available earlier may have a longer duration of 
follow-up, possibly resulting in different outcomes. This form of potential bias 
may be circumvented by ensuring the same maximum duration of follow-up for 
all patients.  
 
Immortal time bias will be discussed in more detail in the context of our 
analysis of cerebrovascular disease in Alzheimer’s disease patients (Chapter 6). 
 
3.3.5   Avoiding information/observation bias 
 
The potential for information bias can be reduced through careful attention to 
the design of data collection instruments and the procedures used by study 
interviewers. Questionnaires should be constructed using specific, closed-ended 
questions that leave little room for interpretation by the interviewer or subject. 
Standardized training in data collection procedures, such as physical 
examinations and interviews, limits the likelihood of detection bias. If possible, 
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interviewers should be blinded to the disease status of subjects when 
determining exposure in a case-control study, or to the exposure status of 
subjects when ascertaining outcome in a cohort study. Investigators can 
minimize the potential for recall bias on the part of subjects by concealing the 
hypothesis of the study. In an investigation evaluating the association between 
alcohol consumption and cardiovascular disease, for example, interviewers may 
ask about other risk factors in addition to alcohol use, such as exercise, 
smoking, and diet, to mask the study purpose. 
 
The use of dummy variables with a known relationship to exposure or outcome 
provides a way to assess for detection bias or recall bias. In a case-control study 
of the association between aspirin use and cardiovascular disease, the 
interviewer might inquire about the use of other types of analgesic. If cases and 
controls differed in their use of aspirin but not other analgesics, the 
investigators would find support for the conclusion that there was a real 
difference in aspirin intake between the study groups. On the other hand, if the 
reported use of both aspirin and the other medications was increased among 
cases, a suspicion of detection or recall bias would be warranted 11. 
 
Inclusion of multiple data sources allows independent verification of exposure 
or disease status 11. Opportunities for improving the quality of data are expected 
from the increase in use of electronic medical records that encompass both 
clinical and administrative information 224. 
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Compared to selection bias, misclassification bias is more amenable to 
correction during data analysis 187. According to Gustafson and Greenland, 
several methods of controlling for misclassification have been described in the 
literature. Most study investigators, however, “rely on intuition to comment 
qualitatively on how misclassification might impact their findings,” rather than 
conducting a formal statistical analysis of the impact of the bias. Given that the 
effects of misclassification are difficult to estimate intuitively, Gustafson and 
Greenland call for greater use of such analysis in future studies 225. 
 
3.4   CONFOUNDING 
 
Confounding refers to the effect of the exposure under study being mixed with 
the effect of a third factor that is associated with the exposure and 
independently affects the risk of developing the disease 11. The extraneous 
factor is the confounding variable, such as age or sex.  
 
For instance, in a study of the risk of heart disease in people who exercise 
frequently and those who do not, confounding would occur if the people 
who exercised frequently smoked less than those who did not exercise. 
Participants who exercise might thus have a lower risk of heart disease because 
they smoked less, and not because they exercised more. 
 
170 
 
Confounding is an important concept in pharmacoepidemiology because, if 
present, it can cause an over- or under-estimate of the observed association 
between exposure and disease. The distortion introduced by a confounding 
factor can be large, and it can even change the apparent direction of an effect. 
However, confounding is easier to adjust for in the analysis compared to 
selection and information bias. 
The key issue for interpretation is whether adequate steps have been taken to 
identify and control for possible confounders. Even in the best studies it may be 
hard to totally exclude the possibility of confounding by some unknown factor. 
One of the main advantages of randomization is that it controls for known 
confounders. 
 
3.4.1   Necessary conditions for confounding 
 
If no other biases are present, three conditions are necessary for a factor to be a 
confounder 180: 
1) Must be a risk factor for the disease 
A confounder is a factor which is predictive of disease in the absence of the 
exposure under study. Note that a confounder need not be a genuine cause of 
disease, but merely “predictive.” Therefore, surrogates for causal factors (e.g., 
age) may be regarded as potential confounders, even though they are rarely 
directly causal factors.  
2) Must be associated with the exposure under study in the source population 
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A confounder is associated with exposure in the source population at the start of 
follow-up (i.e., at baseline). In case-control studies this implies that a 
confounder will tend to be associated with exposure among the controls. An 
association can occur among the cases simply because the study factor and a 
potential confounder are both risk factors for the disease, but this does not 
cause confounding in itself unless the association also exists in the 
source population.  
3) Must not be affected by the exposure or the disease 
Thirdly, a variable which is affected by the exposure or the disease (e.g., 
an intermediate in the causal pathway between exposure and disease, or 
a symptom of disease) should not be treated as a confounder because to do so 
could introduce serious bias into the results 226. 
For example, in a study of high fat diet and colon cancer, it would 
be inappropriate to control for serum cholesterol levels if it was considered that 
high serum cholesterol levels were a consequence of a high fat diet, and hence a 
part of the causal chain leading from diet to colon cancer. On the other hand, if 
serum cholesterol itself was of primary interest, then this should be studied 
directly, and a high fat diet would be regarded as a potential confounder if it 
also involved exposure to other risk factors for colon cancer. Evaluating this 
type of possibility requires information external to the study to determine 
whether a factor is likely to be a part of the causal chain. Intermediate variables 
can sometimes be used in the analysis, but special techniques are then required 
to avoid adding bias 227. 
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3.4.2   Confounding by indication 
 
Confounding by indication is a frequent problem in pharmacoepidemiology. 
This term refers to the fact that patients at particular risk of an adverse outcome 
tend to receive specific drugs. For example, in a comparison of gastrointestinal 
bleeding rates in patients treated with selective COX-2 inhibitors and those 
using standard NSAIDs, the risk may appear to be higher with COX-2 
inhibitors. This is due to the patients rather than the drug, however; COX-2 
inhibitors are selectively prescribed to patients at high risk. The same methods 
used to control for confounding in general are used for confounding by 
indication. 
 
3.4.3   Control of confounding 
 
Avoidance of confounding bias is limited by the source of data used to describe 
practice patterns, especially when using administrative databases to compare 
outcomes among patients who receive different treatments. Confounding bias 
arises from many factors such as the treatment under study, comorbid diseases, 
severity of illness, and patient, physician and environmental factors. Factors 
such as these are likely to influence treatment decisions but are difficult to 
capture in recorded data 228. Pharmacoepidemiologists who use administrative 
databases cannot adjust for imbalances in prognostic factors that are not 
captured or poorly categorized. Clinical details from patient charts may be 
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needed to permit full adjustments. Further data collection might solve this issue, 
but this is not always possible. Confounding can be controlled in the study 
design, in the data analysis, or both. 
 
3.4.3.1   Control of confounding at the design stage 
 
Control at the design stage involves three main methods: randomization, 
restriction and matching 180: 
 
Randomization 
As random allocation to exposure categories is not an option in studies using 
administrative data, it will not be discussed further. 
 
Restriction 
Confounding can be controlled for by restricting the study population to those 
who are unexposed to one or more confounding variables.11 Another approach 
is to restrict the study to narrow ranges of values of the potential confounders, 
e.g., by limiting the study to white males aged 35-54. Restriction of some sort is 
always part of study design, since virtually all studies deal with delimited 
geographical area and specific age range, though the motive may be feasibility 
rather than avoidance of confounding. If it is known or suspected that an 
association is strongest in a particular population subset, then it may make 
sense to focus the study on that group. Or, if there are few data available that 
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apply to a particular population, it may make sense to restrict study participants 
to persons in that population. This approach has a number of conceptual and 
computational advantages, but may severely limit the number of potential study 
subjects and the generalizability of the study, as effects in younger or 
older people will not be observable.  
 
Matching 
A third method of control involves matching study subjects on 
potential confounders. Matching involves constraining the control group (for 
case-control studies) or the unexposed group (for cohort studies) such that the 
distribution of the confounding variables within these groups is similar or 
identical to the corresponding distribution within the other study group 12. 
Matching can be viewed as imposing a “partial restriction” on the values of the 
confounding variables, since only the control or unexposed group is restricted. 
For example, in a cohort study one would match a white male non-exposed 
subject aged 35-39 with an exposed white male aged 35-39. This will prevent 
age-sex-race confounding in a cohort study, but is seldom done because it may 
be very expensive. Matching can also be expensive in case-control studies, and 
does not prevent confounding in such studies, but it can be beneficial, though, 
since if important potential confounders are similarly distributed in cases and 
controls, the comparison of these two groups can be more statistically efficient 
– with the same number of participants, the confidence interval for the odds 
ratio estimate will be narrower, therefore more precise. In some cases, matching 
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can lead to reduced statistical efficiency. If the matching variables are strongly 
associated with the exposure, then the exposure prevalence in matched controls 
will be more similar to that in cases than would occur for an unmatched control 
group, thereby diminishing the observed strength of association between 
exposure and disease. If the matching factors are not strong risk factors for the 
disease, then “overmatching” has occurred and a true association may be 
completely hidden 11. 
 
Matching may actually reduce precision in a case-control study if it is done on 
a factor which is associated with exposure, but is not a risk factor for 
the disease of interest. However, matching on a strong risk factor will 
usually increase the precision of effect estimates. Techniques for analyzing 
matched data include conducting the data analysis separately for each level of 
confounder (stratified analysis) and using conditional logistic regression. 
 
3.4.3.2   Control of confounding in the analysis 
 
Some confounders should be controlled for in the study design stage, rather 
than in the analysis, particularly when the confounder is very strong and when 
the anticipated sample size is large enough to allow it. When study investigators 
cannot control for confounding in the design (and this is possible only rarely), 
they adjust for confounders in the analysis 11. 
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Common methods of adjusting are: stratification, modeling/multivariate 
analysis, standardization, and instrumental variable analysis. A fifth method 
consists of balancing by propensity score. This method avoids the problem of 
sparse cells and allows many potential confounders to be taken into account.  
 
Stratified analysis 
This technique involves stratifying the data according to the levels of 
the confounder(s) and calculating an effect estimate which summarizes 
the association across all strata 229. It is usually not possible to control 
simultaneously for more than two or three confounders in a stratified analysis 
because as the number of strata grows large, understanding and interpreting the 
results may present a major challenge, especially if the results vary from one 
stratum to another without any obvious pattern 230. Such strata 
are uninformative; thus, fine stratification is wasteful of information. This 
problem can be mitigated to some extent by the use of multiple regressions 
which allows for simultaneous control of more confounders by “smoothing” the 
data across confounder strata. Despite these limitations, stratified analyses are a 
popular approach to control for confounding. 
 
Modeling/multivariate analysis 
Modeling, also known as multivariate analysis, consists in identifying possible 
confounders, measuring them, and then statistically controlling for them. The 
relationship between risk factors and outcome is modeled mathematically to 
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allow the assessment of many factors simultaneously 12. This approach, 
although the most common in practice, is far from optimal. First, researchers 
can never be sure that all the confounders have been identified, and second, 
some might have been measured inadequately. Another limitation is that the 
results from these analyses rely on the linearity of the model 231. 
An important consideration when using regression adjustment is proper 
specification of the model, which can be difficult when several potential 
confounders exist. One solution is to summarize covariate information using a 
propensity score (discussed below) which then can be used as a single covariate 232. 
 
Standardization 
Standardization controls confounding by application of a standard distribution 
of confounding variables to all exposure groups 233. There are two methods of 
standardization, direct and indirect. In direct standardization, the stratum-
specific event rates in study populations are applied to the distribution of 
confounding variables present in a “standard” or “reference” population. In 
indirect standardization, a set of stratum-specific event rates is selected from the 
reference population and applied to the distribution of the confounding 
variables in the study population 229. 
 
For example, in an adjustment for age using direct standardization, the external 
standard is an age distribution. This can be the world age distribution, country 
or province age distribution, or can be the distribution in one of the populations 
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being compared. Stratum-specific event rates (i.e., age-specific rates) of each 
study population are then extrapolated to the number of individuals in the 
corresponding stratum in the standard population. In indirect age 
standardization, the external standard is a set of age-specific event rates in the 
reference population, which are then applied to the age distribution in the study 
sample. What distinguishes standardization from other stratified methods of 
controlling for confounding is use of an external standard as the basis for 
comparison. 
 
Instrumental variables analysis 
The core of the method is to use one or more instrumental variables to isolate 
the effect of treatment variation that is independent of unobserved patient 
characteristics 234. Instrumental variables are observable factors that influence 
treatment but do not directly affect patient outcomes. The use of this method 
enables statistical pseudo-randomization and accounts for any residual 
confounding 235. 
 
There are two key assumptions of the instrumental variable technique: that the 
instrument has no independent effect on the outcome and that variation in the 
instrumental variable causes substantial variation in the treatment variable.236 If 
the instrumental variable fulfills these two assumptions, and the sample size is 
adequate, a reasonably good estimate of the effect of the treatment on the 
outcome variable can be obtained.  
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The most challenging part of applying the instrumental variable approach is 
finding ‘good’ instruments which influence the choice/quantity of treatment yet 
do not introduce further bias by being directly correlated with treatment 
outcome. 
 
Propensity scores 
One technique that is gaining ground in adjustment to control for confounding 
by indication is the propensity score. The propensity score is defined as the 
probability of being assigned to a particular treatment conditional to the 
observed covariates 237. The basic idea of propensity score methods is to 
summarize the observed covariate information for each subject as a single score 
(propensity score), which is used to match or group subjects into 
subclassifications 238. When covariates contain no missing data, the propensity 
score can be derived from a discriminant analysis or multivariable logistic 
regression in which those variables that are significantly associated with 
exposure are included. It is important that the outcome variable is not included 
as a covariate 231. 
 
Matching, stratification, and regression adjustment are three of the most 
common techniques that use propensity scores to make an adjustment for 
covariates prior to (matching and stratification) or during (stratification and 
regression adjustment) the calculation of treatment effect. All three methods 
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calculate the propensity score in the same manner but differ in the way the 
estimated score is applied 238. 
 
An important advantage of these methods over regression adjustment is that the 
investigator may discover that there is essentially no overlap in the distributions 
of the covariates in the treated and control groups. In that case, there is no hope 
of drawing valid causal inferences from these data without making strong 
external assumptions involving extrapolation.  
 
Despite the broad utility of propensity score methods, when addressing causal 
questions from observational studies, it is important to keep in mind that even 
propensity score methods can only adjust for observed confounding covariates 
and not for unobserved ones. Another limitation of propensity score methods is 
that they work better in larger samples. A final possible limitation of propensity 
score methods is that a covariate related to treatment assignment but not to 
outcome is handled identically to a covariate with the same relation to treatment 
assignment but strongly related to outcome. 
 
3.4.4   Limitations of methods to control for confounding 
 
Unknown and unmeasured potential confounders can be controlled only 
through randomization. This unique advantage of randomized designs is a 
primary reason for their particular strength. Even for potential confounders that 
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are controlled (through restriction, matching, stratified analysis, modeling, etc.), 
limitations or errors in the conceptualization, measurement, coding, and model 
specification will compromise the effectiveness of control. Such incomplete 
control results in “residual confounding” by the potential confounder. Residual 
confounding, like uncontrolled confounding, can lead to bias in any direction 
(positive or negative, away from the null or towards the null) in the adjusted 
measure of effect between the study factor and outcome. Even if measurement 
error in the potential confounder is nondifferential (i.e., independent of the 
study factor and outcome), the bias in the association of primary interest can be 
in any direction. It is important to be aware of these limitations while planning 
observational studies whether using administrative data or not. 
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4.0   ORIGINAL STUDIES OF CHOLINESTERASE INHIBITORS FOR 
ALZHEIMER’S DISEASE 
 
4.1   BACKGROUND 
 
As comprehensively described in Chapter 2, dementia is a widespread public 
health problem that affects tens of millions of individuals worldwide, and is a 
leading contributor to disability, institutionalization, and death in the elderly 
population. As of 2001, a Delphi panel of experts estimated that 24.3 million 
people aged 60 years and older had dementia, yielding a global prevalence rate 
of 3.9% among older individuals 1. Because the prevalence of dementia 
increases with age 239, experts anticipate that the aging of the world population 
will trigger a surge of 4.6 million new dementia cases per year, such that 81.1 
million patients may be diagnosed with dementia by the year 2040 1. An 
estimate of global economic burden placed the direct medical costs of dementia 
at more than $150 billion in 2003 alone 240. Clearly, a growing number of 
elderly dementia patients has grave health economic implications.  
 
Among the various forms of dementia, AD is widely considered to be the most 
common, accounting for up to 76% of all dementia cases 2. The next most 
common dementia subtype is thought to be vascular dementia (VaD) 241-244, 
which was identified in 19% of Canadian dementia patients 2. Traditionally, 
AD and VaD have been construed as discrete entities, with AD representing a 
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progressive, irreversible, degenerative disorder, and VaD conceptualized as the 
product of stroke and other forms of cerebrovascular disease (CVD) 245. 
Challenging this traditional notion, however, accumulating evidence suggests 
that AD and VaD share common pathophysiological mechanisms, and that the 
two subtypes frequently co-exist 98. When a patient presents with dementia in 
the context of CVD, it may be difficult to determine whether the CVD is the 
primary cause of cognitive decline (as in VaD), a contributor to AD pathology 
(as in AD with CVD), or simply an unrelated phenomenon. Difficulties in 
differentiating between VaD and AD with CVD (or “mixed dementia”) have 
led some researchers to lump both groups together under the classification of 
VaD or, more recently, vascular cognitive impairment 4. 
 
Studies comparing dementia subtypes generally find a higher mortality rate in 
patients with vascular forms of dementia (VaD or AD with CVD), compared 
with AD alone 148,246,247. In addition, stroke patients who develop dementia 
(VaD or AD with CVD) have exhibited an increased risk of death, relative to 
those without cognitive decline 150. Taken together, these data suggest that AD 
and CVD may be associated with a high death rate in combination than alone, 
and raise the question of whether anti-dementia treatment has differential 
effects on mortality and other important outcomes in patients with and without 
CVD.  
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The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine 
have been approved for the treatment of AD in Canada, based on evidence 
obtained from randomized controlled trials showing a beneficial effect on 
symptomatic progression. Although some studies have found similar benefits 
of ChEIs in VaD 242,244,248-250, the evidence to date has been deemed 
inconclusive to merit this indication. Diagnostic uncertainty in patients 
presenting with dementia following CVD creates an important treatment 
dilemma, as it remains unclear whether the presence of CVD, which might be 
associated with more complex functional gaps and higher disease burden, is 
sufficient to deny a patient access to ChEI treatment. To address this question, 
we conducted the retrospective cohort study of ChEIs in patients with dementia 
described in Chapter 5 and the methodological analysis of the impact of bias 
presented in Chapter 6. 
 
4.2   OBJECTIVES & HYPOTHESIS 
 
The retrospective cohort study reported in Chapter 5 was designed to facilitate 
treatment decisions by examining whether co-existing CVD is associated with 
outcomes of AD patients receiving ChEIs. The outcomes of interest included 
mortality and nursing home placement (NHP), which has been identified as one 
of the most significant cost drivers for dementia 251 and vascular cognitive 
impairment 152.  
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Based on the current literature, we hypothesize that times to death and NHP are 
shorter among ChEI-treated patients with CVD than in those without CVD. 
Accordingly, the primary objective of the retrospective cohort study reported in 
Chapter 5 was to determine whether concomitant CVD significantly decreases 
time to the composite outcome of death or NHP (or, stated differently, whether 
the hazard ratio for death and NHP, comparing patients with CVD to those 
without, is greater than one). Secondary objectives of this study were to 
determine whether concomitant CVD significantly decreases time to the 
separate outcomes of death or NHP, and to identify predictors of death or NHP 
during and after ChEI treatment in AD patients with and without CVD.  
 
As detailed in section 3.3.4, observational cohort studies may be subject to 
immortal time (and follow-up) bias unless appropriate analytic methods that 
circumvent these biases are undertaken. However, the potential impact of these 
biases in studies of patients with AD has not previously been assessed. We 
hypothesized that retrospective analyses using the RAMQ databases of 
outcomes in AD patients associated with ChEI treatment would yield 
misleading results if these biases were not avoided. Thus, the primary objective 
of the methodological analysis of the RAMQ databases reported in Chapter 6 
was to evaluate the impact of immortal time bias on the estimated risk of death 
or NHP among AD patients who took rivastigmine or galantamine compared to 
those who were prescribed donepezil. A secondary objective of this study was 
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to examine whether an unbiased analysis would suggest differences in 
effectiveness among the three ChEIs. 
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5.0   A RETROSPECTIVE STUDY OF CHOLINESTERASE 
INHIBITORS FOR ALZHEIMER’S DISEASE AND ALZHEIMER’S 
DISEASE WITH CEREBROVASCULAR DISEASE 
 
5.1   INTRODUCTION 
 
In the Province of Québec, Canada, the Régie de l’Assurance Maladie du 
Québec (RAMQ) is the provincial government agency responsible for public 
health programs, including reimbursement of prescription claims and physician 
services. Data for this study were extracted from two of the RAMQ 
administrative databases, the prescription claims database and the medical 
services database. These databases contain a unique identifier for each patient 
making it possible for subject information to be linked to medical services 
consumed and to prescribed medications dispensed as part of the public 
reimbursement scheme. Eligible beneficiaries of the drug reimbursement 
program are persons 65 years and older, those on social assistance, or working 
individuals not enrolled in an employer-sponsored drug reimbursement 
program. The validity of the prescription claim database as sources of accurate 
information on drugs dispensed to seniors in Québec has been established 252. 
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5.2   METHODS 
 
5.2.1   Study Population 
 
A retrospective cohort study of patients was undertaken using RAMQ 
databases—drug claims and medical services—to examine the time to NHP or 
death for patients 66 years of age or older (universal drug coverage starts at age 
65), diagnosed with AD with or without CVD, who had been treated with a 
ChEI between July 1, 2000, and June 30, 2003. 
 
Data obtained from RAMQ included all patients who had received at least one 
dispensation of a ChEI between January 1, 2000, and June 30, 2003. From the 
extracted data, a cohort of patients who met the following inclusion criteria was 
created: 
• At least one dispensation of a ChEI between July 1, 2000, and June 30, 
2003; 
• A complete drug reimbursement coverage for the year prior to the date of 
the first dispensation of a ChEI (index date); 
• 66 years of age or older (because coverage starts at age 65 years, this 
allowed for the one year of coverage prior to the index date). 
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The index date for each patient was defined as the date of the first prescription 
for a ChEI. Patients in a nursing home at the time of the index date were 
excluded.  
 
From the resulting cohort, two study groups—AD and AD with CVD—were 
defined as follows: 
AD:  
• at least one dispensation of a ChEI; 
• diagnosis of AD on the basis of an ICD-9 diagnostic code for AD (290.0-
290.4, 290.8, 290.9, 331.0, 331.2); 
• no diagnosis for stroke; 
• no endarterectomy; 
• no diagnosis for transient ischemic attack (TIA) in the six months 
preceding the index date; 
• patients with a diagnosis of myocardial infarction (MI) or peripheral 
vascular disease (PVD) (lifetime) were included.  
 
AD with CVD: 
• at least one dispensation of a ChEI; 
• a diagnosis of AD was not required (this allowed capture of not only 
patients with mixed dementia, but also those with pure VaD); 
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• diagnosis of stroke (ICD-9 codes 430–438) or endarterectomy (ICD-9 code 
V151)(lifetime), or TIA (ICD-9 code 435.9) within the six months prior to 
the index date. 
 
These criteria are likely to clearly distinguish between AD and AD with CVD 
except in the subset of AD patients with CVD in whom CVD is subclinical 
(i.e., not yet symptomatic) and therefore undiagnosed. Such patients would be 
incorrectly assigned to the AD-only subgroup. 
 
5.2.2   Assessment of ChEI Medication Use 
 
Three ChEIs are approved for use in Canada and are reimbursed by RAMQ: 
donepezil (first dispensation in database, April 19, 2000), galantamine (listed 
on the Quebec formulary and therefore available in the database since October 
2, 2000), and rivastigmine (available in the database since June 2, 2002). In 
order for a patient’s first prescription claim for one of these ChEIs to be paid 
by RAMQ, the prescribing physician must submit a form with the clinical 
diagnosis (AD, Lewy body dementia, mixed dementia, or other type of 
dementia, which must be specified), the patient’s score on the mini-mental state 
examination (MMSE)—accepted if between 10 and 26—and report on the 
patient’s level of impairment within five domains: cognition, mood, behaviour, 
autonomy, and social interaction. For further reimbursements to be approved, 
the physician must, at 6- to 12-month intervals, record a decline in MMSE 
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score of no more than 3 points per 6-month period, as well as stabilization or 
improvement in three of the five clinical domains. 
 
5.2.3   Outcome Assessment 
 
The study's primary endpoint was time to the composite of NHP and death. 
Secondary endpoints included the following: time to NHP and time to death. 
An additional secondary outcome was the amount of variability in death or 
NHP during and after ChEI treatment in AD patients with and without CVD 
that was explained by different potential confounding factors.  
 
A first survival analysis was done among patients with continuous ChEI use. 
Continuous use was defined as renewal of ChEIs before the end of the 
prescription plus a grace period (50% of the prescription duration) plus 
overlap. An overlap was observed when a patient renewed a prescription before 
its end and was defined as the number of days between the actual date of 
renewal and the estimated end date of the prescription. A second survival 
analysis was performed among patients who discontinued the ChEI therapy. 
 
5.2.4   Statistical Analysis 
 
Bivariate analyses compared the characteristics of AD patients with and 
without CVD. T-test and chi-square test were used for continuous and 
categorical comparisons, respectively. 
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Kaplan-Meier estimators were used to estimate the probability of NHP, death and 
NHP/death for AD patients with and without CVD during the ChEI therapy and 
after the discontinuation of the ChEI therapy. A log-rank test was performed to 
measure the difference between the two groups. This analysis was adjusted for 
several factors including the index drug (donepezil, galantamine, rivastigmine); 
the socio-demographic variables: age at index date and gender; and use of 
healthcare services measured by the number of hospitalizations, the number of 
days of hospitalization, the number of visits to a general practitioner (GP), the 
number of visits to a specialist, and the number of visits to an emergency room 
(ER) during the year preceding the index date. In addition, the impact of several 
different comorbidities, including diabetes and cardiovascular conditions, was 
included in the model using the Chronic Disease Score (CDS), calculated based 
on the use of medications in the year prior to the index date 253. To quantify this 
score, medications for the treatment of specific chronic diseases were assigned a 
weighting factor based on the seriousness of the condition for which they were 
prescribed, and a patient’s CDS was determined by adding up the appropriate 
weighting factors for each medication. Medications that are frequently used only 
for symptom management (e.g., analgesics, anti-inflammatory drugs, 
antidepressant agents) were not included in the score. The scoring rules used to 
calculate the CDS are shown in Table 32. The overall score ranged from 0 to 21. 
Moreover, since patients in the AD with CVD group were not required to have a 
diagnosis of AD, the presence or absence of a diagnosis of AD before or at the 
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index date was controlled for in the analysis. Because diagnosed urinary 
incontinence increases the risk for admission to a nursing facility 254, the presence 
or absence of a diagnosis of urinary incontinence on the basis of ICD-9 code was 
also included as an exploratory variable in the analysis. 
 
Table 32. Scoring rules used to calculate the Chronic Disease Score from 
claims in the RAMQ database for medications for chronic diseases 253 
Chronic disease Score for medication class(es) 
Heart disease One class = 3 
Two classes = 4 
Three classes = 5 
Respiratory illness One class = 2 
Two or more classes = 3 
Asthma Glucocorticoids = 3 
Cromolyn = 2 
Rheumatism 3 
Rheumatoid arthritis 3 
Cancer 3 
Parkinson’s 3 
Hypertension Beta blockers, diuretics = 1 
Other antihypertensives = 2 
Diabetes 2 
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Chronic disease Score for medication class(es) 
Epilepsy 2 
Acne 1 
Ulcers 1 
Glaucoma 1 
Gout, hyperuricemia 1 
High cholesterol 1 
Migraines 1 
Tuberculosis 1 
 
Cox regression analyses were used to identify predictors of NHP or death, 
among patients with either continuous or discontinuous ChEI therapy. Adjusted 
rate ratios were calculated to assess the independent effects of group status 
(AD vs. AD with CVD), index drug (donepezil vs. galantamine vs. 
rivastigmine), and sociodemographic variables, on the primary outcome 
measure.   
 
Statistical analyses were performed using SAS software, version 9.1 (SAS 
Institute Inc, Cary, NC). 
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5.3   RESULTS 
 
The RAMQ databases provided information on 17,940 patients who met the 
inclusion/exclusion criteria; 13,512 were included in the AD group, while 
4,428 were classified as having AD with CVD. In the group with AD alone, 
629 patients (4.7%) had had a TIA more than six months before their index 
date, or had experienced PVD or MI within their lifetime. In the AD with CVD 
group, 4,211 patients (95.1%) had incurred stroke only, 79 (1.8%) had 
experienced TIA only, and 138 (3.1%) had a history of both TIA and stroke. 
 
Table 33 shows demographics and characteristics of the study groups at index 
date. There was a greater number of women (p<0.05) in the group with AD 
only, which is consistent with observations of a female predominance in AD 
and a predominance of males in vascular forms of dementia 2. Donepezil was 
dispensed as the index drug for the majority of patients in both the AD and AD 
with CVD groups (82% and 78% respectively, p<0.05).  
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Table 33. Patient demographics, index drug, and index year 
 
 AD 
(n=13,512) 
AD with CVD 
(n=4,428) 
Age (years)*   
 mean ± SD 79.4 ± 6.2 80.3 ± 6.0 
   
Age group: n (%)   
 66–75 years* 3,718 (27.5) 967 (21.8) 
 76–85 years* 7,477 (55.3) 2,532 (57.2) 
 86–95 years* 2,268 (16.8) 920 (20.8) 
 96 +  years      49 (0.4)     9 (0.2) 
   
Women: n (%)* 9,343 (69) 2,783 (63) 
   
Index drug: n (%)   
 donepezil* 11,025 (82) 3,468 (78) 
 galantamine* 1,008 (7) 389 (9) 
 rivastigmine* 1,479 (11) 571 (13) 
   
Chronic Disease Score (CDS) 3.80 ± 3.10 4.58 ± 3.30 
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 AD 
(n=13,512) 
AD with CVD 
(n=4,428) 
Incontinence (%) 1,323 (10) 580 (13) 
   
Year of index date (%)   
 2000* 3,172 (24) 883 (20) 
 2001 3,619 (27) 1,205 (27) 
 2002* 4,518 (33) 1,560 (35) 
 2003* 2,203 (16) 780 (18) 
*p<0.05 
AD: Alzheimer’s disease; CVD: cerebrovascular disease 
 
Relative to patients with AD alone, those in the AD with CVD group were 
dispensed significantly more drugs (in addition to the index ChEI) during the 
year prior to index date (p<0.05) (Table 34). Of these additional medications, 
the majority were cardiovascular drugs such as anti-platelets, anti-
hypertensives, and lipid-lowering agents. 
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Table 34. Prescriptions for medications, other than ChEIs filled in the year 
prior to index date 
 
 AD 
(n=13,512) 
AD with CVD 
(n=4,428) 
Dispensations   
 mean* ± SD 60 ± 86 83 ± 95 
   
Other medications dispensed: n (%)   
 Statins* 2,489 (18) 1,149 (26) 
 NSAIDs 3,584 (27) 1,221 (28) 
 anti-hypertensive* 8,222 (61) 3,239 (73) 
 anti-platelets* 191 (1) 495 (11) 
 Antipsychotic* 2,095 (16) 759 (17) 
*p<0.05 
AD: Alzheimer’s disease; CVD: Cerebrovascular disease; NSAIDs: Non-
steroidal anti-inflammatory drugs 
 
In terms of healthcare resource utilization during the year prior to the index 
date (Table 35), AD with CVD patients were hospitalized significantly more 
frequently and for significantly longer periods of time (p<0.05) than were the 
patients with AD alone (3.6 vs. 2.2 days respectively). In addition, the AD with 
CVD patients were more likely than those with only AD to have seen a 
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specialist or visited the ER in the year prior to the index date, despite having 
been followed for a shorter time by the prescribing physician. (p<0.05).  
 
Table 35. Healthcare resource use/patient in the year prior to index date 
 
 AD 
(n=13,512) 
AD with CVD 
 (n=4,428) 
Hospitalizations (all causes)*   
 mean ± SD 0.7 ± 1.4 1.1 ± 1.7 
   
Days of hospitalization*   
 mean ± SD 2.2 ± 5.7 3.6 ± 7.3 
   
Specialty of physician prescribing ChEI at index 
date: n (%) 
  
 GP 10,029 
(74) 
3,238 (73) 
 Neurologist 1,934 (14) 697 (16) 
 Geriatrician 760 (6) 254 (6) 
 Psychiatrist 509 (4) 146 (3) 
 Internist 125 (1) 44 (1) 
 Other 128 (1) 44 (1) 
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 AD 
(n=13,512) 
AD with CVD 
 (n=4,428) 
Duration of follow up (days)*   
 mean ± SD 533 ± 334 496 ± 325 
   
GP visits*   
 mean ± SD 5.4 ± 4.9 6.3 ± 5.5 
   
Specialist visits*   
 mean ± SD 3.9 ± 5.2 5.0 ± 6.0 
   
Emergency room visits*   
 mean ± SD 1.0 ± 2.0 1.7 ± 2.5 
   
*p<0.05 
AD: Alzheimer’s disease; CVD: cerebrovascular disease; ChEI: cholinesterase 
inhibitor; GP: general practitioner 
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Six hundred patients reached the main study endpoint (NHP or death) within the 
study’s time frame. In the group with AD only, a total of 430 patients (3.2%) 
reached the study endpoint (159 patients died and 271 were admitted to a nursing 
home), compared with 170 patients (3.8%) in the group with both AD and CVD 
(52 had died and 118 had been placed in a nursing home for a total 170). For the 
composite endpoint of NHP or death, 1,000-day survival rates differed 
significantly between groups (Figure E: AD: 86%, AD with CVD: 84%, 
p=0.0072) and among those who discontinued ChEI therapy (Figure F: AD: 
78%, AD with CVD: 77%, p=0.0011). The large sample sizes yielded by the 
RAMQ database likely account for the statistical significance of these differences 
between patients with AD and those with AD with CVD despite their small 
absolute magnitude. Of the secondary endpoints, time to death was shorter for 
AD patients with versus without CVD (p<0.01), but time to NHP did not differ 
between groups.  
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Figure E. Time to death or NHP among patients with continuous ChEI use 
(adjusted for covariates) 
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Figure F. Time to death or NHP among patients who discontinued ChEI 
therapy (adjusted for covariates) 
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Using Cox regression models, adjusted rate ratios were calculated to determine 
which, if any, factors predicted time to NHP or death among patients with 
either continuous or discontinuous ChEI use (Table 36). In this analysis, rate 
ratios for each factor were adjusted for all other variables simultaneously. For 
patients who persisted on ChEI treatment, significant risk factors included 
increased age, male sex, use of rivastigmine as the index drug, a diagnosis of 
AD at or before the index date, and the occurrence of hospitalizations and ER 
visits in the year prior to the index date (p<0.05). For patients who 
discontinued ChEI therapy, index dispensations of galantamine and 
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rivastigmine were found to delay NHP or death by 63% and 42%, respectively, 
whereas higher age, male sex, increased CDS, and diagnosis of AD at or before 
the index date were identified as negative prognostic factors (p<0.05). A 
classification of AD with CVD did not predict the study endpoint in either 
regression analysis.   
 
Table 36. Results of multivariate analyses comparing adjusted rates of the 
primary endpoint (time to nursing home placement or death) between 
patients with AD and those with AD with CVD. Rate ratios for each factor 
are adjusted for all other variables. Results are stratified by ChEI use 
(continuous vs. discontinuous). 
 
 Continuous use of 
ChEIs 
Discontinuous use of 
ChEIs 
Factor Rate Ratio (95% CI) Rate Ratio (95% CI) 
Patient group   
 AD 1.00 (reference) 1.00 (reference) 
 AD with CVD 1.08 (0.90–1.30) 1.05 (0.95–1.16) 
Index drug   
 Donepezil 1.00 (reference) 1.00 (reference) 
 Galantamine 0.99 (0.68–1.45) 0.37 (0.28–0.48) * 
 Rivastigmine 1.39 (1.09–1.78) * 0.58 (0.49–0.69) * 
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 Continuous use of 
ChEIs 
Discontinuous use of 
ChEIs 
Factor Rate Ratio (95% CI) Rate Ratio (95% CI) 
Age (years)   
 66–75 1.00 (reference) 1.00 (reference) 
 76–85 1.74 (1.39–2.17)* 1.44 (1.28–1.62)* 
 86–95 2.58 (1.98–3.35)* 2.07 (1.81–2.38)* 
 ≥ 96 6.46 (2.82–14.81)* 2.89 (1.54–5.43)* 
   
Sex   
 Female 1.00 (reference) 1.00 (reference) 
 Male 1.29 (1.09–1.53) * 1.48 (1.35–1.62) * 
   
Chronic Disease Score 
(CDS) 
1.02 (0.99-1.05) 1.04 (1.02-1.05)* 
   
Resource use/person in year 
prior to index date 
  
 Hospitalizations (all 
causes) 
1.08 (1.03–1.13)* 1.03 (0.99–1.06) 
 Duration of 
hospitalization (days) 
1.01 (0.99–1.02) 1.00 (0.99–1.01) 
 visits to GP 1.00 (0.99–1.02) 1.01 (0.99–1.01) 
 visits to specialist 
(all) 
1.00 (0.98–1.02) 1.01 (1.00–1.02) 
 visits to emergency 
room 
1.04 (1.01–1.08)* 1.02 (0.99–1.04) 
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 Continuous use of 
ChEIs 
Discontinuous use of 
ChEIs 
Factor Rate Ratio (95% CI) Rate Ratio (95% CI) 
Diagnosis of urinary 
incontinence before or at 
index date  
  
No 1.00 (reference) 1.00 (reference) 
Yes 1.097 (0.85-1.42) 0.89 (0.77-1.04) 
   
Diagnosis of AD before or at 
index date 
  
 No 1.00 (reference) 1.00 (reference) 
 Yes 1.20 (1.01–1.42)* 1.26 (1.15–1.39) * 
*p<0.05 
AD: Alzheimer’s disease; CVD: Cerebrovascular disease; ChEI: cholinesterase 
inhibitor 
 
This study also examined the differences in secondary outcomes for AD 
patients with versus without CVD. As shown in Table 37, small, but 
statistically significant differences between AD and AD with CVD groups 
were found in unadjusted rates of NHP among patients with continuous ChEI 
use (0.2% vs. 0.3%, p=0.009) and death among patients who discontinued 
ChEI treatment (0.09% vs. 0.10%, p=0.0007). No differences between groups 
were found in other secondary outcomes.  
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Table 37. Results of univariate analyses comparing unadjusted rates of 
secondary outcomes (nursing home placement or death) between patients 
with AD and those with AD with CVD. Results are stratified by ChEI use 
(continuous vs. discontinuous). 
 
 AD  
 
(n=13,512) 
AD with 
CVD 
(n=4,428) 
p-
value 
Death with continuous ChEI use (%) 159 (0.01%) 52 (0.01%) 0.9898 
NHP with continuous ChEI use (%) 271 (0.02%) 118 (0.03%) 0.0090 
Death with discontinuous ChEI use 
(%) 
1,183 
(0.09%) 
463 (0.10%) 0.0007 
NHP with discontinuous ChEI use 
(%) 
301 (0.02%) 91 (0.02%) 0.4955 
AD: Alzheimer’s disease; CVD: Cerebrovascular disease; ChEI: cholinesterase 
inhibitor; NHP: nursing home placement 
 
5.4   DISCUSSION 
 
After application of the study’s inclusion/exclusion criteria, information was 
extracted for 13,512 patients with AD only and for 4,428 patients with AD with 
CVD. There were more women than men in the AD-only group, which reflects 
the usual demographics of the diseases. The AD patients with CVD in the 
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study population tended to be somewhat older than the patients with AD alone. 
Donepezil was the most frequently dispensed ChEI in both groups of patients, 
which can be explained by the fact that it was the first to market and the only 
ChEI available until October 2000.  
 
In contrast to what was expected based on previous evidence, rates of NHP, 
death, and NHP/death were virtually identical for AD patients with and without 
CVD, after adjustment for covariates. Although some of the differences 
between AD and AD with CVD patients reached statistical significance, the 
absence of large absolute differences suggests that these statistical findings are 
attributable mainly to the large sample sizes. Although greater statistical power 
is an advantage of using large administrative claims databases like those of the 
RAMQ, it increases the need to carefully judge the clinical significance of 
differences rather than only their statistical significance. Similar cautions have 
been raised regarding the clinical vs. statistical significance of efficacy results 
from large clinical trials of ChEIs in patients with AD 255. The small 
differences revealed in the present study suggest that there is little clinically 
relevant association between co-occurring CVD and survival or NHP among 
AD patients receiving ChEIs, and that expectations of poorer outcomes should 
not be used to deny AD patients access to potentially beneficial ChEI therapy. 
This finding has important implications to the healthcare system and 
prescribing physicians, who may be reassured about the appropriateness of 
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providing ChEIs for patients presenting with AD symptoms and a recent 
history of CVD.  
 
Given the disease burden associated with cardiovascular disease, it is not 
surprising that the data revealed that AD with CVD patients used healthcare 
resources to a greater extent than the patients with AD alone. Relative to 
patients in the AD group, those with AD with CVD were hospitalized more 
often, spent a greater number of days in the hospital, had a higher number of 
specialist and ER visits, and received significantly more additional medications 
(p<0.05) during the year prior to the index ChEI prescription. By contrast, 
patients with AD only had a longer duration of follow-up, relative to AD with 
CVD patients, which may reflect earlier initiation of ChEI therapy in patients 
thought to have AD in its “restrictive” form. Regardless of CVD status, 
patients were largely dispensed the same medications: antihypertensives, 
cholesterol-lowering drugs, NSAIDs, and anti-psychotics. Patients in the AD 
with CVD group were dispensed more antiplatelet drugs, compared with AD 
only patients, but the difference was not significant. 
 
This study included patients who received donepezil, rivastigmine, or 
galantamine, all of which increase cholinergic function in the central nervous 
system. Evidence from randomized controlled trials suggests that the three 
ChEIs included this study have clinically detectable benefits not only in AD 
242,244,249,256, which is associated with cholinergic deficits in the basal forebrain 
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and neocortex 257, but also in VaD 242,245,248,256,258,259, which may be associated 
with cholinergic losses in all sectors of the cerebral cortex 245. Given the 
diagnostic uncertainty in patients who develop dementia following CVD, it is 
possible that the AD with CVD group in this analysis included a subset of 
patients for whom VaD was the true cause of dementia. Thus, the lack of 
clinically relevant difference between AD and AD with CVD groups in this 
study may support previous findings of ChEI benefits in AD and VaD patients. 
However, it is not possible to estimate the proportion of patients in the AD with 
CVD group who may have had VaD because the detailed clinical signs and 
symptoms diagnostic for VaD (reviewed in Section 2.7.3 above) are not 
recorded in the RAMQ database. 
 
The finding that index ChEI was a statistically significant predictor of NHP or 
death may be due either to differences in efficacy or to differences in the 
clinical characteristics of the individuals to whom the different ChEIs are 
prescribed. Given that the indications of the three ChEIs at the time the data 
were collected were similar (i.e., mild-to-moderate AD; the severe AD 
indication for donepezil was not approved until June 2007), the latter 
explanation seems unlikely. Furthermore, while one trial has suggested greater 
functional benefits of rivastigmine compared with donepezil 260, evidence on 
the relative efficacy of donepezil versus galantamine is conflicting 261,262, and 
most head-to-head comparisons find little difference between the effectiveness 
of ChEIs 263,264. Thus, it is possible that the finding of an association between 
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index ChEI and death or NHP was simply an artifact, due to only a few patients 
remaining in these cells throughout the study period.  
 
A number of possible biases may have affected the results of this study. As 
with any retrospective database study, it was necessary to rely on existing 
records, which may be less accurate or complete than data collected in a 
randomized trial. The RAMQ databases used for data extraction are large and 
have been validated for accuracy and comprehensiveness 252. Nevertheless, 
they are those of a public payer and are designed primarily for drug and 
physician services reimbursement. As a result, the ICD-9 coding may, in some 
cases, be unreliable. To reduce this effect, data were drawn only for subjects 
who had received a dispensation of a ChEI—medications approved solely for 
the treatment of AD patients. This approach helped to reduce selection bias by 
ensuring that all patients receiving ChEIs were included even if a diagnosis of 
AD had not been formally coded. In all cases, the presence of an AD diagnosis 
was tracked, and its impact examined.  
 
As stated, the classification and diagnosis of dementia continues to be difficult, 
with overlap between AD, VaD, and what is termed AD with CVD or “mixed 
dementia.” As a result, it is possible that systematic selection 
(misclassification) bias may have affected our results. To minimize this, the 
research was based on clearly defined criteria, selected to increase the 
likelihood that AD was the primary cause of dementia in the AD group and that 
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CVD had contributed to cognitive decline in patients classified as AD with 
CVD. Nevertheless, it remains possible that recent stroke was causally 
unrelated to dementia in some “AD with CVD” patients, and that CVD may 
have been an important contributor to cognitive decline in “AD only” patients 
with a cerebrovascular event in the distant past or with undiagnosed CVD. 
Indeed, because of its high prevalence, subclinical CVD may underlie many 
cases of cognitive impairment 265. On the basis of imaging studies, for every 
patient in the US who experienced a symptomatic stroke in 1998, an estimated 
12 other individuals had subclinical infarcts and 2.5 had asymptomatic 
microhemorrhages 266. Inability to assess the potential impact of such 
subclinical cases of CVD is an inherent limitation of the present study, because 
the claims data in the RAMQ databases are generated only for treated 
conditions. 
 
A related limitation applies to the calculation of the CDS on the basis of 
reimbursed medications for chronic conditions. The method we used has been 
applied in previous retrospective studies using the RAMQ databases 267,268. 
However, it should be acknowledged that this method will not capture medical 
conditions for which no prescriptions are recorded, potentially resulting in an 
underestimation of the degree of comorbidity for some indeterminable 
percentage of patients. Conversely, the CDS score for a patient may be 
incorrect in cases where a drug was prescribed off-label for a condition with a 
different weighting than the indicated condition. 
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A previous retrospective cohort study of elderly individuals revealed that, even 
after adjusting for comorbid conditions, diagnosed urinary incontinence 
increased the risk for NHP two-fold in women, and over three-fold in men 254. 
Furthermore, clinical trials of some (though not all) antimuscarinic agents used 
for urinary incontinence therapy have shown an increased risk for cognitive 
impairment 269-271. Urinary incontinence was not a significant predictor of time 
to NHP or death in the present study, in which this condition was identified on 
the basis of ICD-9 codes. A more definitive assessment of the potential 
influence of this variable would have required scoring of dispensations for 
medications used to treat urinary incontinence, in addition to ICD-9 codes. 
However, since urinary incontinence was an exploratory variable and not a 
primary focus of the present study, this more labour-intensive analysis was not 
performed. 
 
In an earlier analysis, AD patients with cardiovascular disease had been 
excluded, but this rendered the AD group unrepresentative of the overall AD 
patient population. The reality is that many AD patients do have cardiovascular 
conditions 272-274. To better reflect the real world, AD patients were included 
who had a history of PVD or MI, or who had experienced a TIA more than six 
months before the index date.  
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Confounding bias, where some of the variables are related both to the exposure 
and to the outcome, was handled though the use of regression models 
controlling for a large number of covariates. However, because MMSE scores 
for the patients included in this study were unavailable to the researchers, some 
may have been more severely affected by their disease than others, thus 
affecting their outcomes. Furthermore, the RAMQ database did not contain 
information on smoking and Body Mass Index, which may also have had 
influenced study results. Finally, the duration of ChEI therapy was not 
documented in this study, raising the possibility of unequal treatment lengths in 
the two study groups. Given that nearly 28% of Canadians in a previous study 
discontinued donepezil within seven months of an initial prescription 275, it is 
possible that a sizable proportion of patients in the current analysis did not 
receive ChEIs long enough to achieve optimum benefits. 
 
The length of the observation period, the large number of subjects, and the 
strict inclusion/exclusion criteria are, however, strengths of this study and 
would be hard to equal in a randomized trial. Further research with a control 
group is needed to clarify the findings of this study. One possible control group 
would include AD patients with or without recent CVD, who have not received 
ChEI treatment, although such patients would be difficult to identify in a 
retrospective database. Comparisons between patients with and without ChEI 
treatment would help to clarify whether ChEIs have actual benefits on survival 
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or NHP in patients with AD, while also examining whether the magnitude of 
such benefits differs according to CVD status. 
 
5.5   CONCLUSIONS 
 
The presence of co-existing CVD in this analysis was not associated with a 
clinically relevant reduction in time to death or NHP among AD patients 
treated with ChEIs. The lack of relevant clinical difference between AD 
patients with and without CVD in this study was unexpected based on previous 
findings, and suggests that patients who develop symptoms of AD after CVD 
should not be denied access to ChEIs solely based on expectations of early 
death or nursing home care.  
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6.0   ASSESSMENT OF IMMORTAL TIME BIAS IN A 
RETROSPECTIVE STUDY OF ALZHEIMER’S DISEASE 
 
6.1   INTRODUCTION 
 
As mentioned in the literature review, immortal time bias is a form of information 
bias and refers to an error in the statistical analysis of cohort data in which a time-
dependent exposure is treated as a time-invariant factor 222,223. In clinical settings, 
the immortal time phenomenon was first recognized in the early 1970s when heart 
transplant studies incorrectly demonstrated a survival benefit of heart 
transplantation based on statistical analyses which did not account for the inbuilt 
survival advantage among those undergoing the surgery 223. Some early 
occupational cohort studies also suffered from this bias thereby masking the 
deleterious health effects of vinyl chloride and asbestos 223. Others have 
demonstrated that bias from immortal time is responsible for the observation that 
popes have a longer life expectancy than artists 276, and that Oscar winners live 
longer than less successful performers 277. For example, Oscar winners had to 
survive long enough to win whereas performers who did not win had no minimum 
survival requirement. Analyses that credit the immortal years before winning 
toward survival after winning will incorrectly conclude that Oscar winners outlive 
their peers 277.  
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Based on a review of recent observational studies of medication effects, Suissa 
published a comprehensive description of the bias in pharmacoepidemiology for a 
variety of cohort designs: time-based cohorts, event-based cohorts, exposure-based 
cohorts, multiple-event-based cohorts, and event-exposure-based cohorts 223. These 
cohort definitions vary in the way patients are eligible for cohort entry and in the 
definition of exposure status. End of follow-up is in all cohort designs defined by 
the occurrence of an event or the end of the study period, whichever comes first. In 
time-based cohorts, cohort entry is defined by a time point (usually a calendar 
date). In these studies, exposure is defined by a prescription or an average number 
of prescriptions during follow-up, and the time between cohort entry and the first 
prescription is inappropriately credited toward survival after treatment. Event-
based cohorts are characterized by cohort entry based on the date of a clinical 
event, such as first diagnosis or hospitalization for a given condition. Exposure is 
defined by a given number of prescriptions within a certain period after cohort 
entry, for example, two or more prescriptions for a certain drug within 90 days 
after first diagnosis. In this situation, the time between cohort entry and the second 
prescription is “immortal”. Analyses will be biased if this time is considered 
exposed because it underestimates the event rate among exposed patients. In 
exposure-based cohorts, subjects who receive the treatment of interest are 
considered exposed and enter the cohort at the time they start the treatment. All 
other patients are considered unexposed and enter the cohort when they start a 
comparison treatment or are first diagnosed with a particular condition. Given this 
definition of exposure, exposed patients may also have undergone the comparison 
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treatment and would have been considered unexposed if they had died prior to 
receiving the medication under study. Thus, the preexposure time period is 
immortal which, if not accounted for as unexposed time, will lead to study bias 
because it will result in an overestimation of the event rate among the unexposed. 
In multiple-event-based cohorts, cohort entry is defined by requiring completion of 
several events over time such as a minimum number of diagnoses or prescriptions. 
If follow-up time starts at the first of the events, subjects who die after the first 
event will be considered unexposed. Consequently, the time between the first and 
last required event is immortal and will provide an artificial survival advantage to 
the exposed group. Finally, in event-exposure-based cohorts patients enter the 
cohort based on the first diagnosis of a condition and exposure is defined by a 
treatment of interest on the same day as the diagnosis. Thus, patients who are 
hospitalized or first diagnosed and receive a prescription on the same day are 
considered exposed, whereas those who did not receive a prescription on the day of 
diagnosis or hospitalization and were not treated with the medication of interest 
during follow-up are classified as unexposed. In this design, patients who were not 
treated at diagnosis but received the prescription during follow-up are excluded 
from the analysis, thereby not considering their immortal unexposed person-time 
and mortal person-time. This approach overestimates the event rate in the 
unexposed group and underestimates the event rate in the exposed group, therefore 
leading to a spurious health benefit of treatment. 
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Several authors have recommended corrections in study design and statistical 
analysis to mitigate immortal time bias in cohort studies of drug effects. In general, 
cohort studies should include follow-up time prior to treatment initiation, and 
immortal time should be correctly classified with regards to exposure by using 
time-dependent analyses 223. Initially, three different approaches were proposed to 
alleviate immortal time bias 182. In the design phase, patients could be classified as 
treated or untreated at the start of the study without considering subsequent changes 
in treatment status (i.e., intention-to-treat analysis). However, this approach may 
lead to conservative estimates of treatment benefit if a substantial number of 
patients switch to treatment during follow-up 182. Other recommended solutions 
involve the use of multiple regression techniques, in particular Cox proportional 
hazard regression since most cohort studies involve the analysis of time-to-event 
data 278. Immortal time bias can be eliminated by using treatment initiation as a 
time-dependent covariate to adjust for the time at which treatment is initiated. 
Typically, proportional hazard models in observational treatment studies assume 
that once treatment has started, the patient remains exposed for the duration of 
follow-up. If data are available, a better approach would be to consider information 
on all prescriptions after entry into the cohort 279. As an alternative to regression 
analysis, a modified Kaplan-Meier survival analysis could be conducted accounting 
for immortal time by simultaneous use of left-truncation and right-censoring 182.  
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In addition to these approaches controlling for immortal time bias, the “new-
user design” has been proposed to handle bias introduced by immortal time and 
other difficulties related to the probability and timing of treatment initiation in 
pharmacoepidemiologic studies 280-283. In studies with this design, all patients 
in a defined population who start treatment with the medication of interest are 
identified and follow-up begins at the time of treatment initiation. Patients who 
received the specific treatment during a minimum period prior to the new 
treatment initiation are excluded from the study. Unexposed patients, that is, 
those not under treatment and eligible for follow-up, are usually individually 
matched to exposed patients by time of new treatment and demographic 
variables that may impact the outcome. Follow-up of the comparison group 
starts at the same time as follow-up of the newly-treated patients. 
 
In one of the most comprehensive assessments published to date, Zhou and 
colleagues described five methods to examine the impact of immortal time bias 
in the context of evaluating the effectiveness of statins for secondary 
prevention in elderly patients who survived an acute myocardial infarction 221. 
The data sources for establishing this cohort and obtaining information on 
treatment were the hospital discharge summary database and the physician and 
prescription claims databases in Quebec, Canada. Death information was 
available from provincial death registries. A retrospective cohort was 
established of elderly patients who were discharged alive with a diagnosis of 
acute myocardial infarction between 1996 and 2000. Survival data was 
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available until 2002. Patients who filled at least one statin prescription less than 
90 days after discharge were considered exposed, and patients were classified 
as unexposed otherwise. The event of interest was a recurrent acute myocardial 
infarction or death due to any cause.  
 
In their analysis of bias due to immortal time, they described two methods 
introducing the bias and three methods controlling for the bias 221. The first 
biased method (method 1) classified statin use as a binary variable based on the 
presence or absence of treatment initiation within 90 days after discharge. 
Follow-up was from the date of discharge until a study endpoint or the end of 
follow-up. Immortal time prior to the first prescription was inappropriately 
considered as exposed in this analysis and gives users an artificial survival 
advantage. The second biased method (method 2) also classified statin use as a 
binary variable based on the use of statins within 90 days of discharge. 
However, the date of start of follow-up differed from the previous approach. 
For statin users, follow-up started on the day of treatment initiation whereas for 
non-users the day of start of follow-up was randomly selected between the day 
of discharge and 90 days post discharge. Both groups were then followed from 
the start of follow-up until the study event or end of follow-up. Non-users who 
died prior to the randomly selected day of start of follow-up were excluded 
from this analysis. If the start of follow-up was on average substantially later 
among non-users than among users, this would give an artificial survival 
advantage to the non-users.  
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Zhou et al. also described three correct methods for analyzing their data, two of 
which relied on an appropriate classification of exposure time and one was 
based on a time-dependent Cox regression variable 221. In one approach 
(method 3), statin use was represented by a binary variable as described above, 
that is, taking a value of 1 for those who initiated a statin within 90 days after 
discharge and taking a value of 0 for patients who did not. Both users and non-
users were followed from 90 days post discharge until the occurrence of an 
event or the end of follow-up. Thus, this requires that patients in both groups 
survived for at least 90 days which eliminates a survival advantage for either 
group. In another method (method 4), statin use was considered a binary 
variable as above, and follow-up started at the time of first prescription among 
users. For non-users, the start of follow-up was randomly selected based on the 
distribution of the number of days from discharge to dispensing time among 
users. This approach ensures that the start of follow-up, expressed as the 
number of days post discharge, is on average the same for users and non-users 
thereby removing a survival advantage. Finally, a regression method was 
utilized in which a time-dependent variable for statin initiation was used to 
classify users and non-users (method 5). Statin use took the value of 0 until the 
time of first prescription, if any, after which the statin use variable took the 
value 1. This approach correctly classified follow-up prior to treatment as 
unexposed. As mentioned previously, this method could be improved by 
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considering changes in treatment after the first prescription since the number of 
prescriptions and patterns of use likely vary among users.  
 
In analyses where the end of follow-up was restricted to one year post 
discharge, the authors found that the risk of recurrent acute myocardial 
infarction or death among statin users was 10 to 38 percent lower than the risk 
among non-users, depending on how which approach was taken to define 
exposure and start to follow-up. Assigning an artificial survival advantage to 
users (method 1) resulted in a statistically significantly 38 percent reduced risk, 
whereas introducing this survival advantage to non-users resulted in a much 
smaller health benefit; a 10 percent risk reduction which was not statistically 
significant. The correct analytic approaches yielded a much more consistent 
statistically significant reduction in risk of 20-22 percent. Differences in health 
benefit across methods were stronger when the duration of follow-up was 
limited to six months post discharge (42 percent reduction to one percent 
increase in risk among users), while less variation in results was seen when the 
duration of follow-up was lengthened to two years post discharge (20 to 32 
percent risk reduction) 221.   
 
Others have corroborated these findings 222,284. This speaks to the importance 
of controlling for this bias in pharmacoepidemiology as it can significantly 
influence the interpretation of results 222,223,285. For example, studies 
demonstrating an increased risk of mortality due to treatment would have found 
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an even stronger hazard if the time-dependent initiation of treatment had been 
correctly considered. Similarly, studies demonstrating no treatment effect 
would likely have shown an increased risk of death. Studies showing a health 
benefit of treatment may have continued to do so, but with a more conservative 
estimate, or they may have demonstrated a lack of effect or even an adverse 
effect after correcting for the bias 222. Therefore, it is especially prudent to 
consider the potential for immortal time bias in studies reporting unexpectedly 
large beneficial treatment effects 286. 
 
Although bias from immortal time has been recognized in clinical research for 
several decades, this bias is still common 284 and has recently appeared in a 
variety of observational studies examining the effects of medications in 
computerized healthcare databases. The impact of bias due to immortal time is 
particularly well illustrated in observational treatment studies of patients with 
chronic obstructive pulmonary disease (COPD). The prescription of inhaled 
corticosteroids in this population is controversial 287-290. However, several 
studies have in recent years found reduced rates of COPD-related morbidity 
and all-cause mortality among COPD patients taking inhaled corticosteroids as 
compared to COPD patients who take other medications, which may have 
important implications for prescription consideration.  
 
Sin and Tu identified a cohort of 22,620 patients aged 65 and older diagnosed 
with COPD between 1992 and 1997 from the Ontario version of the Canadian 
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Institute for Health Information hospital discharge database 212. Information on 
prescription medication, including inhaled corticosteroids, was obtained from 
the Ontario Drug Benefit database. Exposed patients were those who received 
inhaled corticosteroid therapy within 90 days post discharge. The beginning of 
follow-up was defined as the date of discharge from COPD and end of follow-
up was determined by the first repeat hospitalization of COPD, mortality from 
any cause, 365 days after discharge from the COPD admission, or the end of the 
study period, whichever occurred first. Patients who died before 30 days post 
discharge were excluded from the analysis. The authors found a 26 percent 
reduction in the risk for a combined event (either repeat COPD hospitalization 
or all-cause mortality) among inhaled steroid users as compared to unexposed 
patients. In this study, the 90-day exposure period represented immortal time 
since users were by design required to survive until treatment initiation whereas 
non-users could experience the event at any time during this exposure window. 
After accounting for this bias, Suissa found no benefit of inhaled corticosteroid 
use with a 6 percent reduction in risk that was not statistically significant 216. 
Despite a rebuttal by Sin and Tu 211, Samet in an editorial concurred that their 
findings should be dismissed for the time being 279. 
 
In another analysis addressing the effectiveness of inhaled corticosteroids in 
the treatment of COPD, Soriano and colleagues in the UK General Practice 
Research Database compared three-year survival between 1,045 treated COPD 
patients and 3,620 COPD patients over the age of 50 who regularly used other 
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bronchodilators but were not treated with inhaled corticosteroids 215. Users 
were defined as those who received three or more corticosteroid prescriptions 
over a 6-month period whereas non-users received three of more prescriptions 
of select bronchodilators (not inhaled corticosteroids or long-acting β2-
agonists) during this time period. All patients in the analysis were required to 
survive for at least six months; follow-up was defined as the period between six 
months after the date of being newly diagnosed with COPD by a physician 
until the time of death or censoring. The rate of death was 52 percent lower 
among exposed patients as compared to patients treated with other 
bronchodilators. In this study, immortal time was introduced by not accounting 
for the time during which users of inhaled corticosteroid users may have been 
treated with regular bronchodilators (i.e., the analysis did not account for 
unexposed time among the treated patients). After Suissa replicated this bias in 
another cohort of 3,524 newly-treated COPD patients identified from 
computerized databases of Saskatchewan Health and subsequently accounted 
for unexposed person-time, no survival benefit due to inhaled corticosteroids 
was found 291. 
 
Other examples of potential immortal time bias in the assessment of treatment 
effectiveness include studies of interferon-β in multiple sclerosis 218, and 
multidisciplinary care of patients with chronic kidney disease 217. In both 
instances, beneficial effects of treatment were substantially overestimated. Li 
and colleagues further demonstrated the large impact of this bias in a study of 
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statin therapy and subsequent risk of dementia, resulting in a 50 percent risk 
reduction when in truth the treatment had no effect 219. Unfortunately, even 
studies properly accounting for immortal time remain susceptible to potential 
errors in the definition of exposure status and follow-up time, such as time-
dependent analyses using broad units of time or immeasurable time bias 292-295. 
Therefore, in spite of the methodological improvements in the analysis of 
observational data on treatment effects, their results should be carefully 
scrutinized before they are allowed to influence clinical practice. 
 
To examine the extent to which the findings reported in the previous literature 
also apply to AD studies, we evaluated the impact of immortal time bias and 
follow-up bias in our retrospective analysis of the RAMQ databases comparing 
the risk of death or NHP among AD patients who take rivastigmine or 
galantamine to those who were prescribed donepezil. We used seven Cox 
proportional hazard regression models which varied in the definition of the 
index date (start of follow-up) and the duration of follow-up. 
 
6.2   METHODS 
 
6.2.1   Study Population and Measures 
 
The study setting, study population and variables used in this analysis were 
described in detail in Chapter 5 and are briefly summarized here. From the 
RAMQ databases, we included all patients 66 years of age or older who had a 
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diagnostic code for AD (ICD-9 codes: 290.0-290.4, 290.8, 290.9, 331.0, 331.2) 
or who had received at least one dispensation of a ChEI between January 1, 
2000, and June 30, 2003. We assessed patients’ time to the composite of NHP 
and death in relation to the use of donepezil (first dispensation in RAMQ 
database, April 19, 2000), galantamine (available in the RAMQ database since 
October 2, 2000), and rivastigmine (available in the RAMQ database since 
June 2, 2002). 
 
6.2.2   Statistical Analysis 
 
Similar to Zhou and colleagues 221, we evaluated the impact of immortal time 
(and follow-up) bias (see section 3.3.4) in our retrospective analysis of the 
RAMQ databases using a series of Cox proportional hazard regression models. 
The models varied in the definition of the index date (start of follow-up) and 
the duration of follow-up.  
 
The hazard of a combined event (death or NHP) in the three different 
medication groups was compared (reference: donepezil) in an analysis without 
immortal time bias (analysis 1), and in models introducing immortal time and 
follow-up bias (analysis 2), immortal time bias only (analysis 3), follow-up 
bias only (analysis 4), and models that correct for these biases (analyses 5-7). 
In analysis 1, the index date (or start of follow-up) was at the entry of 
galantamine in the database (June 2, 2002), thereby eliminating immortal time 
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from July 1, 2000 to June 2, 2002. The duration of follow-up for all patients 
was from June 2, 2002 until event occurrence or the end of the study (June 30, 
2003), whichever occurred first. In analysis 2, both immortal time and follow-
up bias are introduced by starting follow-up at the beginning of the study (July 
1, 2000) and following people until an event or the end of the study (June 30, 
2003), whichever came first. In this analysis, immortal time is introduced by 
requiring those on rivastigmine (October 2, 2000) or galantamine (June 2, 
2002) to have survived until these drugs were in the Québec formulary. Due to 
differences in the date of entry into the database, more immortal time was 
introduced for galantamine than for rivastigmine. Follow-up bias was 
introduced by allowing a longer duration of follow-up for patients who were 
prescribed a medication found earlier in the database. Analysis 3 introduced 
immortal time but not follow-up bias by defining the beginning of the study as 
the index date, and limiting follow-up for all patients to the time of an event or 
one year after the index date (June 2, 2003), whichever occured first. Analysis 
4 introduced follow-up bias but not immortal time bias by defining the index 
date as June 2, 2002 and following patients until June 30, 2003. In analysis 5, 
immortal time bias introduced in model 2 was corrected by starting follow-up 
at June 2, 2002. Analysis 6 corrected follow-up bias in model 2 by limiting the 
duration of follow-up to a maximum of one year from the index date. In 
analysis 7, both biases introduced in analysis 2 were corrected by starting 
follow-up on June 2, 2002 and ending follow-up on June 2, 2003 (unless an 
event occurred prior to this date). 
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Statistical analyses were performed using SAS software, version 9.1 (SAS 
Institute Inc, Cary, NC). 
 
6.3   RESULTS 
 
Table 38 demonstrates the impact of immortal time (and follow-up) bias on the 
association between type of ChEI therapy and death or NHP. In the unbiased 
analysis, no association between medication type and outcome was found. 
Introduction of bias due to immortal time and differential follow-up resulted in 
an apparent beneficial effect of galantamine and, to a lesser extent, 
rivastigmine on a combined event of death or NHP. The observed bias was 
primarily due to immortal time; follow-up bias appeared to have little effect as 
no association with medication type was found in models in which only this 
type of bias was present.  
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Table 38. Adjusted rate ratio for death or NHP during ChEI therapy: 
assessment of impact of immortal time bias 
 
 Rate ratio* (95% CI) 
Analysis 1: Baseline (no ITB and no FUB) 
(no. of events = 189) 
Donepezil 
Rivastigmine 
Galantamine 
 
 
1.000 
1.182 (0.801 – 1.744) 
0.988 (0.652 – 1.499) 
 
Analysis 2: Introduction of both biases (ITB and FUB) 
(no. of events = 602) 
Donepezil 
Rivastigmine 
Galantamine 
 
 
1.000 
0.812 (0.637 – 1.036) 
0.381 (0.262 – 0.555) 
Analysis 3: Introduction of ITB only 
(no. of events = 602) 
Donepezil 
Rivastigmine 
Galantamine 
 
 
1.000 
0.852 (0.639 – 1.137) 
0.527 (0.356 – 0.780) 
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 Rate ratio* (95% CI) 
 
Analysis 4: Introduction of FUB only 
(no. of events = 212) 
Donepezil 
Rivastigmine 
Galantamine 
 
 
 
1.000 
1.268 (0.885 – 1.817) 
0.959 (0.642 – 1.431) 
Analysis 6: Second analysis with correction of FPB 
only     (no. of events = 426) 
 
Donepezil 
Rivastigmine 
Galantamine 
 
 
1.000 
0.852 (0.639 – 1.137) 
0.527 (0.356 – 0.780) 
Analysis 7: Second analysis with correction of ITB 
and FUB   (no. of events = 189) 
 
Donepezil 
Rivastigmine 
Galantamine 
 
 
1.000 
1.155 (0.783 – 1.703) 
1.060 (0.692 – 1.623) 
 
 
6.4   DISCUSSION 
 
We did not find an association between ChEI treatment type and death or NHP. 
After we introduced immortal time bias, however, a strong beneficial effect of 
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galantamine compared to donepezil was observed. The impact of immortal 
time bias on hazard ratios was smaller for rivastigmine than for galantamine, 
which is consistent with the shorter immortal time for the former (July 1, 2000 
– October 2, 2000) as compared to the latter (July 1, 2000 – June 2, 2002) 
medication. Our findings of the impact of immortal time bias are consistent 
with the bias reported in previous retrospective observational database studies 
of inhaled corticosteroid treatment in patients with chronic obstructive 
pulmonary disease and asthma 210-216, multidisciplinary care and mortality 
among patients with chronic kidney disease 217, interferon-β treatment in 
multiple sclerosis 218, and statin therapy and the risk of dementia 219,220. In these 
studies, an apparent treatment benefit disappeared, as it did in our study, after 
properly accounting for unexposed person-time in the analysis either by 
modeling exposure as a time-dependent factor or adjusting the index date such 
that immortal time is eliminated. Thus, care is required in the interpretation of 
retrospective database studies, in particular when unexpected beneficial 
treatment effects are reported.  
 
6.5   CONCLUSIONS  
 
Dementia is a widespread public health problem that affects tens of millions of 
individuals worldwide. Costs to the world economy are upwards of $150 
billion per year. The consequences of dementia are grave, ranging from 
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declines in cognition and daily functioning to complete functional dependence, 
institutionalization, and ultimately, death.  
 
Scientific evidence regarding factors that increase the risk of AD or prevent its 
occurrence is primarily based on observational studies of human populations. 
Due to their non-experimental nature, these epidemiological studies are subject 
to a variety of study limitations potentially leading to bias. Bias in 
epidemiologic research is any systematic error that distorts an estimate of the 
relationship between exposure and outcome. Biases are generally categorized 
into three types. Selection bias refers to errors that occur in identifying the 
study population. Information bias, also known as observation bias, consists of 
error in ascertaining data on exposure or outcome. Immortal time bias is a form 
of information bias in which a time-dependent exposure is treated as a time-
invariant factor, and is of particular concern in retrospective cohort analyses. 
Confounding occurs when the relationship between exposure and outcome is 
affected by another factor 11. 
 
Minimization of bias is imperative for the design of epidemiologic studies, 
given that its presence raises doubts about the quality and credibility of results. 
Whereas the effects of confounding may be controlled at the time study data 
are analyzed, it is critical to prevent selection bias and information bias at the 
design stage in order to avoid compromising study validity 12. 
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The interpretation of epidemiologic data should take into account the 
possibility of bias. Key contributors to bias include the type of study design, 
which may be susceptible to particular forms of bias, and the conduct of 
investigators during study implementation. Although quantitative analysis of 
the magnitude of potential bias is not always possible, the likely effect of the 
error on study findings can often be deduced 11. The present methodological 
analysis reveals that immortal time bias in a retrospective analysis of the 
RAMQ database can lead to the incorrect conclusion that different ChEIs differ 
in their effectiveness in terms of time to death or NHP among patients with 
AD. Correcting for immortal time bias yields the qualitatively different 
conclusion that the ChEIs are equivalent for this endpoint. 
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7.0   ORIGINAL STUDIES OF CHOLINESTERASE INHIBITORS FOR 
ALZHEIMER’S DISEASE: DISCUSSION 
 
Globally, over 24 million individuals are estimated to have dementia 1. In most 
studies in Western countries, 50% to 70% of the total dementia prevalence is 
attributed to AD, and 20% to 30% to VaD, with a smaller percentage accounted 
for by other forms of dementia 93. Traditionally, AD and VaD were considered to 
be discrete entities 245. However, AD and VaD share common pathophysiological 
mechanisms, and frequently co-exist 98. Given the high prevalence of dementia 
with a vascular component, there is a clear and urgent need for effective therapy 
for this patient population. However, identifying which therapeutic strategies are 
most appropriate to treat dementia depending on its etiology (i.e., AD, VaD, or a 
combination of the two) has posed a longstanding challenge to clinicians 10, and 
remains unresolved 8. Thus, additional research is required to compare outcomes 
of treatment in patients with different forms of dementia. 
 
Studies comparing dementia subtypes generally find a higher mortality rate in 
patients with VaD or AD with CVD than in those with AD alone 148,246,247. 
Conversely, stroke patients who develop dementia (VaD or AD with CVD) 
exhibit an increased risk of death, compared to those without cognitive decline 150. 
Taken together, these data suggest that AD and CVD may be associated with 
higher mortality in combination than alone, and raise the question of whether anti-
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dementia treatment may have differential effects on mortality and other important 
outcomes in patients with and without CVD.  
 
To address this question, we conducted the retrospective cohort study of ChEIs in 
patients with dementia described in Chapter 5. Rates of NHP, death, and 
NHP/death were virtually identical for AD patients with and without CVD, after 
adjustment for covariates. Although some of the differences between the AD and 
AD with CVD groups reached statistical significance, the absence of large 
absolute differences suggests that these statistical findings are not clinically 
significant. The small differences revealed in the present study suggest that there 
is little clinically relevant association between co-occurring CVD and survival or 
NHP among AD patients receiving ChEIs. This finding has important 
implications for clinical practice, as it suggests that prescribing ChEIs for patients 
presenting with AD symptoms and a recent history of CVD is a rational 
therapeutic strategy. However, since retrospective studies are susceptible to 
several types of bias, as explained in Chapter 3, these results require verification 
in prospective, randomized, placebo-controlled trials that include the endpoints of 
death and NHP. 
 
Previous prospective trials of ChEIs in patients with vascular forms of dementia 
have yielded conflicting results 8. For example, in the combined analysis of 2 
identical randomized, placebo-controlled trials with 1219 enrolled VaD patients, 
donepezil was associated with significant improvements on the MMSE, ADAS-
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cog, CIBIC-plus, CDR-SB, and ADFACS 296. Conversely, in a randomized, 
placebo-controlled trial in 799 VaD patients, galantamine yielded significant 
improvements in ADAS-cog, but not CIBIC-plus or ADCS-ADL 297. Discrepant 
results may arise from focus on different endpoints, differences in patient 
populations, and possible differences in the efficacy of different ChEIs in patients 
with VaD.  
 
A definitive answer to the question of whether ChEIs are meaningfully effective 
in this patient population will require testing in large, long-term, prospective, 
randomized, placebo-controlled trials using efficacy measures sensitive to the 
disease course and symptomatology of VaD. However, clinicians should not be 
expected to postpone treating their dementia patients until such trials might be 
conducted. In the interim, treatment decisions can be informed by the results of 
other study designs, such as prospective open-label trials and retrospective 
observational studies. For instance, in the absence of randomized, controlled trials 
of rivastigmine focused on patients with mixed dementia, physicians may refer to 
results of an open-label study in which rivastigmine was associated with 
stabilization of ADAS-cog, MMSE, and GDS scores over 26 weeks in 119 
patients with mixed dementia 298. Although the present retrospective cohort 
analysis did not use detailed clinical measures of efficacy such as those employed 
in clinical trials, the outcomes of death and NHP are clearly relevant to both 
patients and clinicians.  
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The results reported here are also valuable because these outcomes were observed 
in real-world practice. Even after results of randomized, controlled trials are 
available, there remains a niche for naturalistic studies, because results seen in the 
closely supervised conditions of randomized trials, with their rigorous inclusion 
and exclusion criteria, may not always apply in routine clinical practice with 
unselected patients. For example, verification of the efficacy of rivastigmine in 
AD as shown in randomized, placebo-controlled trials was recently provided by 
the EXPLORE study, a naturalistic, open-label study in 3800 AD patients 
receiving rivastigmine in regular clinical practice 299. At 6 and 12 months of 
follow-up, a higher percentage of patients improved than deteriorated on all six 
subscales of a Clinical Global Impression of Change scale.  
 
Our finding of similar outcomes of ChEI therapy in AD patients with and without 
co-existing CVD contrasts to expections of poorer outcomes in the former group, 
based on previous evidence. For example, in a recent double-blind, randomized, 
placebo-controlled trial of 710 patients diagnosed with probable VaD, 
rivastigmine showed a significant treatment effect on the Vascular Dementia 
Assessment Scale, ADAS-cog, and MMSE, but this was attributable to efficacy 
seen in the subgroup of older patients, who were assumed to be more likely to 
have AD 300. The trial investigators suggested that ChEIs were ineffective in 
patients with VaD in the absence of concomitant AD. Unfortunately, due to 
limitations of the data available for our retrospective analysis comparing patients 
with AD only with those with AD with CVD, it is not possible to determine what 
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percentage of patients in the latter category may have had dementia with primarily 
vascular causes as opposed to dementia primarily due to AD.  
 
A number of novel therapeutic strategies are currently under investigation for 
their potential as dementia therapy. These include statins 126, beta-secretase 
inhibitors 301, gamma-secretase inhibitors 302, peroxisome proliferator-activated 
receptor gamma (PPARγ) agonists 303, serotonin 6 (5-HT6) receptor antagonists 
304, receptor for advanced glycation end products (RAGE)/Aβ blockers 305, Aβ 
immunotherapy 306, medium-chain triglycerides 307, and various experimental 
approaches to counteract tau neurotoxicity 308. In the near future, randomized 
clinical trials will hopefully clarify the role of these strategies in the treatment of 
AD and other forms of dementia. While randomized controlled trials 
demonstrating symptomatic improvement and/or disease-modifying effects would 
be required for regulatory approval of any new dementia therapy 9, such carefully 
supervised and selective trials may not capture all outcomes of concern to patients 
and clinicians in real-world practice. By examining endpoints like survival and 
institutionalization in different patient subgroups, retrospective analyses of 
administrative healthcare databases—such as the present research—could provide 
valuable insight into the post-marketing effectiveness of future dementia 
treatments. 
 
Similar retrospective cohort studies carried out in future will need to be designed 
with care to avoid biases to which such studies are susceptible. Although bias 
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from immortal time has been recognized in clinical research for several decades, 
this bias is still common 284 and has recently appeared in a number of 
observational studies examining the effects of medications in administrative 
healthcare databases.  
 
However, no previous study has explored the impact of immortal time bias in 
studies of dementia treatments. The retrospective cohort analysis reported in 
Chapter 5 was designed from the outset to avoid immortal time bias. To 
demonstrate the impact immortal time bias would have had on our conclusions, 
we conducted a methodological analysis in which we used seven Cox 
proportional hazard regression models that varied in the definition of the index 
date and the duration of follow-up. 
 
In the retrospective cohort analysis, we did not find an association between ChEI 
treatment type and death or NHP. Introduction of immortal time bias resulted in 
the apparent superiority of galantamine compared to donepezil. Subsequently 
removing the influence of immortal time with appropriate adjustment of the 
definition of index date and follow-up period returned the model results to their 
original state. These findings support demonstrations of the impact of immortal 
time bias reported in previous retrospective observational database studies of 
inhaled corticosteroid treatment in patients with chronic obstructive pulmonary 
disease and asthma 210-216, multidisciplinary care and mortality among patients 
with chronic kidney disease 217, interferon-β treatment in multiple sclerosis 218, 
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and statin therapy and the risk of dementia 219,220. In these studies, an apparent 
treatment benefit disappeared, as it did in our study, after properly accounting for 
unexposed person-time. Thus, the present methodological analysis reinforces the 
need for care in the design and interpretation of retrospective database studies to 
avoid misleading conclusions as a result of immortal time bias.  
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8.0   ORIGINAL STUDIES OF CHOLINESTERASE INHIBITORS FOR 
ALZHEIMER’S DISEASE: CONCLUSIONS 
 
Dementia is a widespread public health problem that affects tens of millions of 
individuals worldwide. Annual costs to the world economy are upwards of $150 
billion. The consequences of dementia are grave, ranging from declines in 
cognition and daily functioning to complete functional dependence, 
institutionalization, and ultimately, death.  
 
Although AD is the most common cause of dementia, dementia associated with 
CVD accounts for a significant percentage of cases. Although three ChEIs are 
approved in Canada to treat AD dementia, the role of these agents in the therapy 
of other forms of dementia remains poorly defined. The retrospective analysis of 
the RAMQ administrative databases reported in Chapter 5 was undertaken to 
assess whether concomitant CVD worsened the prognosis for patients with AD 
receiving ChEIs. The presence of co-existing CVD in this analysis was not 
associated with a clinically relevant reduction in time to death or NHP among AD 
patients treated with ChEIs. This finding suggests that patients who develop 
symptoms of AD after CVD should not be denied access to ChEIs solely based on 
expectations of early death or institutionalization. This conclusion requires 
confirmation from prospective, randomized, placebo-controlled trials of adequate 
duration and using clinically relevant outcome measures in patients with clearly 
defined VaD and mixed dementia. 
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Retrospective epidemiologic analyses such as the study reported in Chapter 5 are 
susceptible to a number of types of bias that need to be taken into account to 
avoid misleading results and conclusions. Key contributors to bias include the 
type of study design and the conduct of investigators during study 
implementation. The methodological analysis reported in Chapter 6 reveals that 
introduction of immortal time bias into a retrospective analysis of the RAMQ 
database can lead to the incorrect conclusion that different ChEIs differ in their 
effectiveness in terms of time to death or NHP among patients with AD. 
Correcting for immortal time bias yields the qualitatively different conclusion that 
the ChEIs are equivalent for this endpoint. This represents the first demonstration 
of the potential impact of immortal time bias in any retrospective study of therapy 
for dementia. The results highlight the need to carefully avoid introducing 
immortal time bias into retrospective analyses of administrative databases. 
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